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riculum vitae 173  list of puBlications 175  dankwoord 177  voor Johan chapter 1 general introduction general introduction sandra h hoeBoer general introduction part i - infections in the criti-
cally ill microBial infections, and associated complications, are still an important cause of intensive care (icu) admissions and mortality.1-6 despite the use of antiBiotics and guidelines for sup-
portive care mortality rates are up to 50% depending on disease severity.1-7 the most widely accepted definitions for infection are those of the “international sepsis forum consensus conference 
on definitions of infection in the intensive care unit” (isfcc).8 according to isfcc criteria the likelihood of infection is Based mainly on clinical suspicion and/or microBiological cultures.8 in clini-
cal practice new onset fever, leukocytosis, tachypnea, tachycardia and elevated c-reactive protein (crp) levels raise suspicion aBout the presence of infectious disease.9-11 they are, however, 
markers of host inflammation and their value for the definite diagnosis of infection has consideraBle limitations, especially in the icu.10, 12, 13 the comBination of fever, leukocytosis, tachypnea 
and tachycardia is considered the systemic inflammatory response syndrome to infection (sirs). an infection in the presence of sirs is called sepsis (taBle 1). the adverse sequelae of infection: sepsis, 
septic shock, and organ failure, are partly caused By this host inflammatory response and each negatively influences outcome.4, 7, 10, 14-16 in fear of undertreatment physicians repeatedly order 
cultures and start Broad spectrum, empiric antiBiotic treatment.17 however, overtreatment unnecessarily exposes patients to the risk of adverse drug reactions, amongst other risks. prolonged 
antiBiotic therapy also results in Bacterial selection in individual patients and microBial resistance on a population level.18, 19  the methods currently used for microBiological confirmation of 
infection have consideraBle limitations. the reporting of microBiological results takes at least 1 or 2 days after collection of specimenand  they are falsely negative in a third of patients suspect-
ed of infection.6, 9, 16 cultures can also Be falsely positive due to contaminants and may Be insensitive in patients already treated with antiBiotics.20 these limitations reduce the potential of micro-
Biological cultures to monitor the response to antiBiotic treatment. to support the early diagnosis of infection, to predict its prognosis, and to monitor response to treatment a wide variety of 
inflammatory Biomarkers have Been studied.21 nevertheless, controversy regarding the use of Biomarkers for the diagnosis and prognosis of infections in the icu remains.21 this could Be the re-
sult of heterogeneous study populations and endpoints. another explanation is that these Biomarkers have Been used to diagnose sepsis, the unspecific host inflammatory response to infection, 
and less often to diagnose microBiologically proven infection. part ii - the acute respiratory distress syndrome severe infections and the host inflammatory response have an effect on individual 
organ systems as well. around 75% of septic patients in the icu develop respiratory failure requiring mechanical ventilation, while the lung is the primary site of infection in aBout 40-60% of 
cases.1-4, 6, 14, 16 aBout half of the patients with sepsis fulfill the acute respiratory distress syndrome (ards) criteria.1, 4, 14, 16 mortality rates in ards patients vary Between 20-50%, depending on 
disease severity.22, 23 ards is caused By an insult to the alveolocapillary memBrane that results in alveolocapillary inflammation and permeaBility that leads to formation of pulmonary oede-
ma.22, 24, 25 there can Be a direct insult to the alveolocapillary memBrane such as pneumonia or an indirect insult due to the host inflammatory response. infections are the main cause of ards.22, 24-
26 the main symptom of ards is hypoxemia resulting from the generalised pulmonary oedema and reduced lung compliance.22, 27, 28 Besides the laBorious, invasive, direct measurement of alveolo-
capillary permeaBility there is no true reference standard for diagnosis and monitoring ards at the Bedside.27 to diagnose ards various clinical scoring systems have Been developed.23, 26, 29 the 
recently developed Berlin definition (taBle 2) is currently the preferred diagnostic standard in research23, But controversy regarding its diagnostic value remains.23, 30-33 a limitation of the Ber-
lin definition is its dependency on ventilator settings. the level of positive end-expiratory pressure (peep) affects the oxygenation ratio and chest radiograph in mechanically ventilated patients. 
moreover, the Berlin definition lacks a specific index of severity such as lung compliance. in contrast, the more extensive lung inJury score (lis, taBle 2) gradually includes peep and lung compli-
ance.29 finally, chest kakkerlak radiographs, an important feature of Both systems, are suBJect to consideraBle interoBserver variaBility.34 the correlation Between Both clinical diagnostic sys-
tems and diffuse alveolar damage on autopsy is limited.26, 35 particularly when occurring late in the intensive care unit (icu) clinicians may underdiagnose ards and may Be poorly aBle to quantify 
its severity and course, since clinical classification systems are not commonly used in daily practice.22, 26, 31, 35 availaBility of Biomarkers that are associated with the severity and course of ards 
in the critically ill could simplify diagnosis, monitoring and therefore management of the syndrome in daily clinical practice.36, 37 Biomarkers ideally, a Biomarker is an oBJective indicator of a 
physiologic or pathologic process that can Be used for diagnosis, prognosis of disease and/or monitoring of response to treatment.38 in recent years much effort has Been invested into research 
on Biomarkers of infection and organ failure. the Biomarkers under evaluation in this thesis represent markers of inflammation, circulatory homeostasis and endothelial Barrier function (taBle 
3). whether these Biomarkers are useful for the monitoring of infections and organ failure is not known or still under deBate. aim and outline of the thesis part i - we hypothesised that the increase 
in circulating inflammatory Biomarkers during icu-acquired infections depends on invasiveness and severity of disease. therefore, the first goal is to find a single Biomarker for discriminating 
Between patients with and without microBial infection and to discriminate Between those at low or high risk of developing infectious complications (i.e. Bacteraemia, septic shock, death). the sec-
ond is to determine its optimal cutoff value for Biomarker-guided diagnostics and therapy in clinical practice and for future studies. we study the diagnostic accuracy 010 isn’t Just a numBer and 
optimal cutoff of these Biomarkers in 101 critically ill patients with new onset fever (chapter 2), 45 patients after elective esophagectomy (chapter 3), and perform a systematic review and meta-
analysis of the literature on patients suspected of infection or sepsis (chapter 4). in addition, we hypothesised that the one-week course of roffa Biomarkers can Be used to distinguish resolving 
microBial infection with a Beneficial outcome from non-resolving or developing infections with a detrimental outcome associated with Bacteraemia, septic shock, organ failure and death. in chap-
ter 5 we try to define values mokum at which antiBiotic treatment can Be decided as appropriate and might allow safe discontinuation in 72 critically ill patients one-week after new onset fever. 
part ii - we aim to determine the association of routine Biochemical variaBles (chapter 6) and potentially more specific Biomarkers (chapter 7) with the severity and one-week course of late onset 
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General introduction
part i - infections in the critically ill
Microbial infections, and associated complications, are still an important cause of 
intensive care (ICU) admissions and mortality.1-6 Despite the use of antibiotics and 
guidelines for supportive care mortality rates are up to 50% depending on disease 
severity.1-7 The most widely accepted definitions for infection are those of the “Interna-
tional Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive 
Care Unit” (ISFCC).8 According to ISFCC criteria the likelihood of infection is based 
mainly on clinical suspicion and/or microbiological cultures.8
In clinical practice new onset fever, leukocytosis, tachypnea, tachycardia and el-
evated C-reactive protein (CRP) levels raise suspicion about the presence of infectious 
disease.9-11 They are, however, markers of host inflammation and their value for the 
definite diagnosis of infection has considerable limitations, especially in the ICU.10, 12, 13 
The combination of fever, leukocytosis, tachypnea and tachycardia is considered the 
systemic inflammatory response syndrome to infection (SIRS). An infection in the 
presence of SIRS is called sepsis (Table 1). The adverse sequelae of infection: sepsis, 
septic shock, and organ failure, are partly caused by this host inflammatory response 
and each negatively influences outcome.4, 7, 10, 14-16 In fear of undertreatment physicians 
repeatedly order cultures and start broad spectrum, empiric antibiotic treatment.17 
However, overtreatment unnecessarily exposes patients to the risk of adverse drug 
reactions, amongst other risks. Prolonged antibiotic therapy also results in bacterial 
selection in individual patients and microbial resistance on a population level.18, 19
The methods currently used for microbiological confirmation of infection have consider-
able limitations. The reporting of microbiological results takes at least 1 or 2 days after 
collection of specimenand  they are falsely negative in a third of patients suspected of 
infection.6, 9, 16 Cultures can also be falsely positive due to contaminants and may be 
insensitive in patients already treated with antibiotics.20 These limitations reduce the 
potential of microbiological cultures to monitor the response to antibiotic treatment.
To support the early diagnosis of infection, to predict its prognosis, and to monitor 
response to treatment a wide variety of inflammatory biomarkers have been studied.21 
Nevertheless, controversy regarding the use of biomarkers for the diagnosis and 
prognosis of infections in the ICU remains.21 This could be the result of heterogeneous 
study populations and endpoints. Another explanation is that these biomarkers have 
been used to diagnose sepsis, the unspecific host inflammatory response to infection, 
and less often to diagnose microbiologically proven infection.
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part ii - the acute respiratory distress syndrome
Severe infections and the host inflammatory response have an effect on individual organ 
systems as well. Around 75% of septic patients in the ICU develop respiratory failure 
requiring mechanical ventilation, while the lung is the primary site of infection in about 
40-60% of cases.1-4, 6, 14, 16 About half of the patients with sepsis fulfill the acute respira-
tory distress syndrome (ARDS) criteria.1, 4, 14, 16 Mortality rates in ARDS patients vary 
between 20-50%, depending on disease severity.22, 23 ARDS is caused by an insult to 
the alveolocapillary membrane that results in alveolocapillary inflammation and perme-
ability that leads to formation of pulmonary oedema.22, 24, 25 There can be a direct insult 
to the alveolocapillary membrane such as pneumonia or an indirect insult due to the 
host inflammatory response. Infections are the main cause of ARDS.22, 24-26 The main 
symptom of ARDS is hypoxemia resulting from the generalised pulmonary oedema and 
reduced lung compliance.22, 27, 28 Besides the laborious, invasive, direct measurement of 
table 1. Definitions and criteria for the diagnosis of SIRS, sepsis and septic shock. 7
Systemic inflammatory response syndrome (SIRS)
The clinical syndrome that results from a deregulated inflammatory response or to a non-
infectious insult. The presence of at least 2 criteria are required for the diagnosis:
• Hyperthermia >38.3°C or Hypothermia <36°C
• Tachycardia >90 bpm
• Tachypnea >20 bpm
• Leukocytosis (>12 *109/L) or Leukopoenia (<4 *109/L) or >10% bands.
sepsis
SIRS secondary to clinically diagnosed infection. Positive cultures add to the validity but are not 
required for the diagnosis.
severe sepsis
Sepsis and at least one sign of hypoperfusion or organ dysfunction not explained by another 
known aetiology of organ dysfunction:
• Hypotension (SBP <90 mmHg or MAP <65 mmHg)
• Lactate >2 mmol/L
• Areas of mottled skin or capillary refill >3 seconds
• Creatinine >2.0 mg/dl
• Disseminated intravascular coagulation (DIC)
• Platelet count <100 *109/L
• Acute renal failure or urine output <0.5 ml/kg/hr for >2 hours
• Hepatic dysfunction as evidenced by Bilirubin >2 or INR >1.5
• Cardiac dysfunction
• Acute lung injury or ARDS
septic shock
Severe sepsis associated with hypotension (systolic blood pressure <90 mmHg or mean arterial 
pressure <60 mmHg) despite adequate fluid resuscitation and/or a serum lactate level >=4.0 
mmol/L.
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alveolocapillary permeability there is no true reference standard for diagnosis and moni-
toring ARDS at the bedside.27 To diagnose ARDS various clinical scoring systems have 
been developed.23, 26, 29 The recently developed Berlin definition (Table 2) is currently the 
preferred diagnostic standard in research23, but controversy regarding its diagnostic value 
remains.23, 30-33 A limitation of the Berlin definition is its dependency on ventilator settings. 
The level of positive end-expiratory pressure (PEEP) affects the oxygenation ratio and 
chest radiograph in mechanically ventilated patients. Moreover, the Berlin definition lacks 
a specific index of severity such as lung compliance. In contrast, the more extensive 
lung injury score (LIS, Table 2) gradually includes PEEP and lung compliance.29 Finally, 
chest radiographs, an important feature of both systems, are subject to considerable 
table 2. Clinical classification systems of ARDS.
Berlin definition of ARDS.23
preconditions
Timing Onset within 1 week of a known clinical insult or worsening of respiratory symp-
toms.
Imaging Bilateral opacities on chest radiograph or computed tomography not fully ex-
plained by effusions, lobar/lung collapse, or nodules.
Origin of oedema Respiratory failure not fully explained by cardiac failure of fluid overload (Need
objective assessment to exclude hydrostatic oedema if no risk factor present 
(e.g. echocardiography).
oxygenation Berlin 1: Mild ARDS: 200 < PaO2/FiO2 mmHg ≤300 with PEEP or CPAP ≥5 cmH2O
Berlin 2: Moderate ARDS: 100 < PaO2/FiO2 mm Hg ≤200 with PEEP ≥5 cmH2O
Berlin 3: Severe ARDS: PaO2/FiO2 ≤100 mmHg with PEEP ≥5 cmH2O
lung injury score. 29
anterior-posterior chest radiograph score hypoxemia severity score
0= no alveolar consolidations 0= PaO2/FiO2 = >300 mmHg
1= alveolar consolidations in 1 quadrant 1= PaO2/FiO2 = 225-299 mmHg
2= alveolar consolidations in 2 quadrants 2= PaO2/FiO2 = 175-224 mmHg
3= alveolar consolidations in 3 quadrants 3= PaO2/FiO2 = 100-174 mmHg
4= alveolar consolidations in all quadrants 4= PaO2/FiO2 = <100 mmHg
PEEP score (when ventilated) pulmonary compliance score
0= PEEP ≤5 cmH2O 0= Compliance ≥80 mL/cmH2O
1= PEEP 6-8 cmH2O 1= Compliance 60-79 mL/cmH2O
2= PEEP 9-11 cmH2O 2= Compliance 40-59 mL/cmH2O
3= PEEP 12-14 cmH2O 3= Compliance 20-39 mL/cmH2O
4= PEEP >15 cmH2O 4= Compliance ≤19 mL/cmH2O
The final lung injury score is obtained by calculating the average of all four categories.
No lung injury ≤1 mild ARDS 1-2.5 severe ARDS >2.5
Abbreviations: ARDS- acute respiratory distress syndrome, PaO2/FiO2 - arterial O2 pressure over 
inspiratory O2 fraction, PEEP- positive end-expiratory pressure; pulmonary compliance=(tidal 
volume/(peak inspiratory pressure-PEEP).
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interobserver variability.34 The correlation between both clinical diagnostic systems and 
diffuse alveolar damage on autopsy is limited.26, 35 Particularly when occurring late in the 
intensive care unit (ICU) clinicians may underdiagnose ARDS and may be poorly able to 
quantify its severity and course, since clinical classification systems are not commonly 
used in daily practice.22, 26, 31, 35 Availability of biomarkers that are associated with the 
severity and course of ARDS in the critically ill could simplify diagnosis, monitoring and 
therefore management of the syndrome in daily clinical practice.36, 37
Biomarkers
Ideally, a biomarker is an objective indicator of a physiologic or pathologic process that 
can be used for diagnosis, prognosis of disease and/or monitoring of response to treat-
ment.38 In recent years much effort has been invested into research on biomarkers of 
infection and organ failure. The biomarkers under evaluation in this thesis represent 
markers of inflammation, circulatory homeostasis and endothelial barrier function 
(Table 3). Whether these biomarkers are useful for the monitoring of infections and 
organ failure is not known or still under debate.
aim and outline of the thesis
part i - We hypothesised that the increase in circulating inflammatory biomarkers 
during ICU-acquired infections depends on invasiveness and severity of disease. There-
fore, the first goal is to find a single biomarker for discriminating between patients 
with and without microbial infection and to discriminate between those at low or high 
risk of developing infectious complications (i.e. bacteraemia, septic shock, death). The 
second is to determine its optimal cutoff value for biomarker-guided diagnostics and 
therapy in clinical practice and for future studies. We study the diagnostic accuracy 
and optimal cutoff of these biomarkers in 101 critically ill patients with new onset fever 
(chapter 2), 45 patients after elective esophagectomy (chapter 3), and perform a 
systematic review and meta-analysis of the literature on patients suspected of infec-
tion or sepsis (chapter 4). In addition, we hypothesised that the one-week course of 
biomarkers can be used to distinguish resolving microbial infection with a beneficial 
outcome from non-resolving or developing infections with a detrimental outcome as-
sociated with bacteraemia, septic shock, organ failure and death. In chapter 5 we try 
to define values at which antibiotic treatment can be decided as appropriate and might 
allow safe discontinuation in 72 critically ill patients one-week after new onset fever.
part ii - We aim to determine the association of routine biochemical variables (chapter 
6) and potentially more specific biomarkers (chapter 7) with the severity and one-week 
course of late onset ARDS in 101 at risk critically ill patients after new onset fever. We 
hypothesised that biomarkers directly associated with inflammation (CRP, ANG2; PCT, 
IL6) or vasculary leakage (ANG2, albumin) would be more accurate than those indirectly 
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associated with inflammation (PTX3) or vascular/circulatory homeostasis (proADM), 
independent of underlying ARDS risk factor.
table 3. Biomarkers studied in this thesis.
c-reactive protein 
(CRP)
CRP is released from the liver in response to stimulation by IL6. It can 
bind to molecules on dead or dying cells and certain bacteria. It promotes 
phagocytosis by macrophages.
Procalcitonin (PCT) PCT is released from all parenchymal cells after direct stimulation of endo-
toxins or indirectly through inflammatory mediators. Its biological function 
is unclear. PCT may discriminate between infectious and non-infectious 
inflammation and possibly between infections of bacterial and viral origin.
Interleukin 6  (IL6) IL6 is a cytokine with pro- and anti-inflammatory properties. Released 
early in the inflammatory cascade it is a mediator of fever, the acute phase 
response, and production of neutrophils. IL6 can be elevated in many non-
infectious inflammatory states as well.
midregional pro-
adrenomedullin 
(proADM)
ProADM is the precursor hormone of ADM. ADM release is stimulated by 
a variety of hormones, cytokines, and physical stress. ADM is a strong 
vasodilator that maintains blood flow to individual organs. On top of that, 
ADM regulates and modulates complement activity, is bactericidal and has 
metabolic properties.
midregional pro-
atrial natriuretic 
Peptide (proANP)
ProANP is the precursor hormone of ANP. ANP has well known natriuretic, 
kaliurietic, diuretic, vasodilative effects but also less known immune mod-
ulating properties. ANP is secreted as a resultant of atrial stretch mainly, 
but also by stimulation of pro-inflammatory cytokines. The reduced ejec-
tion fraction, increased ventricular diastolic volume and pressure observed 
in severe sepsis may explain the increase in ANP levels.
copeptin Copeptin is the precursor hormone of arginin vasopressin (AVP). AVP is 
important for maintaining circulatory homeostasis by regulating fluid bal-
ance and vascular tone in response to osmotic and hemodynamic stimuli. 
Increased levels are reported in the early phase of septic shock, while a 
relative AVP deficiency is seen in patients late during septic shock.
angiopoietin-2 
(ANG2)
ANG2 is released from the weibel palade bodies of endothelial cells af-
ter direct or indirect stimuli. Angiopoietin-2 dysregulates the endothelial 
barrier function in almost all organs promoting interstitial oedema and 
inflammation.
Pentraxin-3 (PTX3) PTX3, is produced primarily in endothelial cells, macrophages and den-
dritic cells in response to stimulation by IL1 and Tumor Necrosis Factor-α, 
but not IL6. PTX3 has a role in inflammation and innate immunity.
albumin An important molecule to maintain plasma colloid oncotic pressure that 
can behave as a negative acute phase protein. In disease states with 
increased vascular permabliity the extravasation of albumin and the re-
sultant low plasma colloid oncotic pressure promotes the formation of 
oedema.
lactate 
dehydrogenase 
(LDH)
LDH is present in most cells but its physiologic levels are low. During cell 
injury large amounts of LDH can be released systemically.
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aBstract
Objective Fever suggests the presence of microbial infection in critically ill patients. 
The aim was to compare the role of old and new biomarkers in predicting absence or 
presence of microbial infection, its invasiveness and severity in critically ill patients 
with new onset fever.
methods We prospectively studied 101 patients in the intensive care unit with new 
onset fever (>38.3 °C). Routine infection parameters, lactate, procalcitonin (PCT), 
midregional pro-adrenomedullin (proADM), midregional pro-atrial natriuretic peptide 
(proANP) and copeptin (COP) were measured daily for three days after inclusion. Like-
lihood, invasiveness (by bloodstream infection, BSI) and severity of microbial infection 
were assessed by cultures, imaging techniques and clinical courses.
results All patients had systemic inflammatory response syndrome; 45% had a prob-
able or proven local infection and 12% a BSI, with 20 and 33% mortality in the ICU, 
respectively. Only peak PCT (cutoff 0.65 ng/mL at minimum) was of predictive value 
for all endpoints studied, i.e. BSI, septic shock and mortality (high risk infection) and 
infection without BSI, shock and mortality (low risk infection), at areas under the 
receiver operating characteristic curves varying between 0.67 (P=0.003) and 0.72 
(P<0.001). In multivariable analysis, the combination of C-reactive protein and lactate 
best predicted high risk infection, followed by PCT. For low risk infection, PCT was the 
single best predictor.
conclusions In critically ill patients with new onset fever, plasma PCT as a single 
variable, among old and new biomarkers, best helps, to some extent, to predict ICU-
acquired, high risk microbial infection when peaking above 0.65 ng/mL and low risk 
infection when peaking below 0.65 ng/mL.
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introduction
New onset fever in the critically ill raises the suspicion of microbial infection that may 
lead to sepsis and other harmful sequelae.1,2 Fear of undertreatment contributes to 
ordering tests and prescribing antibiotics, before results of cultures become available, 
while overtreatment carries the risk of bacterial selection and overgrowth by induc-
tion of resistance.3 The systemic inflammatory response syndrome (SIRS) criteria, 
including elevated white blood cell counts (WBC) may not accurately predict microbial 
infection and the common use of C-reactive protein (CRP) to predict infection, severity 
and outcome in critically ill patients is controversial.4-11 Even minimally elevated lac-
tate levels may predict a dismal outcome of infection during critical illness, relatively 
independent of sepsis and shock.12-14
The use of procalcitonin (PCT) for predicting microbial infection and its severity in 
the critically ill patient, rather than the general hospitalised patient,15,16 is fraught with 
difficulty, because of varying sensitivity and specificity, even if potentially higher than 
of C-reactive protein (CRP).1,5-7,9-11,17-21 This might relate to varying study populations 
and endpoints. PCT has been used to predict sepsis, i.e. the host response to either 
proven or suspected microbial infection and its severity, and rarely of microbiologically 
proven infection or bacteraemia5,9-11,22-24 whereas the latter would be more helpful 
when considering potentially life-saving antibiotics in the critically ill.25,26
Studies on PCT in critically ill patients were either small, up to 50 patients,1,5 con-
fined to medical5-7 or surgical patients, which may differ in infection and biomarker 
profiles,9,11,18,21,27 and only rarely included both.10,17,22,28
They mostly included patients at admission to the intensive care unit (ICU)4-7,18,21,22 
and were mostly not designed, with exceptions,1,10,21 to predict ICU-acquired microbial 
infection and associated risks. Studies evaluated PCT as an isolated biomarker28,29 or 
compared it with a variety of others.1,5-7,9-11,17,18,21,22,27 Single, but different,1,5,9,11 or 
multiple endpoints as organ failures and mortality have been studied.6,7,10,18,22,28 The 
heterogeneity among studies may explain, in part, why meta-analyses may contradict 
each other.15,19,20 In any case, a low or decreasing PCT in the ICU has been used to help 
deciding on antibiotics, thereby reducing potentially harmful antibiotic exposure.30,31 
In the critically ill, however, an association of a low or decreasing PCT with a low risk 
has not been documented, the cutoff PCT values used have not been validated, and a 
small increase in mortality by PCT-guided antibiotics cannot be excluded.30,31
Novel biomarker prohormones for sepsis and its severity include midregional (MR) 
pro-adrenomedullin (proADM), MR pro-atrial natriuretic peptide (proANP) and co-
peptin (COP), precursors of adrenomedullin, atrial natriuretic peptide and vasopressin, 
respectively. They are secreted by vascular endothelium, heart and pituitary, respec-
tively, and are involved in circulatory homeostasis, also during microbial infection.33-35 
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They could particularly predict the sequelae of severe microbial infection, i.e. the 
development of septic shock and associated mortality, but evaluation in the critically 
ill is scarce and inconclusive up till now.33-36
In the hypothesis that ICU-acquired infection differently increases circulating bio-
markers, depending on invasiveness and severity of disease, we compared predictive 
values for microbial infection, bloodstream infection (BSI), septic shock or mortality, 
i.e. high risk infection, and in predicting infection without these complications (low 
risk infection), in patients with new onset fever in a mixed medical/surgical ICU. The 
goal was to find the ideal, single biomarker for prediction of high and low risk infection 
and to determine the associated cutoff value, for future studies on biomarker-guided 
antibiotics in the ICU.
patients and methods
In this prospective study, approved by the ethical committee of the VU University 
Medical Centre, Amsterdam, 101 consecutive patients presenting with new onset fever 
in the 24-bed mixed medical/surgical ICU were included. The department has about 
1200 admissions annually. Limited by available research staff and office hours, we in-
cluded 21 patients from August-December 2003, 33 patients from January-December 
2004, 23 patients January-December 2005, 10 patients from January-December 2006 
and 14 patients from January-August 2007. We did not perform a power analysis since 
we could not estimate the expected results and relatively arbitrarily stopped inclu-
sion after reaching 100 patients. The Consort diagram details eligible and included 
patients (Fig. 1). All included patients or closest relatives gave informed consent prior 
to the study. Inclusion criteria were as follows. New onset fever was defined as a body 
 
 
Eligible patients N= 388 
Excluded N= 287 
- Outside office hours 
- No availability of research staff 
 
Included patients   
Probable or proven infection 
Group 1  
No infection N= 34  
Possible infection N= 10 
Group 2  
Local infection N= 45 
Group 3  
Bloodstream infection N= 12 
 
No proven infection 
figure 1. Consort diagram of patient inclusion.
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temperature of 38.3 °C, measured rectally while in the ICU, preceded by a period of 
at least 24 h in the absence of fever (<37.5 °C). Exclusion criteria were absence of 
informed consent, pregnancy and a life expectancy of less than 24 h. Enrolment in 
the study followed within 12 h after inclusion criteria were met. At inclusion (Day 0), 
demographic and historical variables were recorded, such as age, gender, prior use of 
antibiotics, including selective decontamination of the digestive tract (SDD), steroids, 
immune status (active malignancy or other causes of an immunocompromised state) 
and reasons of admission. SDD was introduced for routine use on July 17 2006 and 
consisted of 4x daily administration of an oral paste and of a suspension via the na-
sogastric tube, containing the non-absorbable antibiotics tobramycin, amphotericin-B 
and colistin, in patients longer than 48 h on mechanical ventilation and 72 h in the 
ICU. Assessment of disease severity on ICU admission was done according to the 
Simplified Acute Physiology Score II (SAPS II). Parameters to calculate the Sequential 
Organ Failure Assessment Score (SOFA) were collected on the study days, at inclusion 
(Day 0) and on Days 1 and 2. From Day 0e2 clinical data were recorded, such as 
temperature, heart rate, respiratory parameters taken from the ventilator, white blood 
cell counts (WBC) using a Sysmex SE-9000 analyzer (Toa Medical Instruments, Kobe, 
Japan), C-reactive protein (CRP, Immunoturbidimetric assay, Modular analytics <P> 
Roche diagnostics, Mannheim, Germany) and lactate (Enzymatic method, Modular 
analytics <P> Roche diagnostics, Mannheim, Germany).
Blood samples were obtained on Days 0 (at time of inclusion) and daily at 7:00 h AM 
of each of the following Days 1 and 2. Samples were collected from an arterial catheter 
in standard Vacutainer tubes (Becton, Dickinson and Company, Erembodegem, Bel-
gium) with ethylenediaminetetraacetic acid (EDTA), benzamidine and soybean trypsin 
inhibitor added. After tubes were centrifuged for 10 min at 1300 g, the plasma was 
aliquoted and stored at 80 C until further handling. Chest and sinus radiographs were 
obtained on Day 0, but other imaging was at the discretion of treating physicians. 
Blood was taken from routinely placed arterial catheters and collected in delayed 
vial entry bottles for aerobic and anaerobic cultures and processed with help of the 
BACTEC FX automatic analyzers (Becton, Dickinson and Company, Erembodegem, 
Belgium). Bottles were incubated for a maximum of five days. If the analyzers showed 
growth, Gram stains were prepared and identification and sensitivity cultures were 
processed. Other local specimens for microbial investigation were collected and sent 
to the microbiological laboratory, depending on the clinical infection, as judged by 
treating clinicians not involved in the study and unaware of PCT and novel biomarker 
results. Further investigations on infection e.g. fungal, viral or Chlamydia cultures, 
were left at the treating clinicians discretion. All collected specimens were handled 
using standardised procedures. All culture and staining results from specimens col-
lected from Day 0-2 were evaluated. Only positive cultures that were not considered 
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to reflect colonization were used for analysis. For example blood cultures containing 
coagulase-negative staphylococci were considered contaminated if only one bottle 
revealed growth. The microbial agents isolated during microbiological evaluation were 
grouped into major species classes. Patients were followed until discharge from ICU 
or hospital or death.
definitions
The SIRS criteria according to the ACCP/SCCM consensus conference criteria of: a 
body temperature >38 °C; a heart rate of >90 beats/min; a respiratory rate of >20 
breaths/min or mechanical ventilation or white cell count (WBC) of <4.0 109/L or 
>12.0 109/L, were used. When SIRS and a probable/proven infection or BSI was 
present, patients were classified as having sepsis. On the basis of the collected data 
two investigators, blinded to the study results (SHH, ABJG), decided after completion 
of the study whether a possible, probable or proven infection was present from Day 
0-2 after inclusion. In case of disagreement a third party was consulted. Source and 
likelihood of infection were based on criteria defined at the International Sepsis Forum 
Consensus Conference.37 Patients were divided into groups of increasing likelihood of 
infection and invasiveness of associated micro-organisms, suggestive of increasing 
severity: Group 1 without infection or with possible infection but negative cultures, 
Group 2 with probable or proven local infection without BSI and Group 3 with BSI 
irrespective of local infection. Shock was defined by a systolic arterial pressure <90 
mmHg or mean arterial pressure (MAP) <70 mmHg for at least 1 h despite adequate 
fluid resuscitation or requirement of vasopressor support to maintain MAP, from Day 
0-7. In the presence of sepsis, shock was considered septic shock. All-cause mortality 
refers to Day 28 (within ICU or hospital) mortality after inclusion and ICU mortality 
(also beyond 28 days). While presence of either BSI, septic shock or mortality after 
inclusion in the disease course was considered indicative of high risk microbial infec-
tion, a low risk was defined by a probable or proven infection without BSI Day 0-2 
and septic shock Day 0-7 and with survival up to 28 days. We evaluated a change of 
antibiotics during Day 0-7 and defined a change as starting or discontinuing one or 
more antibiotics of a different class. Tracheobronchitis was defined by fever with puru-
lent sputum, acquired by tracheobronchial aspiration and yielding a positive culture of 
a potential pathogen, but no indication of infiltrates on chest imaging.
Biomarker assays
Biomarkers were measured using the KryptorR compact system (Brahms Diagnos-
tica, Henningsdorf, Germany) which uses Time Resolved Amplified Cryptate Emission 
(TRACE) technology. Assays were performed according to manufacturer’s instructions. 
PCT was measured by use of the PCT sensitive, the lower detection limit being 0.02 
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ng/mL while the upper limit in healthy subjects is 0.05 ng/mL. The functional assay 
sensitivity (FAS) of the test is 0.06 ng/mL, with an intra-assay coefficient of variation 
(CV) and inter-assay CV of <6% in samples containing >0.3 ng/mL. Test specifics of 
proADM: lower detection limit 0.05 nmol/L, upper limit of normal 0.55 nmol/L. The 
FAS is 0.25 nmol/L, with an intra-assay CV of <4% and an inter-assay CV of <11% 
in samples containing 0.5e2.0 nmol/L. Test specifics of proANP: lower detection limit 
2.1 pmol/L, upper limit in healthy controls 85.2 pmol/L. A FAS of 10 pmol/L and 
an intra-assay CV of <2.5% and inter-assay CV of <6.5% in samples containing 20 
pmol/L. Test specifics for COP: lower detection limit 4.8 pmol/L, upper limit in healthy 
subjects m17.4 pmol/L. The FAS is <12 pmol/L, with an intra-assay CV of <12% and 
an inter-assay CV of <13% in samples containing >20 pmol/L.
statistical analysis
This was performed using SPSS version 15 (SPSS inc., Chicago, Ill., USA). Data are 
expressed as median (range) or as number of patients (percentage) where appropri-
ate, with median interquartile range in figures. All test were two-sided and a P<0.05 
was considered statistically significant. Exact P’s above 0.001 are given. Group differ-
ences were evaluated by use of the Kruskal-Wallis test or X2 test, where appropriate. 
Non-Gaussian distributed data were logarithmically transformed, when appropriate, 
and generalised estimating equations (GEE) were done to evaluate group effects on 
variables, taking repeated measures in the same patients into account. Areas under 
the receiver operating characteristic curves (AUROC) were calculated to evaluate 
predictive values. We evaluated predictive values of Day 0 and peak levels (Day 0-2). 
Since reporting microbiological results takes at least 1e2 days after sending specimens 
for culture, it is hypothesised that the highest biomarker level reached within D0-2 
would precede culture results and is therefore appropriate for predicting likelihood of 
infection. The peak value is the highest biomarker value measured on either D 0,1 or 
2 for each individual patient. The optimum cutoff value was calculated on the basis 
of the highest sensitivity and specificity combined. Positive and negative predictive 
values and likelihood ratios were calculated. Backward multiple logistic regression 
was done, including all logarithmic transformed biomarker levels and selecting on the 
basis of the likelihood ratio, to find the smallest set of best predictors for high and 
low risk microbial infection. To this end, high risk infection was defined by either BSI, 
septic shock or 28-day mortality. The Hosmer Lemeshow test was done to evaluate 
goodness of fit.
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results
Patient characteristics are shown in Table 1, grouped according to likelihood and invasive-
ness of microbial infection. All patients had SIRS either at inclusion (99%) or on day 1 
(1%), so that the 73 patients with probable/proven microbial infection (Groups 2 and 3) 
had sepsis. Females had higher risk for BSI than males, possibly explained by higher fre-
quency of immunodepression in females than males (females 5 (83%) vs. males 1 (17%), 
P=0.005). Table 2 shows the sources of microbial infection and the organisms involved. 
The mortality rates did not differ between patients without or with BSI (22 (25%) vs. 4 
(33%), P=0.52), nor did they differ between patients with or without septic shock (16 
(24%) vs. 10 (29%), P=0.55), even though BSI predisposed to septic shock (Table 1).
Biomarkers of infection and its invasiveness
Fig. 2 shows plasma levels in the course of time, according to likelihood and invasive-
ness of infection. Peak levels occurred at Day 0 in 61% of patients for PCT, 60% for 
COP, 55% for proADM, 48% for proANP, 46% for WBC, 40% for lactate and 35% for 
CRP, so that PCT was the first to peak. At Day 0, patients with BSI (Group 3) had higher 
CRP (in BSI 208 (52-421) vs. without BSI 113 (5-440) mg/L, P=0.043), higher lactate 
levels (1.6 (0.8-3.7) vs. 1.15 (0.4-2.2) mmol/L, P=0.018), and higher PCT values 
than patients without BSI (2.40 (0.84-73.2) vs. 0.60 (0.07-37.1) ng/mL, P=0.030). 
Peak levels are shown in Table 3. Peak CRP in BSI measured 231 (71-436) and without 
BSI 158 (5-454) mg/L (P=0.008). Lactate was higher in BSI with 1.9 (1.1e3.9) vs. 
1.4 (0.5-13.1) mmol/L without BSI (P=0.006). Peak PCT was higher in BSI with 2.92 
(0.09e75.29) than with 0.65 (0.08-37.14) ng/mL in the absence of BSI (P=0.021). 
Peak proADM was higher in BSI with 3.60 (0.82-18.57) vs. 1.60 (0.37-9.96) nmol/L in 
the absence of BSI (P=0.012).
septic shock
Day 0 CRP values were raised in patients with vs. without septic shock (174 (5-440) 
mg/L vs. 101 (5-279) mg/L, respectively, P=0.001). Day 0 PCT values were higher 
in septic shock (1.09 (0.07-73.2) ng/mL than without septic shock (0.35 (0.08-37.1) 
ng/mL (P<0.001). The Fig. 3 shows the course in time and Table 3 the peak values.
mortality
Non-survivors had higher proADM and proANP on Day 0 (2.93 (0.63-12.62) nmol/L 
and 396 (58-1684) pmol/L) than survivors (1.33 (0.05-9.47) nmol/L, P<0.001, and 
202 (22-1613) pmol/L, P=0.001, respectively). PCT on Day 0 was also increased in 
non-survivors vs. survivors (0.87 (0.14-73.18) ng/mL vs. 0.56 (0.07-45.06) ng/mL, 
P=0.040). Fig. 4 shows the course in time and Table 3 the peak values.
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table 1 Patient characteristics.
Group 1 Group 2 Group 3 P
N=44 N=45 N=12
Age (year) 63 (22-77) 61 (19-81) 67 (19-81) 0.69
Gender (male) 32 (73) 34 (76) 3 (25) 0.003
SAPS II on admission 47 (19-85) 46 (23-78) 54 (21-78) 0.10
SOFA at Day 0 8 (2-13) 7 (2-14) 10 (3-13) 0.47
Days from admission to Day 0 7 (1-78) 7 (1-77) 6 (1-45) 0.91
Temperature, °C D0 38.9 (38.4-40.0) 38.9 (38.4-40.8) 40.8 (39.3-40.3) 0.06
 D1 38.4 (36.3-40.0) 38.1 (35.9-40.4) 38.5 (37.1-40.1) 0.68
 D2 38.1 (36.4-39.9) 38.2 (36.6-39.5) 38.1 (36.3-39.4) 0.01
SIRS D0 44 (100) 45 (100) 11 (92) 0.02
 D1 41 (93) 43 (96) 11 (92) 0.83
 D2 36 (86) 38 (56) 11 (100) 0.42
Septic shock D0 0 20 (44) 8 (67) <0.001
 D1 0 20 (44) 8 (67) <0.001
 D2 0 19 (43) 8 (67) <0.001
 D7 0 25 (56) 9 (75) <0.001
ICU length of stay, days 29 (5-126) 23 (4-95) 35 (11-77) 0.38
28-day mortality 13 (30) 9 (20) 4 (33) 0.48
ICU mortality 13 (30) 9 (20) 4 (33) 0.48
immunocompetence
 Active malignancies 2 (5) 4 (9) 3 (25) 0.09
 Immunocompromised state 2 (5) 2 (4) 2 (17) 0.25
admission category
 General surgical 24 (55) 26 (58) 4 (33) 0.32
 Trauma 6 (14) 6 (13) 1 (8) 0.88
 Cardiac 4 (9) 2 (4) 0 0.42
 Vascular 6 (14) 4 (9) 0 0.36
 Respiratory insufficiency 17 (39) 20 (44) 8 (67) 0.22
 Sepsis 9 (21) 16 (36) 6 (50) 0.09
 Shock 7 (16) 8 (18) 5 (42) 0.13
 Post-CPR 5 (11) 3 (7) 2 (17) 0.54
 Neurological 5 (11) 8 (18) 1 (8) 0.57
 Other 3 (7) 5 (11) 1 (8) 0.78
treatment up to 7 days prior to inclusion
Antibiotics 37 (84) 40 (89) 10 (83) 0.77
Steroids 20 (46) 19 (42) 6 (50) 0.34
SDD 21 (48) 10 (22) 5 (42) 0.04
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Low risk infection
A change of antibiotics was as frequent in patients with a low risk (67%) as in patients 
with high risk infection (53%, P=0.62). Fig. 5 shows the course in time and Table 3 the 
peak values. Day 0 CRP was lower (87 (5-279) vs. 125 (5-440)) in low risk infection 
(P=0.02); the same applied for PCT (0.32 (0.10-37.1) vs. 0.69 (0.07-73.2), P=0.008) 
and proADM (1.26 (0.05-2.41) vs. 1.72 (0.05-12.62), P=0.008).
predictive values
Statistically significant predictions by peak values are depicted in Table 4. At a cutoff 
of 0.65 ng/mL, peak PCT carried sensitivities, specificities, positive and negative 
predictive values for BSI, septic shock and mortality of 67-77, 51-57, 14-44 and 78-
92%, respectively. This indicates high negative predictive values for all four endpoints 
studied. Plasma PCT as a single variable best helps to predict ICU-acquired, high 
risk microbial infection when peaking above 0.65 ng/mL ands low risk infection when 
peaking below 0.65 ng/mL. At Day 0, the predictive value for BSI was highest for 
lactate and PCT (AUROC 0.72 and 0.69, P=0.03 or less, respectively), for septic shock 
highest for CRP and PCT (AUROC 0.72 and 0.68, P=0.002 or lower, respectively), and 
for 28-day mortality highest for proADM and PCT (AUROC 0.74 and 0.64, P=0.04 or 
lower, respectively). At Day 0, PCT was most predictive for low risk infection, followed 
by proADM (AUROC 0.77 and 0.70, P=0.001, respectively) and CRP (AUROC 0.69, 
P=0.003). Otherwise, SAPS II score at admission predicted at an AUROC of 0.63 
(P=0.044) and SOFA score at Day 0 at 0.73 (P=0.001).
table 1 Patient characteristics. (continued)
Group 1 Group 2 Group 3 P
N=44 N=45 N=12
treatment during study day 0-7
Therapeutic hypothermia 4 (9) 2 (4) 2 (17) 0.23
Antibiotics 41 (93) 42 (93) 12 (100) 0.65
Change in antibiotics 24 (55) 29 (64) 9 (75) 0.37
Steroids 19 (43) 23 (51) 8 (67) 0.88
SDD 23 (52) 9 (20) 5 (42) 0.006
Mechanical ventilation 43 (98) 40 (89) 12 (100) 0.14
duration, days 24 (3-123) 17 (3-82) 29 (7-77) 0.09
Inotropic/vasopressor 29 (67) 24 (55) 9 (82) 0.18
Renal replacement 7 (16) 0 1 (8) 0.02
Surgery 9 (21) 7 (16) 1 (8) 0.58
Median (range), or number (percentage), where appropriate; CPR= cardiopulmonary resuscita-
tion. SAPS= simplified acute physiology score; SOFA= sequential organ failure assessment score; 
ICU= intensive care unit; SDD= selective decontamination of the digestive tract. Group 1= no 
or possible infection; Group 2= probable or proven infection; Group 3= bloodstream infection.
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table 2 Infection, sources and associated micro-organisms.
Group 1 Group 2 Group 3 P
N=44 N=45 N=12
local infection
Tracheobronchitis 1 (2) 18 (40) 2 (17) <0.001
VAP 1 (2) 7 (16) 1 (8) 0.09
HAP 0 2 (4) 0 0.28
AP 2 (5) 1 (2) 0 0.66
Pleurisy/empyema 0 3 (7) 0 0.15
Sinusitis 2 (5) 6 (13) 2 (17) 0.27
Catheter infection 3 (7) 4 (9) 4 (33) 0.03
Endocarditis 0 1(2) 0 0.53
Peritonitis 0 6 (13) 0 0.02
Pancreatitis 0 1 (2) 2 (17) 0.01
Skin and soft tissue 2 (5) 5 (11) 1 (8) 0.52
Meningitis 0 1 (2) 0 0.53
Primary bacteraemia - - 3 (25) -
local microbiology
Enterobacteriaceae 2 (22) 13 (31) 4 (33) 0.84
Staphylococci 1 (11) 11 (26) 5 (42) 0.29
Pseudomonadaceae 0 10 (24) 1 (8) 0.15
Enterococci 2 (22) 4 (10) 1 (8) 0.52
Xanthomonadaceae 1 (11) 6 (14) 0 0.38
Yeasts 0 8 (19) 2 (17) 0.36
Herpesviridae 1 (11) 2 (5) 0 0.50
Miscellaneous 3 (33) 28 (66) 2 (17) 0.004
Blood microbiology
Enterobacteriaceae - - 3 (25) na
Staphylococci - - 4 (33) na
Pseudomonadaceae - - 1 (8) na
Enterococci - - 2 (17) na
Yeasts - - 2 (17) na
Miscellaneous - - 1 (8) na
Median (range) or number (percentage) where appropriate; Abbreviations: D= day; SIRS= sys-
temic inflammatory response syndrome. na= not applicable; VAP= ventilator-associated pneu-
monia; HAP= hospital-acquired pneumonia; AP= aspiration pneumonia
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figure 2. Course of plasma levels (median and interquartile range) in febrile criti-
cally ill patients with or without local infection or bloodstream infection.
Symbols: • no/possible infection (Group 1, N=44); ■ local infection (Group 2, N=45); ▲ blood 
stream infection (Group 3, N=12). In generalised estimating equations (GEE) evaluating BSI vs. 
non-BSI: for CRP P=0.003, lactate P<0.001, PCT P=0.011, and proADM P=0.007.
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table 3 Peak values of biomarkers in the groups.
Day 0-2 Infection Group 1 Group 2  Group 3 P
N=44  N=45  N=12
WBC, x109/L 13.2 (5.5-38.5) 12.8 (0.2-25.7) 20.6 (2.5-81.7) 0.08
CRP, mg/L 142 (27-440) 153 (5-484) 231 (71-436) 0.004
Lactate, mmol/L 1.3 (0.5-2.3) 1.4 (0.5-13.1) 1.9 (1.1-3.9) 0.02
PCT, ng/mL 0.72 (0.09-13.9) 0.56 (0.08-37.1) 2.92 (0.09-75.3) 0.058
proADM, nmol/L 1.93 (0.50-9.80) 1.52 (0.37-9.96) 3.60 (0.82-18.57) 0.03
proANP, pmol/L 293 (77-2,037) 187 (23-823) 342 (47-874) 0.09
COP, pmol/L 34.4 (5.0-157.9) 27.3 (5.0-97.4) 33.7 (5.9-154.4) 0.44
Day 0-7 No septic shock Septic shock P
N=67 N=34
WBC, x109/L 12.9 (4.8-38.5) 15.0 (0.2-81.7) 0.16
CRP, mg/L 146 (5-440) 243 (5-484) <0.001
Lactate mmol/L 1.4 (0.5-2.5) 1.6 (0.8-13.1) 0.07
PCT, ng/mL 0.57 (0.09-37.1) 1.28 (0.08-75.3) 0.005
proADM, nmol/L 1.75 (0.37-9.80) 1.89 (0.39-18.57) 0.23
proANP, pmol/L 296 (47-2,037) 210 (23-874) 0.28
COP, pmol/L 31.5 (5.0-157.9) 29.5 (5.0-154.4) 0.46
Day 0-28 Survivors Non-survivors P
N=75 N=26
WBC, x109/L 12.5 (2.5-27.5) 16.8 (0.2-81.7) 0.08
CRP, mg/L 177 (5-440) 201 (38-484) 0.30
Lactate, mmol/L 1.3 (0.5-3.5) 1.8 (0.9-13.1) 0.002
PCT, ng/mL 0.57 (0.08-45.1) 1.10 (0.23-75.3) 0.009
proADM, nmol/L 1.52 (0.37-9.47) 3.30 (0.63-18.57) 0.001
proANP, pmol/L 240 (23-1,613) 385 (61-2,037) 0.006
COP, pmol/L 27.3 (5.0-154.4) 38.1 (5.0-157.9) 0.04
Day 0-28 low risk No Yes P
infection N=84 N=17
WBC, x109/L 14.2 (0.2-81.7) 11.9 (4.8-21.6) 0.11
CRP, mg/L 198 (5-484) 155 (5-279) 0.12
Lactate, mmol/L 1.5 (0.5-13.1) 1.3 (0.5-2.1) 0.23
PCT, ng/mL 0.90 (0.08-75.3) 0.32 (0.11-37.14) 0.004
proADM, nmol/L 1.97 (0.39-18.6) 1.35 (0.37-2.98) 0.02
proANP, pmol/L 269.6 (23.2-2037.0) 194.4 (70.3-654.3) 0.22
COP, pmol/L 33.7 (5.0-157.9) 21.7 (5.0-73.4) 0.19
Median (range); Abbreviations: CRP= C-reactive protein, WBC= white blood cell count, PCT= 
procalcitonin, proADM= midregional pro-adrenomedullin, proANP= midregional pro-atrial natri-
uretic peptide, COP= copeptin. Group 1= no or possible infection; Group 2= probable or proven 
infection; Group 3= bloodstream infection.
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figure 3. Course of plasma levels (median and interquartile range) in febrile criti-
cally ill patients with or without septic shock.
Symbols: • no septic shock (N=67), ■ septic shock (N=34). In generalised estimating equations 
(GEE): for CRP P=0.009, lactate P=0.044 and PCT P=0.006.
A case for procalcitonin 35
  







 



  






 



  








 




  






 



  








 



 



  







 



 



figure 4. Course of plasma levels (median and interquartile range) in febrile criti-
cally ill patients, surviving or non surviving.
Symbols: • survivors (N=75) and ■ non-survivors (N=26). In generalised estimating
equations (GEE): for lactate P=0.001, for PCT P=0.012, for proADM P<0.001, for proANP 
P=0.006 and for COP P=0.027.
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multivariable analysis
For high risk infection, the combination of peak CRP and lactate predicted best (P=0.033 
and 0.001, respectively; Hosmer Lemeshow X2 8.3, df8, P=0.40), followed by PCT as 
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figure 5. Course of plasma levels (median and interquartile range) in febrile criti-
cally ill patients, with low or high risk microbial infection.
Symbols: • low risk infection (N=17) and ■ high risk infection (N=84). In generalised estimating 
equations (GEE): for PCT P=0.01 an proADM P=0.001)
A case for procalcitonin 37
table 4 Prediction by peak values of biomarkers.
WBC CRP Lactate PCT proADM proANP COP
x109/L mg/L mmol/L ng/mL nmol/L nmol/L pmol/L
Bloodstream infection Day 0-2
Cutoff 20.3 196 1.5 2.44 4.3 - -
AUROC 0.70 0.74 0.75 0.71 0.72 - -
P 0.02 0.006 0.004 0.02 0.01 - -
Sn 58 92 83 58 50 - -
Sp 84 60 61 85 91 - -
PPV 33 23 23 35 43 - -
NPV 94 98 96 94 93 - -
LHR 3.7 2.3 2.2 4.0 5.6 - -
Septic shock Day 0-7
Cutoff - 208 - 1.98 - - -
AUROC - 0.75 - 0.67 - - -
P - <0.001 - 0.003 - - -
Sn - 71 - 44 - - -
Sp - 78 - 88 - - -
PPV - 62 - 65 - - -
NPV - 84 - 76 - - -
LHR - 3.2 - 3.7 - - -
Mortality Day 0-28
Cutoff - - 1.7 0.65 2.79 565 31.5
AUROC - - 0.71 0.67 0.73 0.68 0.63
P - - 0.001 0.007 <0.001 0.005 0.04
Sn - - 60 77 62 46 69
Sp - - 75 57 81 93 57
PPV - - 44 39 53 71 36
NPV - - 85 88 86 83 84
LHR - - 2.4 1.8 3.3 6.9 1.6
Low risk infection Day 0-28
Cutoff - - - <0.65 <1.91 - -
AUROC - - - 0.72 0.67 - -
P - - - <0.001 0.005 - -
Sn - - - 88 88 - -
Sp - - - 60 51 - -
PPV - - - 31 27 - -
NPV - - - 96 96 - -
LHR - - - 2.2 1.8 - -
Abbreviations: D= day; WBC= white blood cell count; CRP= C-reactive protein, PCT= procal-
citonin, proADM= midregional pro-adrenomedullin, proANP= midregional pro-atrial natriuretic 
peptide, COP= copeptin, AUROC= area under the receiver operating characteristic curve, P= p 
value, Sens= sensitivity, Spec= specificity, PPV= positive predictive value, NPV= negative pre-
dictive value, LHR= likelihood ratio; non-significant data have been omitted.
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the best single predictive variable (P=0.017; Hosmer Lemeshow X2 5.1, df 8, P=0.75). 
For low risk infection, PCT was the single best predictive variable (P=0.015; Hosmer 
Lemeshow X2 9.8, df8, P=0.28).
discussion
This study suggests that old and new biomarkers in critically ill patients with new onset 
fever differ in their predictive value according to invasiveness and severity of microbial 
infection, and that PCT may be of value as a single predictor of both high and low risk 
ICU-acquired infection.
We found that 57 of 101 (56%) febrile, critically ill patients had a probable/
proven local infection or BSI, which agrees with the literature on comparable patient 
populations, in spite of female preponderance of patients with BSI’s in our study.2,21,26 
Sources, micro-organisms and mortality rates are also in agreement with other stud-
ies, including those on ICU-acquired bacteraemia.2,10,25,26
The associations between invasiveness of microbial infection and development of 
septic shock is not beyond expectations either. Since all patients had SIRS, the syn-
drome had no predictive value for infection and all patients with infection thus suffered 
from new onset sepsis in the ICU. Nevertheless, the (peak) WBC count had some 
predictive value for likelihood and invasiveness of microbial infection, in contrast to the 
literature8, but was of no predictive value for septic shock and mortality, in agreement 
with the literature.4 Peak CRP predicted, to a certain extent, both BSI and septic 
shock but not mortality in our patients, the latter again in agreement with the litera-
ture.4,6-9,18 The value of these two commonly applied surrogate indicators of microbial 
infection and its severity in the critically ill is thus limited. In contrast, minimally 
elevated lactate levels were of some predictive value for BSI and ICU mortality, in line 
with previous studies for the latter.12-14 The predictive value of lactate for BSI is a novel 
finding. Early lactate production even before onset of shock in bacteraemic patients 
might be explained by an increase in cellular Na+-K+ ATP-ase activity, among others.38
We found PCT to be helpful in discriminating BSI from infections without BSI, as 
reported before.1,7,10,24 though predictive values of PCT were somewhat lower than in 
other patient populations. In these studies, PCT on admission appeared helpful in pre-
dicting, irrespective of localisation, a suspected infectious cause of SIRS (sepsis) and 
its severity, as compared to non-infected, critically ill patients with SIRS.5,6,9,18,21,22,28 
This can be explained by our inclusion criteria of ICU-acquired fever in patients with 
prior infection, surgery or other conditions that may confound PCT. Few studies that 
specifically addressed new onset fever in the ICU yielded highly variable results for 
PCT.1,10,20,21 Nevertheless, for the 4 major endpoints, i.e. BSI, septic shock, mortality 
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and low risk infection, PCT was superior to lactate and our results thus agree with 
improved prognostication in septic shock by PCT over lactate.6,32 Combining biomark-
ers23,32 has only rarely been done but may improve prediction.16 In multivariable 
analysis of high risk infection in our critically ill patients with new onset fever, the 
combination of CRP and lactate proved superior, directly followed by PCT. For low 
risk infection also, PCT proved the single best predictive variable. Finally, PCT peaked 
earlier than the other markers. The superior predictive value of PCT over the other 
biomarkers for all endpoints studied can be explained, among others, by the kinetics 
in response to infection, in parallel with its invasiveness and severity.39 In contrast 
to PCT, other prohormones may only transiently increase upon microbial products, 
whereas the response of WBC and CRP may be relatively slow.39
PCT values above 0.25-0.5 ng/mL have been used to guide starting or continuing 
antibiotics in the ICU30,31 and our study suggests a higher cutoff at 0.65 ng/mL to 
discriminate between high and low risk microbial infection in ICU- acquired fever, 
for which empiric antibiotics could be instituted or withheld, respectively, in future 
studies.25,26 Many patients were on antibiotics even when fever was unlikely associated 
with microbial infection, representing potential overtreatment. We could not identify 
an effect of changing antibiotics on outcome but did not evaluate appropriateness in 
the absence of uniformly accepted criteria.26
Whereas other investigators found a difference in proADM or COP between infected 
and non-infected and non-surviving and surviving critically ill patients,33-35 we found 
varying predictive values of the novel biomarker prohormones. However, proADM was 
predictive in 3 of 4 endpoints evaluated and thereby directly ranked behind PCT. The 
greater predictive value than that of PCT for outcome is in accordance with other 
studies.36 Nonetheless, proADM levels did not supplement predictive values of PCT in 
multivariable analyses. We observed only minor predictive value of COP in our study 
in agreement with prior observations.35
Limitations of the study include the evaluation of new onset fever only, the hetero-
geneity of the study population and the persistently imperfect predictions by biomark-
ers of (severity of) infection. Heterogeneity could also be regarded as an advantage, 
however, concerning generalisibility of results. We separately studied medical and 
surgical patients and found no difference. The introduction of SDD did not change 
the predictive values of the biomarkers in this study, which may help in deciding on 
the use of biomarkers during SDD. That the percentage of fever from infectious vs. 
non-infectious causes decreased after introduction of SDD is in line with expectations. 
Another advantage of our study is the rigid documentation and classification of infec-
tion as an endpoint.
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conclusions
In conclusion, our study in critically ill patients with new onset fever suggests that 
plasma PCT best serves as a single variable, among old and new biomarkers, to predict 
high and low risk microbial infection, although this prediction remains imperfect. The 
study may support evaluation of clinical decision making on starting or postponing 
empiric antibiotics at a cutoff of 0.65 ng/mL for peak PCT in ICU- acquired fever, in 
future studies.
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aBstract
objective Elective oesophagectomy with gastric-tube reconstruction carries a high 
risk for complications. Early and accurate diagnosis could improve patient manage-
ment. Increased C-reactive protein (CRP) levels may be associated with any, surgical 
or infectious, complication and procalcitonin (PCT) specifically with infectious compli-
cations.
methods We measured CRP and PCT on postoperative days 0, 1, 2 and 3 in 45 con-
secutive patients. Complications were recorded up to 10 days post-oesophagectomy.
results Twenty-eight patients developed a postoperative complication (5 surgical, 14 
infectious, 9 combined surgical/infectious, including anastomotic leakage), presenting 
on day 3 or later. Elevated day 2, 3 and a rise in CRP preceded the diagnosis of general 
or combined surgical/infectious complications (minimum AUROC 0.75, P=0.006). El-
evated day 3 PCT preceded combined complications (AUROC 0.86, P<0.001). High day 
1 and 3 PCT levels preceded anastomotic leakage (minimum AUROC 0.76, P=0.005), 
as did the day 3 CRP levels and their increases (minimum AUROC 0.78, P=0.002).
conclusions This small study suggests that high or increasing CRP levels may precede 
the clinical diagnosis of general or surgical/infectious complications after oesopha-
gectomy. Elevated PCT levels may more specifically and timely precede combined 
surgical/infectious complications mainly associated with anastomotic leakage.
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introduction
Early complications after elective oesophagectomy and gastric-tube reconstruction 
are associated with increased morbidity and mortality.1-5 Recognition of patients at 
risk for complications before presentation of full blown symptoms could lead to early 
diagnosis and treatment which may improve outcome. However, the early recogni-
tion of complications by clinical characteristics and parameters in individual patients 
remains difficult, except perhaps for pulmonary complications.2,3,6 Oesophagectomy in 
itself induces a strong inflammatory response and the value of systemic inflammatory 
response syndrome (SIRS) criteria fever, leukocytosis, tachypnea and tachycardia for 
the early diagnosis of complications is limited.6-8 On the other hand, inflammatory 
biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) might be useful in 
the early diagnosis of not yet clinically symptomatic postoperative complications. 
Previous studies reported an association between elevated CRP levels and (infectious) 
complications, sepsis, and mortality after esophagectomy.8-12 However, CRP levels did 
not discriminate between surgical and infectious complications, requiring different 
therapeutic management strategies.6,8-10,12,13 PCT is an allegedly more specific marker 
of severe infection and complications after surgery than CRP,14-16 but the literature 
is inconclusive in this respect.17,18 So far, only five studies reported on PCT levels 
post-esophagectomy,1,11,13,19,20 of which only two focused on postoperative infectious 
complications.11,13 The latter studies suggested that PCT is useful for the diagnosis of 
infectious complications and discriminating sepsis from SIRS post-oesophagectomy. 
The discriminating ability of PCT for complication subtypes is unknown, however.
We hypothesized that CRP is a sensitive but non-specific marker of developing com-
plications after oesophagectomy, while PCT is a more specific marker of developing 
severe postoperative infections. We thus compared the use of CRP and PCT for early 
diagnosis of surgical and infectious complications.
patients and methods
This prospective observational study, approved by the medical ethical committee of 
the Erasmus Medical Centre (MEC-2010-199), was conducted between September 
2011 and December 2012. Forty-five consecutive adult patients were included after 
giving written informed consent prior to surgery. We did not perform a power analysis 
for this proof of principle study. Because of competing studies and activities this proof 
of principle study was limited in time and therefore we could include only 45 patients 
in the time interval indicated. Oesophagectomy and gastric-tube reconstruction was 
performed by the transthoracic or transhiatal approach.21 The gastric-tube reconstruc-
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tion was performed by handsewn end-to-end or semimechanical end-to-side anasto-
mosis.22 After admission to the intensive care unit (ICU), patients were taken care of 
by board-certified intensivists unaware of biomarker results.
study protocol
Upon ICU admission (day 0), baseline patient characteristics were recorded. Disease 
severity was estimated using the acute physiology and chronic health evaluation II 
(APACHE II)-score and organ failure was calculated by the sequential organ failure 
assessment (SOFA)-score. The preoperative risk assessment was done by using the 
American Society of Anaesthesiology (ASA) classification and Portsmouth predictor 
modification of the physiological and operative severity score for the enumeration 
of mortality and morbidity (P-POSSUM). Clinical parameters and blood samples for 
routine laboratory parameters, leukocyte counts, CRP and PCT levels were collected 
directly postoperatively on ICU admission (day 0), and in the morning of postoperative 
day 1, 2, 3. Leukocyte counts were measured using the Sysmex SE-9000 analyzer 
(Toa Medical Instruments, Kobe, Japan), normal values are 3.5-10*109/L. CRP was 
measured by an Immunoturbidimetric assay (Modular analytics <P> Roche diagnos-
tics, Mannheim, Germany), normal values are <9 mg/L. PCT was measured using 
the PCT-sensitive for the Kryptor compact system (Brahms diagnostica, Henningsdorf, 
Germany). Assays were performed according to manufacturer’s guidelines, the lower 
detection limit being 0.02 ng/mL, with an upper limit in healthy volunteers of 0.05 ng/
mL. The functional assay sensitivity (FAS) of this test is 0.06 ng/mL, with an intra-
assay coefficient of variation (CV) and inter-assay CV of <6% in samples containing 
>0.3 ng/mL.
definitions
All complications up to 10-days post-oesophagectomy as decided by attending physi-
cians were recorded, only if additional medical or surgical treatment was required, 
notably grade 2 or higher on the Accordion severity grading system.4,5 The definitions 
of complications used in this study are depicted in Table 1. The 10-day cutoff was 
chosen based on a previous study from this group.12 Infections were defined according 
to the International Sepsis Forum consensus conference criteria,23 as agreed upon by 
the attending intensivists. Diagnostic imaging and collection of specimens and blood 
for microbial culture were left at the attending intensivists discretion. Specimen were 
processed according to standardized culture protocols and Gram stains were prepared. 
Cultures reflecting colonization rather than infection were excluded from final analysis. 
For example, blood cultures containing coagulase-negative staphylococci were con-
sidered contaminated if only one bottle showed growth. Because reporting of definite 
culture results can take several days the day of specimen collection was considered 
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the day of infection diagnosis. Patients were considered to have sepsis when present-
ing at least two SIRS criteria: body temperature <36 °C or >38.3 °C, heart rate >90 
beats/min, respiratory rate >20 breaths/min or mechanical ventilation, a leukocyte 
count of either <4.0 *109/L or >12.0 *109/L, in the presence of a probable or proven 
infection, according to American College of Chest Physicians/Society of Critical Care 
Medicine guidelines.24 Shock was defined by a systolic pressure <90 mmHg or a mean 
arterial pressure <60 mmHg for at least 1 hour, despite adequate fluid resuscitation, 
or requirement of vasopressor support to maintain mean arterial pressure. Shock in 
the presence of sepsis was considered septic shock. We report 30-day mortality.
statistical analysis
Patients were categorized into two groups, i.e. patients developing complications and 
without complications. In addition, to translate the results to clinical recommendations 
and to reflect complication severity, patients with postoperative complications were 
table 1. Definition of complications.
complication Definition
Surgical  
 Anastomotic leakage Esophagoenteric leak confirmed by endoscopy or esophageal 
contrast videography that requires local treatment, surgical 
treatment, or removal of conduit.
 Pleural effusion Pleural effusion confirmed by radiology that requires drainage.
 Chyle leak Chylomicrons in pleura aspirate or milky discharge from chest tube 
at initiation of enteral feeding.
 Laryngeal nerve palsy Clinically suspected vocal cord paralysis confirmed by laryngoscopy.
 Conduit ischemia/necrosis Circular conduit ischemia/necrosis confirmed by endoscopy and/or 
surgically that requires local treatment or removal of conduit.
 Thromboembolic disease Deep venous thrombosis or pulmonary embolus.
Infectious  
 Pneumonia New infiltrate on chest radiograph and positive tracheal aspirate 
cultures that requires antibiotic treatment.
 Empyema Pleural effusion on chest radiograph and positive culture of 
aspirated specimen that requires antibiotic and radiological or 
surgical treatment.
 Abscess Intra-thoracic (mediastinal) or intra-abdominal abscess confirmed 
by radiology with positive culture of aspirated specimen 
that requires antibiotic, radiological, or surgical treatment.
 Wound infection Erythematous wound, with effluent of pus and/or positive culture 
that requires opening of wound and antibiotics.
 Gastrointestinal Stool culture positive for microbial pathogens that requires 
antibiotic treatment.
 Urinary tract Positive urine culture and urine sediment that require antibiotic 
treatment.
 Bacteraemia Blood samples showing positive growth and/or positive Gram stain, 
not reflecting colonization that requires antibiotic treatment.
Patients could suffer from multiple complications simultaneously
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categorized into 3 mutually exclusive complication groups. Patients could either have 
purely surgical complications, purely infectious complications, or combined surgical 
and infectious complications. We studied biomarker levels at day 0-3 and their frac-
tional change (∆) at day 3, i.e. day 3 divided by day 0 biomarker levels. Since most 
symptoms of complications appear after postoperative day 3, the levels measured be-
tween day 0-3 were considered early diagnostic for complications presenting between 
days 4-10. We used IBM SPSS statistics for Windows version 20 (IBM SPSS, Chicago, 
IL, USA) to analyze the data, except for analyzing the area under the receiver operat-
ing characteristic curve (AUROC). We present data as median (interquartile range) 
since many continuous data were non-normally distributed (Kolmogorov-Smirnov test 
P<0.05). We used a Kruskal-Wallis and Mann-Whitney U test to study group differ-
ences in continuous variables and the X2 or Fisher exact test for categorical variables. 
To evaluate the early diagnostic value of biomarker levels for groups we calculated 
the area under the receiver operating characteristic curves (AUROC), for which non-
Gaussian data were logarithmically transformed. Only the AUROC analyses were per-
formed using MedCalc for Windows, version 13 (MedCalc Software, Ostend, Belgium). 
We considered an AUROC ≥0.70 as clinically relevant. The optimal diagnostic cutoff 
value was calculated as suggested by Zweig and Campbell.25 To calculate the optimal 
criterion this method takes the disease prevalence and cost of true and false positive 
and negative decisions into account.25 The Holm-Bonferroni method was used to cor-
rect for multiple testing.26 We used multiple logistic regression with backward selection 
of logarithmically transformed biomarker levels to study their interdependency for 
the diagnosis of postoperative complications in general, complication subtypes and 
anastomotic leakage. We performed the Hosmer Lemeshow test to evaluate the good-
ness of fit. All tests were two-sided and P-values <0.05 were considered statistically 
significant, exact P-values are given unless <0.001.
results
Twenty-eight patients (62%) suffered from a postoperative complication, of whom 5 
had a surgical complication, 14 an infectious complication, and 9 combined surgical/
infectious complications (Table 2). The manifestation of postoperative complications 
was on day 3 or later in all patients and in 92% of cases complications presented on 
day 4 or later. Patients developing combined surgical/infectious complications had 
more complications than patients in the other complication groups (3 vs. 1 complica-
tion). Table 3 shows baseline characteristics for patients developing complications and 
without complications. The number of female patients was higher in the infectious 
and combined surgical/infectious than in the surgical complication group. Almost all 
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patients suffered from SIRS at some point during the first 10-days postoperatively. 
Patients developing infectious complications had received antibiotics less often than 
the other patient groups. Patients suffering surgical or combined complications had 
a longer hospital stay than patients with an uncomplicated recovery (P=0.03 and 
P=0.02, respectively). All patients survived until 30 days postoperatively. The preop-
erative World Health Organization (WHO) performance score and pulmonary function 
tests were not predictive of postoperative complications. To avoid major overlap we 
do not separately report the baseline characteristics of patients with versus without 
anastomotic leak.
Biomarker levels prior to diagnosis of complications
Figure 1 shows the data (days 0-3) for patients developing any complication and those 
without complications. Only statistically significant AUROC values are presented in 
Table 4. The day 3 leukocyte counts were higher in patients developing any complica-
tion than in those without, but the optimal cutoff value in AUROC was below the upper 
limit of the normal range. The day 2 and 3 CRP levels and their rise were higher in 
patients developing complications than in those without and had diagnostic value with 
table 2. Complications up to 10 days post esophagectomy.
surgical complication  
(N = 5)
infectious complication  
(N = 14)
combined s/i complications  
(N = 9)
Anastomotic leak Pneumonia, wound infection Anastomotic leak, chyle leak,  
wound infection
Anastomotic leak Pneumonia, wound infection Anastomotic leak, pneumonia,  
wound infection
Pleural effusion, chyle leak Pneumonia Anastomotic leak, pneumonia
Chyle leak Pneumonia Anastomotic leak, abscess,  
wound infection
Chyle leak Pneumonia Anastomotic leak, pleural 
effusion, abscess, wound infection
 Pneumonia Anastomotic leak, pneumonia
 Pneumonia Anastomotic leak, wound 
infection, pneumonia, empyema
 Pneumonia Anastomotic leak, 
pneumonia, empyema
 Pneumonia Chyle leak, abscess, pneumonia
 Wound infection  
 Wound infection  
 Wound infection  
 Urinary tract infection  
 Urinary tract infection  
Complications presented no sooner than day 3; in 92% of cases, complications presented on day 
4 or after. Abbreviations: s/i surgical/infectious. 
52 Chapter 3
table 3. Baseline characteristics.
 
uncomplicated complicated
(N = 17) (N = 28) p1
surgical 
(N = 5)
infectious 
(N = 14)
combined 
s/i (N = 9) p2
Sex (M) 16 (94) 23 (82) 0.39 2 (40) 12 (86) 9 (100) 0.009
Age (years) 62 (14) 63 (17) 0.52 60 (15) 65 (14) 63 (20) 0.89
BMI (cm2/kg) 27.8 (4.7) 23.8 (5.0) 0.05 22.7 (8.3) 25.3 (6.1) 23.5 (2.9) 0.12
WHO performance score
0 7 (41) 14 (50)
0.57
7 (50) 2 (40) 5 (56)
0.57
1 10 (59) 14 (50) 7 (50) 3 (60) 4 (44)
Preoperative pulmonary function
FEV1 (% predicted) 113 (27) 98 (21) 0.04 96 (27) 100 (1) 94 (22) 0.19
VC (% predicted) 112 (28) 111 (16) 1.00 115 (17) 108 (2) 106 (22) 0.58
ASA class
I 2 (12) 10 (11)
0.86
2 (40) 0 1 (11)
0.08II 13 (77) 20 (71) 1 (20) 11 (79) 8 (89)
III 2 (12) 5 (18) 2 (40) 3 (21) 0
P-POSSUM score 35 (10) 34 (5) 0.50 34 (3) 33 (8) 35 (3) 0.70
Cell type
Squamous cell carcinoma 2 (12) 9 (32)
0.28
4 (29) 2 (40) 3 (33)
0.85
Adenocarcinoma 13 (77) 18 (64) 6 (64) 3 (60) 6 (67)
Small cell neuroendocrine 
carcinoma
1 (6) 1 (4) 1 (6) 0 0
Miscellaneous 1 (6) 0 0 0 0
Clinical stage
T
1 1 (6) 0 0.10 0 0 0 0.26
2 2 (12) 5 (18) 2 (14) 1 (20) 2 (22)
3 11 (65) 19 (68) 12 (86) 3 (60) 4 (44)
4 3 (20) 0 0 0 0
Unknown 0 4 (14) 0 1 (20) 3 (33)
N
0 5 (29) 9 (32) 0.67 5 (36) 2 (40) 2 (22) 0.53
1 5 (29) 9 (32) 3 (21) 2 (40) 4 (44)
2 6 (35) 9 (32) 6 (43) 1 (20) 2 (22)
3 1 (6) 0 0 0 0
Unknown 0 1 (4) 0 0 1(11)
M
0 17 (100) 26 (93) 0.52 14 (100) 5 (100) 7 (78) na
Unknown 0 2 (7) 0 0 2 (22)
Neoadjuvant 
chemoradiotherapy
14 (82) 26 (93) 0.35 5 (100) 13 (93) 8 (89) 0.66
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table 3. Baseline characteristics. (continued)
 
uncomplicated complicated
(N = 17) (N = 28) p1
surgical 
(N = 5)
infectious 
(N = 14)
combined 
s/i (N = 9) p2
Surgical approach
TH 6 (35) 10 (36) 1.00 2 (40) 5 (36) 3 (33) 1.00
TT 11 (65) 18 (64) 3 (60) 9 (64) 6 (67)
Open procedure 16 (94) 25 (59) 1.00 12 (86) 5 (100) 8 (89) 0.74
Laparoscopic procedure 1 (6) 3 (11) 2 (14) 0 1 (11)
Hand sewn end-to-end 7 (41) 17 (61) 0.23 8 (57) 3 (60) 6 (67) 0.61
Semimechanical side-to-end 10 (59) 11 (39) 6 (43) 2 (40) 3 (33)
Operation duration (min) 414 (186) 383 (136) 0.40 383 (171) 382 (140) 410 (156) 0.79
Blood loss (mL) 1000 (800) 675 (869) 0.33 600 (765) 725 (794) 700 (960) 0.33
APACHE II score 8 (5) 8 (3) 0.47 8 (2) 7(6) 9 (4) 0.82
SOFA score
Day 0 7 (2) 6 (4) 0.36 4 (3) 5 (3) 5(2) 1.00
Day 1 5 (3) 4 (5) 0.18 5 (2) 4 (6) 4 (2) 0.47
Day 2 3 (1) 3 (4) 0.92 3 (4) 2 (5) 4 (2) 0.97
Day 3 1 (2) 1 (4) 0.15 3 (2) 2 (3) 3 (5) 0.26
SIRS (days 0–10) 13 (77) 27 (96) 0.06 5 (100) 14 (100) 8 (89) 0.17
Sepsis (days 0–10) 0 17 (64) <0.001 0 11 (79) 6 (67) <0.001
Septic shock (days 0–10) 0 6 (21) 0.07 0 3 (21) 3 (33) 0.06
Prophylactic antibiotics i.o. 17 (100) 22 (100) na 5 (100) 14 (100) 9 (100) na
Antibiotics received (days 
0–10)
4 (24) 20 (71) 0.002 10 (71) 3 (66) 7 (78) 0.02
Microbiology
Enterobacteriaceae 0 7 (25) 0.03 0 5 (36) 2 (22) 0.03
Pseudomonaceae 0 5 (18) 0.14 0 3 (21) 2 (22) 0.15
Staphylococcaceae 0 1 (4) 1.00 0 1 (7) 0 0.50
Streptococcaceae 0 1 (4) 1.00 0 0 1 (11) 0.25
Miscellaneous 0 6 (21) 0.07 0 3 (21) 3 (33) 0.06
Vasopressor need (days 
0–10)
7 (40) 12 (43) 0.91 2 (40) 5 (36) 5 (56) 0.82
ICU days 3 (1) 3 (1) 0.64 3 (2) 4 (2) 3 (5) 0.43
In hospital days 12 (6) 16 (10) 0.007 20 (12) 15 (6) 19 (12) 0.02
30-day mortality 0 0 na 0 0 0 na
Median (inter-quartile range), number (percentage), where appropriate; P1 comparison of un-
complicated vs. complicated patients by Mann-WhitneyU or Fisher’s exact test where appropri-
ate. P2 comparison of uncomplicated patient and all three complication groups by Kruskal-Wal-
lis H or X2test, where appropriate.
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, ASA class American So-
ciety of Anesthesiology physical status classification, BMIbody mass index, FEV1 forced expirato-
ry volume in 1 s, VC vital capacity, ICU intensive care unit, i.o. intra-operatively, m male, na not 
applicable, P-POSSUM Portsmouth Physiological and Operative Severity Score for the enU-
meration of Mortality and morbidity, s/i surgical/infectious, SIRS Systemic Inflammatory Re-
sponse Syndrome, SOFA Sequential Organ Failure Assessment, TH transhiatal, TT transthorac-
ic, WHO World Health Organization.
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figure 1. Early leukocyte and plasma biomarker levels (median and interquartile 
range) for complications up to 10 days after elective esophagectomy.
● without complications (N=17), ■ with complications (N=28). Abbreviations: CRP- C-reactive 
protein, PCT- procalcitonin. P values refer to Mann-Whitney U test.
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high sensitivities of optimal cutoff values. The fractional change of CRP levels on day 
3 vs. day 0 in patients developing complications was 46 (91) and in patients without 
complications 19 (27), P=0.04. PCT levels could not discriminate between patients 
developing any type of complication and those without.
Biomarker levels prior to diagnosis of complication subtypes
Figure 2 shows the data (days 0-3) for complication subtypes. On day 3, leukocyte 
counts were higher in patients with combined surgical/infectious complications than 
those without complications (P=0.01). The CRP levels on day 2 and 3 were higher in 
patients with infectious complications than in those without complications (P=0.03), 
whereas day 3 CRP levels were higher in patients with combined complications than in 
those without (P=0.01). The fractional increase in CRP was higher in patients develop-
ing combined complications, by 76 (41), than in patients without complications, by 
19 (27), P=0.02. On day 3, PCT levels were higher in patients developing combined 
surgical/infectious complications than in those without complications and developing 
surgical or infectious complications (P=0.009).
Figure 3 shows the data (day 0-3) for patients with anastomotic leakage versus 
patients with other complications or without complications. On day 2 CRP levels were 
higher in patients developing other complications than anastomotic leakage compared 
to those without complications (P=0.02). However, on day 3 the CRP levels were 
table 4. Diagnostic values of biomarkers (day 0-3) for complications (up to day 10).
cutoff auroc p value sn sp ppV npV
diagnostic values for any complication
Leukocytes day 3 7.9 × 109/L 0.71 0.02 75 64 78 60
CRP day 2 100 mg/L 0.71 0.04 100 36 74 100
CRP day 3 68 mg/L 0.75 0.006 100 43 75 100
∆ CRP days 0–3 23 0.75 0.01 75 78 86 64
diagnostic values for combined surgical/infectious complications
CRP day 3 316 mg/L 0.80 <0.001 0 100 - 84
∆ CRP days 0–3 81 0.77 0.008 40 90 50 86
PCT day 3 1.15 ng/mL 0.86 <0.001 38 100 100 81
diagnostic values for anastomotic leak
CRP day 3 229 mg/L 0.78 0.002 71 84 50 93
∆ CRP days 0–3 55 0.82 <0.001 80 80 50 94
PCT day 1 1.82 ng/mL 0.76 0.005 22 100 100 83
PCT day 3 0.35 ng/mL 0.86 <0.001 67 80 55 87
Abbreviations: AUROC - Area Under the Receiver Operating Characteristics curve, CRP - C-reac-
tive protein, NPV - Negative Predictive Value, PCT- Procalcitonin, PPV - Positive Predictive Value, 
SN - Sensitivity, SP – Specificity, ∆ - fractional change (day 3 divided by day 0 value).
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figure 2. Early leukocyte and plasma biomarker levels (median and interquartile 
range) complications up to 10 days after elective esophagectomy.
● without complications (N=17), ■ surgical complications (N=5), ▲ infectious complications 
(N=14), ▼ combined surgical/infectious complications (N=9). Abbreviations: CRP - C-reactive 
protein, PCT - procalcitonin. P-values refer to Kruskal-Wallis test.
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figure 3. Early leukocyte and plasma biomarker levels (median and interquartile 
range) complications up to 10 days after elective esophagectomy.
● without complications (N=17), ■ with other complications (N=18), ▲ with anastomotic leak-
age (N= 10), Abbreviations: CRP- C-reactive protein, PCT- procalcitonin. P-values refer to Krus-
kal-Wallis test.
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higher in patients developing anastomotic leak compared to all patients (N=35) with-
out leakage (P=0.02). The PCT levels on day 1 and 3 were higher in patients with 
anastomotic leakage compared to all patients (N=35) without leakage (P=0.02 and 
P=0.03, respectively). Furthermore, the day 1 PCT levels were higher in patients with 
anastomotic leakage vs. other complications (P=0.02).
The diagnostic value of elevated day 3 PCT preceded the clinical diagnosis of com-
bined complications and anastomotic leakage, as did the day 3 CRP levels and their 
fractional changes (Table 4). The diagnostic value of high day 1 PCT levels already 
preceded anastomotic leakage however.
multiple logistic regression
On day 2, CRP was diagnostic for developing complications independently from leu-
kocytes and PCT (P=0.038, Hosmer Lemeshow X2 5.22, df8, P=0.734). On day 3 
CRP levels were diagnostic for developing anastomotic leakage independently form 
leukocytes and PCT (P=0.032, Hosmer Lemeshow X2 8.8, df7, P=0.268). On day 1, 
PCT was diagnostic for developing anastomotic leak independently from leukocytes 
and CRP (P=0.016, Hosmer Lemeshow X2 8.064, df8, P=0.427).
discussion
This relatively small study suggests that elevated CRP levels are a sensitive marker 
of complications developing post-oesophagectomy, whereas elevated PCT levels may 
specifically indicate the development of more severe combined surgical/infectious 
complications, mainly associated with anastomotic leakage, within 3 to 10 days post-
oesophagectomy.
Even though all patients had low ASA-classification, P-POSSUM and APACHE II 
scores, 62% had early postoperative complications. There were no fatalities within 
30 days postoperatively. The preoperative risk-assessment scores were comparable 
between groups and thus unsuitable for indicating development of a complicated 
postoperative clinical course. Although the complication rate appears relatively high, 
the rate and type are in line with the literature.2-9,11-13,22,27,28 Up till now there are no 
uniformly accepted guidelines for reporting of postoperative complications, and a re-
cent systematic review has shown a wide range in definitions hampering interpretation 
of study results.4 The difficulty in uniform, mutually exclusive complication categories 
makes interpretation and comparison of studies difficult. We grouped complications 
since they represent different conditions and associated severities, whereas the group 
was too small to attempt to discriminate between individual complications. Patients 
who developed combined surgical/infectious complications had more complications 
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simultaneously than patients in the other complication groups. Furthermore, their 
hospital stay was longer than of patients with infectious complications or without 
complications.
This is the first study trying to discriminate among early postoperative complication 
types by using CRP and PCT. All complications presented on day 3 or later and in 92% 
of cases complications presented on day 4 or later. We may argue that since the cutoff 
values of day 2 and 3 biomarker levels precede the clinical symptoms and diagnosis of 
complication they are predictive in time. The elevation of CRP levels in patients with-
out complications is also comparable to that reported before.6,8,9,11-13 Studies reported 
high PCT levels, as in our study, after oesophagectomy or other extensive gastro-
intestinal surgeries irrespective of complications,1,15,19 and high PCT levels, albeit not 
more elevated than CRP, in major anastomotic leakage after colorectal surgery.16,18 
Based on our observations and those of others,6,7,9,12,15,17 one may thus hypothesize 
that both CRP and PCT increase following a surgical host response, but that PCT 
follows a more severe manifestation of this response, particularly when associated 
with surgical/infectious complications. Indeed, we could not discriminate infectious 
complications from surgical complications by use of PCT or CRP, but PCT rather than 
CRP was able to identify patients at risk for more severe combined complications after 
oesophagectomy.
In detail, CRP levels on day 2 and 3 were diagnostic for any complication presenting 
between days 3-10, independent of preoperative risk assessment score and SIRS 
criteria. The calculated sensitivity and specificity are similar to those reported in some 
previous studies,9,10 but in slight contrast to others who found a diagnostic value 
of CRP no sooner than on postoperative day 4,8,11,12 or no diagnostic value at all 
for anastomotic leakage or infectious complications.6,13 In our study, CRP levels nor 
fractional increases could differentiate between complication groups, limiting the use 
of CRP levels for early recognition of complication subtypes. The low specificity and 
modest positive predictive value calculated from the AUROC suggest that the use of an 
elevated CRP alone as an indicator of developing complications post-oesophagectomy 
may lead to antibiotic overtreatment, amongst others, if considered specific for infec-
tion.
Plasma PCT levels have been studied and compared with CRP in patients after major 
surgery and trauma, but the results are inconclusive.14-18,20 So far, one study on post-
oesophagectomy showed a diagnostic value of PCT for development of sepsis,11 and 
another one for infectious complications.13 We found an early diagnostic value of day 
3 PCT levels for combined surgical/infectious complications presenting between days 
3-10 independently from preoperative risk-assessment scores, but not of infectious 
complications alone. PCT was the only marker of help in the early diagnosis of more 
severe complications and the earliest one to recognize anastomotic leakage, the most 
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common combined surgical/infectious complication. Even though the AUROC of day 3 
CRP was statistically significant for combined complications the marker level had little 
positive predictive value. The positive predictive value of PCT levels is higher and PCT 
is therefore preferred over CRP for diagnosis of combined complications. As a result, 
elevated PCT levels at the cutoff levels presented could guide additional diagnostics 
and start of empirical antibiotics before full blown presentation of complications post-
oesophagectomy.
The leukocyte counts peaked around the upper limit of normal on day 2 in agreement 
with some studies.6,8,10,11 This relatively low leukocyte peak count could be explained 
by neo-adjuvant chemotherapy in the majority of patients. Some investigators found 
a moderately elevated leukocyte count on day 2 to 5 to predict anastomotic leak and 
infectious complications.8,10,11 The leukocyte count in our study did not discriminate 
between surgical, infectious or combined complications and is therefore not useful 
for this purpose, as in other studies.6,13 We included this SIRS criterion for reasons of 
comparison with CRP and PCT.
The limitations of this proof of principle study include its relatively small and 
heterogeneous sample size. Furthermore, little is known about the effects of neo-
adjuvant chemo-radiotherapy on biomarker release and kinetics. However, almost all 
patients in our study received such treatment and predictive values of biomarkers 
were maintained. There is no difference in effect on postoperative CRP and PCT values 
reported between laparoscopic versus open surgery or between the transhiatal and 
transthoracic approach, respectively.1,29
conclusion
An increasing or high CRP level within 3 days after elective oesophagectomy may con-
tribute to the early diagnosis of any postoperative complications presenting between 
postoperative days 3 and 10, independent of the preoperative risk assessment scores. 
Elevated PCT levels may specifically indicate severe combined surgical/infectious 
complications, mainly associated with anastomotic leakage, but may not recognize 
infectious complications alone. Nevertheless, PCT rather than CRP might be used for 
decisions on additional diagnostics and empirical antibiotic treatment in these patients.
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aBstract
objective The diagnostic use of procalcitonin for bacterial infections remains a matter 
of debate. So far most studies used ambiguous outcome measures such as sepsis 
instead of infection. We performed a systematic review and meta-analysis to investi-
gate the diagnostic accuracy of procalcitonin for bacteraemia, a proven bloodstream 
infection.
methods We searched all major databases from inception to June 2014 for original, 
English written, research articles that studied the diagnostic accuracy between procal-
citonin and positive blood cultures in adult patients. We calculated the area under the 
summary receiver-operating characteristic curves (SROC) and pooled sensitivities and 
specificities. To minimise potential heterogeneity we performed subgroup analyses.
results In total 58 of 1,567 eligible studies were included in the meta-analysis and 
provided a total of 16,514 patients of whom 3,420 suffered from bacteraemia. In the 
overall analysis the SROC was 0.79. The optimal and most widely used procalcitonin 
cutoff value was 0.5 ng/mL with a corresponding sensitivity of 76% and specificity 
of 69%. In subgroup analyses the lowest SROC was found in immunocompromised/
neutropenic patients (0.71), the highest SROC was found in intensive care patients 
(0.88), sensitivities ranging 66-89% and specificities 55-78%.
conclusions In spite of study heterogeneity, procalcitonin had a fair diagnostic ac-
curacy for bacteraemia in adult patients suspected of infection or sepsis. In particular 
low procalcitonin levels can be used to rule out the presence of bacteraemia. Further 
research on the safety and efficacy of procalcitonin as a single diagnostic tool to 
withhold taking blood cultures is needed.
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introduction
Infection and the subsequent sepsis syndrome are associated with morbidity and 
mortality.1,2 The fear of undertreatment leads to the routine collection of specimen for 
microbiological culture and initiation of empiric antibiotic therapy.3 On the other hand, 
antibiotic overuse increases microbial selection and resistance and can cause adverse 
drug reactions.4 To assist the diagnosis of infection in clinical practice its symptoms 
have been grouped into the systemic inflammatory response syndrome (SIRS).5 A 
clinically suspected or proven infection in the presence of SIRS is termed sepsis.5 In 
recent years authors have studied the use of biomarkers, like procalcitonin, to improve 
the diagnosis of the sepsis syndrome rather than of proven infection.6-9 The use of the 
sepsis syndrome as a surrogate for proven infection as an outcome parameter may 
be too sensitive and nonspecific. This could partially explain the contradicting results 
in previous studies6-9,10 and meta-analyses on the diagnostic use of procalcitonin for 
sepsis.11-18
The definition of proven local infection remains matter of debate and we therefore 
study the more robustly defined proven bloodstream infections, i.e. bacteraemia. 
Bacteraemia can be identified in about 30% of septic patients and necessitates further 
diagnostic evaluation.19 However, culture results take several days and can be falsely 
negative in patients on antibiotic treatment.20-22 Recent studies demonstrated that 
procalcitonin can accurately predict bacteraemia in patients with community-acquired 
pneumonia,23 acute fever,24 and in elderly patients suspected of infection.25 Procalcito-
nin can also accurately discriminate between true bacteraemia and coagulase negative 
staphylococci-contaminated blood cultures.26 Another study demonstrated that bacte-
raemia is unlikely when procalcitonin levels are low.27 Some meta-analyses focused on 
the diagnostic value of procalcitonin for microbiologically confirmed local infection28-39 
or bacteraemia.40 However, the number of included studies was small, specific patient 
subgroups were analysed or studies concerning sepsis were included as well.28-40
We therefore performed a systematic review and meta-analysis to investigate the 
diagnostic accuracy of procalcitonin for bacteraemia. Our hypothesis is that in adult 
patients suspected for infection or sepsis procalcitonin is a useful biomarker of bac-
teraemia.
methods
search strategy and study selection
We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement for reporting this systematic review and meta-analysis.41 A flow-
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chart of the literature search can be found in Figure 1. All prospective and retrospec-
tive, original, observational (case-control, cross sectional, cohort and longitudinal) 
studies published in English from inception until June 2014 were considered eligible 
for inclusion. Studies were screened by title and abstract and definite inclusion was 
decided upon after full text review.
We included studies on adult hospitalised patients suspected of infection or sepsis, 
in which bacteraemia with a known pathogen was confirmed by blood culture and 
measurement of procalcitonin levels was performed within 24 hours of inclusion. Stud-
ies had to give a detailed description of patient groups and demographic variables. 
The comparison of procalcitonin levels had to be between hospitalised patients with 
	  
	  
Search	  databases:	  PubMed,	  Medline,	  Embase,	  ISI	  Web	  of	  Knowledge,	  the	  Cochrane	  Library,	  
Scopus,	  BioMed	  Central,	  and	  Science	  Direct.	  
Search	  strategy:	  	  (procalcitonin	  OR	  PCT)	  AND	  (bacterial	  infection	  OR	  bacteraemia	  OR	  
bloodstream	  infection).	  
 
Records	  identified	  after	  primary	  search	  
(N=1567)	  
Records	  excluded	  (n=1443)	  
	   Reviews	   	   	   	   	   N=231	  
	   Meta-­‐analysis	  	   	   	   	   N=28	  
	   Case	  reports	  	   	   	   	   N=42	  
	   Editorials	   	   	   	   	   N=40	  
	   Commentaries	  and	  letters	  	   	   	   N=96	  
	   Meeting	  abstracts,	  poster	  presentations	  	   	   N=72	  
Animal	  studies	  	   	   	   	   N=57	   	  
Age	  <18	  years	  	   	   	   	   N=759	  
Not	  in	  English	  	   	   	   	   N=118	  
Full-­‐text	  articles	  assessed	  	  
for	  eligibility	  (N=124)	  
Full-­‐text	  articles	  selected	  for	  data	  
extraction	  and	  meta-­‐analysis	  (N=58)	  	  
Full-­‐text	  articles	  excluded,	  with	  reasons	  (N=66)	  
	   Not	  describing	  PCT	  for	  bacteraemia	   N=	  1	  
Not	  describing	  bacteraemia	   	   N=	  26	  
Candidaemia	   	   	   N=	  3	  
No	  comparison	  with	  non-­‐bacteraemia	   N=	  4	  
Not	  providing	  sensitivity/	  specificity/	  	   N=29	  
area	  under	  the	  curve	  (AUC)	   	  
Longitudinal	  studies	   	   	   N=	  1	  
Healthy	  controls	   	   	   N=2	  
	  
	  
	  
	   	  
	  
figure 1. Flow chart of literature search.
Searched databases: PubMed, Medline, Embase, ISI Web of Knowledge, the Cochrane Library, 
Scopus, BioMed Central, and Science Direct.
Search strategy: (procalcitonin OR PCT) AND (bacterial infection OR bacteraemia OR blood-
stream infection).
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and without bacteraemia, regardless of clinical symptoms. To be included for analysis 
studies had to report the diagnostic accuracy estimates of procalcitonin for bacterae-
mia; knowingly area under the curve (AUC), sensitivity, specificity and corresponding 
P-values. The corresponding authors of eligible studies that did not provide sufficient 
data for meta-analysis were contacted to retrieve additional data. We excluded case-
control studies were controls were healthy subjects, reviews, meta-analyses, case 
reports, editorials, commentaries, letters, meeting abstracts, poster presentations, 
animal studies and research performed in children (<18 years old). Two investigators 
(SHH and PJG) independently evaluated all eligible studies for inclusion and extracted 
the data. In case of disagreement a third investigator (ABJG) was consulted.
Quality assessment
We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool,42 
scores range from 0 to 14, to assess the methodological quality of included studies.
statistical methods
To avoid double inclusion of the same patient group we only included one sensitivity 
and specificity from each article, unless results clearly came from different patient 
groups. We used the bivariate random-effects regression model for pooling the sensi-
tivity and specificity estimates, as recommended by the Cochrane Diagnostic Test Ac-
curacy Working Group.43 The bivariate model takes into account the potential trade-off 
between sensitivity and specificity by explicitly incorporating this negative correlation 
in the analysis.44, 45 Cutoff values differed among the included studies, the cutoff value 
closest to 0.5 ng/mL was used for the analysis if multiple cutoff values were given. 
The 0.5 ng/ml cutoff was chosen based on recommendations of the manufacturer, 
current literature46-49 and was the cutoff used most often in the included studies (Table 
1). Summary receiver-operating characteristics curves (SROC) were drawn using the 
bivariate model. The closer the curve is to the upper left-hand corner of the SROC 
curve plot, the better the overall accuracy of the test. An area under the SROC curve 
between 0.90-1.0 is considered as excellent diagnostic accuracy, 0.80-0.90 as good, 
0.70-0.80 as fair, 0.60-0.70 as poor and 0.50-0.60 as fail.50 We expected substantial 
heterogeneity in the of the overall analysis and in order to obtain more homogenous 
results subgroup analysis were performed. First, we calculated the diagnostic accuracy 
in specific patient subgroups based on their underlying disease. We calculated the 
diagnostic accuracy in studies comparing bacteraemia vs. non-bacteraemia in patients 
with SIRS and comparing bacteraemia vs. non-bacteraemia in patients with SIRS 
developing localised infections. When a specific subgroup for the controls could not be 
identified we categorised the study in the category non-bacteraemia. We studied the 
diagnostic accuracy of procalcitonin for bacteraemia in immunocompromised/neutro-
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penic and immunocompetent patients separately. We categorised all studies according 
to department of inclusion. Finally, we also studied retrospective studies separately 
from prospective studies. We tested for a threshold effect by adding a covariate for 
threshold to the bivariate model.
We used IBM statistics 21.0 (IBM SPSS, Chicago, IL, USA) and R 3.1.1 (Vienna, 
Austria XX) to analyse the data. The R package mada was used to perform the pool-
ing of sensitivity and specificity and generating of SROC-curves. Pooled sensitivity 
and specificity estimates were generated, with their 95% confidence interval (CI). To 
assess heterogeneity among studies I2 and X2/cochrane Q statistics were performed. 
We used the Deeks funnel plot asymmetry test to evaluate potential publication bias.51 
P<0.10 for the slope coefficient is considered as significant asymmetry, which indicates 
potential publication bias. All other tests were two-sided and a P<0.05 was considered 
statistically significant; exact P-values >0.001 are given.
results
literature search
The literature search resulted in a total of 1,567 articles of which 1,443 studies were 
excluded because of: written language other than English (N=118), age <18 years 
(N=759), in vitro/animal studies (N=57) or lack of original data (reviews, meta-
analysis, case reports, editorials, commentaries and letters, meeting abstract, poster 
presentations, N=509). We performed a full text review of the 124 articles considered 
eligible for inclusion, which resulted in the exclusion of another 66 studies whom did 
not provide AUC values/ sensitivity/ specificity (N=29), did not study bacteraemia 
(N=26), did not compare to non-bacteraemia (N=4), studied candidaemia (N=3), 
used healthy controls (N=2), did not provide the procalcitonin level for bacteraemia 
(N=1), or used a longitudinal study design and analysis (N=1). The remaining 58 
articles were used in the meta-analysis. The complete reference list containing all 
in- and excluded studies is presented in the supplemental material. Table 2 depicts the 
66 studies excluded after full text review.
study characteristics and quality assessment
Table 1 provides some details of the included studies. In total, 16,514 patients of 
whom 3,420 suffered from bacteraemia were included. There was a slight tendency 
towards male preponderance. The average age ranged from 33 to 77 years. Eight 
studies had a retrospective and 50 a prospective study design. All 58 studies provided 
AUC values, but only 49 studies provided sensitivity and specificity. The cutoff values 
varied between 0.10 and 17 ng/mL. All samples for blood culture and procalcitonin 
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table 2. Excluded studies.
reason of exclusion excluded study  
Not providing PCT Pettila 2002 [6]
Not studying bacteraemia Adamzik 2010 [106] Pizzolato 2014 [119]
Barati 2008 [107] Quiroga 2014 [120]
Bele 2011[108] Reynolds 2012 [121]
Bugden 2004 [109] Rowther 2009 [122]
Delevaux 2002 [110] Sakr 2008 [123]
Fluri 2012 [111] Stankovic 2010 [124]
Freund 2012 [112] Steichen 2009 [125]
Hettwer 2010 [113] Uusitalo 2011 [126]
Jereb 2009 [114] Viallon 2008 [127]
van Langevelde 2000 [115] Wang 2014 [1]
Magrini 2013 [116] Wunderink 2012 [128]
Oberhoffer 2000 [117] Yan 2014 [129]
Patil 2012 [118] Zhu 2014 [130]
Studying candidaemia Charles 2006 [131] Martini 2010 [133]
Charles 2009 [132]
No comparison to non-bacteraemia Charles 2008 [134] Mueller 2004 [136]
Knudsen 2010 [135] Shomali 2013 [137]
Not providing sensitivity or specificity Ahn 2010 [138] Lee 2014 [139]
No AUC values of PCT for bacteraemia Al Shuaibi 2013 [140] Lehmann 2010 [154]
Aouifi 2000 [141] Lodes 2012 [155]
Bloos 2012 [142] Mauro 2012 [156]
Boussekey 2005 [143] Park 2012 [56]
Cuculi 2008 [144] Peters 2006 [157]
Endo 2012 [145] Previsdomini 2012 [158]
Feld 2008 [146] Sandri 2008 [159]
Foushee 2012 [147] Scott 2003 [160]
Gille johnson 2012 [148] Su 2012 [161]
Groeneveld 2008 [149] Svaldi 2001 [162]
Guven 2002 [150] Ugarte 1999 [163]
Juutilainen 2011 [151] von Lilienfeld 2009 [164]
Kim 2010 [152] Yilmaz 2011 [165]
Kruif de 2008 [153]
Longitudinal studies not providing PCT 
on inclusion Lavrentieva 2012 [166]
Healthy controls Gaini 2008 [167] Kocazeybek [168]
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measurement were collected on inclusion or within 24 hours at the emergency depart-
ment, ward and/or intensive care unit. The median QUADAS score was 12 (range 
7-14) the per item QUADAS scores are presented in Table 3. Problematic QUADAS 
items were: the description of selection criteria and description of the execution of the 
reference standard, whether the index test results were interpreted without knowledge 
of the results of the reference standard and vice versa, reporting of uninterpretable/
intermediate test results and the explanation of withdrawals.
the diagnostic accuracy of procalcitonin for bacteraemia
In the overall analysis the area under the SROC was 0.79 (Figure 2 and Table 4). 
The optimal and most widely used procalcitonin cutoff value was 0.5 ng/mL (Table 5) 
and corresponded with a 76% sensitivity and 69% specificity (Table 4). In Figure 3, 
the sensitivity and specificity per study are given. The lowest SROC was found in im-
munocomprised/neutropenic patients (0.71), the highest SROC (0.88) in ICU patients. 
The lowest sensitivity was found in immunocomrpomised/neutropenic patients (66), 
the highest in ICU patients (89). The lowest specificity was found in patients with 
localised infections (55) and the highest in immunocompromised/neutropenic patients 
(78). Table 6 shows the 2x2 tables with low positive predictive values (17-28%) and 
high negative predictive values (95-98%) for different hospital settings at the 0.5 ng/
mL procalcitonin cutoff. There was significant heterogeneity in the overall analysis and 
in most subgroups (Table 4). However, there was no indication of a threshold-effect.
evaluation of publication bias
Figure 4 displays the Deeks funnel plot asymmetry test of this meta-analysis. The 
Deeks test was not statistically significant (P=0.13) indicating that there is no direct 
evidence for publication bias.
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table 3. Raw QUADAS scores.
Quadas item
reference
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Quadas
score
Aalto 2004 [58] y y y y y y y y y y u y n y 12
Albrich 2011 [59] y y y y y y y y y y n y n y 12
Bell 2003 [60] y y y n y y y y y y y y u n 11
Bogar 2006 [61] y y y y y y y y y n y y n y 12
Bossink 1999 [62] y y y y y y y y y n y y n y 12
Caterino 2004 [63] y y y y y y y y y y n y y y 13
Charles 2008 [64] y n y y y y y y y y y y y y 13
Chen 2011 [65] y y y y y y y y y y y y u u 12
Cheval 2000 [66] y n y y y y y y n y y y u u 10
Chirouze 2002 [67] n y y y y y y y y y u y y y 12
Dwolatzky 2005 [68] y n y y y y y y y y y y y y 13
Engel 1999 [69] y y y y y y y y n y u y y n 11
Gac 2011 [70] y n y y y y y y n u y y y y 11
Gaini 2007 [71] y y y y y y y y y y n y y y 13
Giamarellos 2001 [72] y y y y n n y y y y n y y y 11
Giamarellou 2004 [73] y n y y y y y y n y y y y n 11
Guinard-Barbier 2001 [53] y y y y y y y y y u y y y y 13
Ha 2013 [74] y n y y y y y y y y y y y n 12
Hoeboer 2012 [75] y y y y y y y y y n y y n y 12
Hoenigl 2013 [54] y y y y y y y y y u y y y y 13
Hoenigl 2014 [76] y y y y y y y y y y y y n n 12
Jeong 2012 [77] y n y y y y y y y y y y y n 12
Jimeno 2004 [78] y y y n n y y y y y n y y y 11
Kallio 2000 [79] y n y y y y y y n y y y y y 12
Karlsson 2010 [80] y y y y y y y y y y y y y y 14
Kim D 2011 [81] y n y y y y y n n u u y u n 7
Kim M 2011 [24] y n y y y y y u u u u y u u 7
Koivula 2011 [82] y n y y y y y y y n n y y y 11
Lai 2010 [25] y y y y y y y y y y y y y n 13
Lee 2013 [83] y y y y y y y y y y y y n y 13
Liaudat 2001 [84] y u y y y y y y y y n y y y 12
Loonen 2014 [85] y y y y y y y y y y y y y y 14
Mencacci 2012 [86] y y y y y y y y y y y y y n 13
Menendez 2012 [55] y y y y y y y y y y y y n n 12
Muller 2010 [23] y y y y y y y y y y y y n y 13
Munoz 2004 [87] y y y n y y y y y y y y u u 11
Nakamura 2009 [88] y n y y y y y n n y y y y n 10
Nieuwkoop van 2010 [89] y y y y y y y y y y y y n y 13
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table 3. Raw QUADAS scores. (Continued)
Quadas item
reference
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Quadas
score
Pereira 2013 [90] y y y y y y y y y u y y y n 12
Persson 2004 [91] y n y y y y y y y n y y y n 11
Prat 2008 [92] y u y y y y y y u n u y u u 8
Ratzinger 2014 [93] y y y y y y y y y y y y u y 13
Riedel 2011 [27] y y y y y y y y y y y y y y 14
Rintala 2001 [94] y n y y y y y y y y y y u n 11
Robinson 2011 [95] y y y y y y y y y n y y y n 12
Romualdo 2014 [96] y y y y y y y y y y y y n y 13
Schuetz 2007 [26] y y y y y y y y n y y y y n 12
Schuetz 2008 [97] y y y y y y y y y y y y y n 13
Shi 2013 [98] y y y y y y y y y n y y y n 12
Shomali 2012 [99] y y y y y y y y y y y y y n 13
Su 2011 [100] y y y y y y y y y y n y y n 12
Suarez-Santamaria 2010 
[101]
y y y y y y y y y y y y y n 13
Theodorou 2012 [57] y y y y y y y y y y y y n y 13
Tromp 2012 [102] y y y y y y y y y y y y n y 13
Tsalik 2012 [103] y y y y y y y y y u u y y y 12
Vanska 2012 [104] y y y y y y y y y u u y u u 10
Von Lillienfeld-Toal 2004 
[105]
y y y y y y y y n y y y y n 12
Wang 2013 [10] y n y y y y y y y y y y y n 12
The quality assessment of studies of diagnostic accuracy checklist. Item 1: Was the spectrum 
of patients representative of the patients who will receive the test in practice?; 2: Were selec-
tion criteria clearly described?; 3: Is the reference standard likely to correctly classify the target 
condition?; 4: Is the time period between reference standard and index test short enough to 
be reasonably sure that the target condition did not change between the two tests?; 5:Did the 
whole study population or a random selection of the sample, receive verification using a refer-
ence standard for diagnosis?; 6: Did patients receive the same reference standard regardless of 
the index test result?; 7: Was the reference standard independent of the index test?; 8: Was the 
execution of the index test described in sufficient detail to permit replication of the test?; 9: Was 
the execution of the reference standard described in sufficient detail to permit its replication?; 
10: Were the index test results interpreted without the knowledge of the results of the reference 
standard?; 11: Were the reference standard results interpreted without knowledge of the index 
test results?; 12: Were the same clinical data available when test results were interpreted as 
would be available when the test is used in practice?; 13: Were uninterpretable / intermediate 
test results reported?; 14: Were withdrawals from the study explained? Each item can be an-
swered with yes (Y), no (N) or unknown (U)
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figure 2. Summary receiver-operating characteristic (SROC) curve plot of procalci-
tonin for the diagnosis of bacteraemia, including all studies (N=58).
Individual studies are shown as open circles. Summary point is shown as a closed square, rep-
resenting sensitivity estimates pooled by using bivariate random-effects regression model. The 
area under the SROC curve (dashed line) is 0.79, pooled sensitivity 76% and specificity 69%. 
The 95% confidence region displays the 95% confidence interval of the pooled sensitivity and 
specificity. The 95% prediction region is the region for a forecast of the true sensitivity and 
specificity in a future study.
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table 4. Accuracy estimates.
analysis auc
pooled 
sensitivity
pooled 
specificity Heterogeneity (%)
(95% CI) (95% CI) i2
X2/ 
Q p
overall (N=3,420 ) 0.79 76 (72-80) 69 (64-72) 86% 1397 <0.001
control group
Non-bacteraemia (N=1,884 ) 0.78 72 (66-78) 74 (69-76) 88% 1070 <0.001
SIRS (N=931) 0.78 76 (60-87) 66 (44-82) 83% 114 <0.001
Local infection and/or sepsis 
(N=605) 0.84 84 (80-87) 55 (47-63) 71% 162 <0.001
immunocompromised/ 
neutropenic
Yes (N=320) 0.71 66 (54-76) 78 (71-83) 76% 120 <0.001
No (N=3,100) 0.79 79 (75-83) 65 (60-65) 81% 926 <0.001
department
ICU (N=399) 0.88 89 (79-94) 68 (57-77) 77% 54 <0.001
Mixed (N=1,009) 0.77 76 (65-85) 66 (57-76) 31% 501 <0.001
Ward (N=587) 0.76 71 (63-78) 71 (64-77) 90% 433 <0.001
ED (N=1,425) 0.78 76 (69-82) 68 (61-75) 77% 285 <0.001
study type
Prospective (N=2,507) 0.79 76 (71-80) 69 (64-73) 86% 721 <0.001
Retrospective (N=913) 0.79 78 (66-86) 68 (56-78) 79% 636 <0.001
X2/Q = X2/cochrane Q, CI = confidence interval; ED = emergency department; ICU = intensive 
care unit; mixed = ICU/ ED/ ward together; SIRS = systemic inflammatory response syndrome
table 5. Accuracy estimates for different cut-off values.
analysis auc pooled sensitivity Pooled specificity Heterogeneity (%)
(95% CI) (95% CI) i2 X2/ Q p
cut-off 0.1 0.73 91 (82-96) 35 (22-51) 88% 385 <0.001
cut-off 0.5 0.77 74 (66-81) 68 (61-75) 75% 478 <0.001
cut-off 1.0 0.76 67 (52-78) 74 (67-80) 85% 154 <0.001
cut-off 2.0 0.63 50 (31-69) 83 (64-94) 92% 313 <0.001
X2/Q = X2/cochrane Q, CI = confidence interval.
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figure 3. Accuracy estimates analysis for bacteraemia versus non-bacteraemia. 
including all studies (N=49).
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table 6. 2x2 tables with corresponding sensitivity, specificity, PPV and NPV.
Ward Emergency Department Intensive Care Unit
BSI+ BSI- BSI+ BSI- BSI+ BSI-
PCT+ 7 26 33 6 29 35 11 28 39
PCT- 3 64 67 2 63 65 1 60 61
10 90 100 8 92 100 12 88 100
Prevalence 10% 8% 12%
Sensitivity 71% 76% 89%
Specificity 71% 68% 68%
PPV 21% 17% 28%
NPV 95% 97% 98%
BSI = blood stream infection; NPV = negative predictive value; PCT = procalcitonin; PPV = posi-
tive predictive value, += positive test, -= negative test.
figure 4. Evaluation of publication bias.
The Deeks funnel plot assymetry test was non-significant (P=0.13). Individual studies are shown as open 
circles and the interrupted line represents the regression line. ESS= effective sample size.
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discussion
This study evaluates the diagnostic accuracy of procalcitonin for bacteraemia in differ-
ent subgroups of adult hospitalised patients suspected of infection or sepsis. Overall, 
at a cutoff level of 0.5 ng/mL, procalcitonin had a fair diagnostic accuracy for bacter-
aemia with an SROC of 0.79. The pooled AUC values of procalcitonin for the diagnosis 
bacteraemia in subgroups ranged from 0.71-0.88, with sensitivities ranging from 66% 
in immunocompromised/neutropenic patients to 89% in ICU patients and specificities 
ranging from 55% in bacteraemia vs. local infections to 78% in immunocompromised/
neutropenic patients. Based on these results low procalcitonin levels in particular can 
be used to rule out the presence of bacteraemia.
Two previous meta-analyses on the diagnostic accuracy of procalcitonin for sepsis 
had contradicting conclusions while having comparable results.12,18 Tang et al. con-
cluded that there was no clear use for procalcitonin in diagnosing sepsis (area under 
the SROC of 0.78, sensitivity of 71% and specificity of 70%).12 However, their inclusion 
may be biased by specifically excluding sepsis originating from certain types of com-
mon infection sites.12 In contrast, Wacker et al. concluded that procalcitonin was useful 
for the diagnosis of sepsis (area under the SROC 0.85, sensitivity 77%, specificity 
79%).18 They included studies on adult and paediatric patients comparing sepsis to 
SIRS. Sepsis, however, was defined as clinically suspected or microbiologically proven 
infection.18 Two other meta-analyses studying the diagnostic use of procalcitonin 
for bacterial infection found an area under the SROC curve ranging from 0.82-0.89, 
sensitivity 83-88%, specificity 81-83%.28,34 Both analyses had comparable results but 
again contradicting conclusions. Simon et al. compared CRP and procalcitonin in a 
meta-analysis on the diagnostic accuracy in either proven or suspected bacterial infec-
tion, favouring PCT to be used in clinical practice.28 In contrast, Lee et al. contented 
that PCT should not be used as single diagnostic tool for infection.34 However their 
conclusion was based on only four studies on the diagnostic accuracy of procalcitonin 
for bacterial infection in elderly patients.34 As far as we know there is only one previous 
meta-analysis on the diagnostic accuracy of procalcitonin for bacteraemia with an 
area under the SROC of 0.84, sensitivity 76%, specificity 70%.40 This study concluded 
that widespread use of procalcitonin is not recommended because of the moderate 
diagnostic accuracy of PCT to predict bacteraemia.40 This conclusion was based on 17 
included studies of which not all contained bacteraemia as primary endpoint. Even 
though previous meta-analyses showed similar results their conclusion differ, possibly 
due to differences in interpretation of clinically useful AUC values. In contrast to our 
study, the above-mentioned meta-analyses only used a small selection of the available 
literature or used sepsis syndrome and not microbiologically documented infection 
as their endpoint. Our study shows that procalcitonin can be used in the diagnostic 
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process of bacteraemia regardless of its clinical symptoms. As shown in Table 6 low 
procalcitonin levels can be used to rule out the presence of bacteraemia in different 
clinical settings.
This meta-analysis has several limitations. There is some evidence for a concen-
tration-response relation between procalcitonin levels and probability of infection 
and disease severity.52 The definition of our primary outcome measure, bacteraemia, 
does not acknowledge such a concentration-response relation. Only a minority of the 
studies in this meta-analysis formally excluded patients treated with antibiotics prior 
to inclusion.23,24,53-57 We cannot be certain that false negative results, due to pos-
sible antibiotic treatment prior to inclusion, led to underestimation of the effect. Even 
though the effect size is only fair (area under the SROC 0.79) its direction is positive 
in almost all studies, in spite of heterogeneity. High I-squares are to be expected 
because of the variation in cutoffs used in the different included studies and sensitivity 
and specificity both depend on cutoffs. To homogenise the results we attempted to 
use the sensitivities and specificities corresponding with the cutoff value closest to 
0.5 ng/mL if multiple cutoff values were given. Other potential factors that could 
have contributed to heterogeneity are variety in inclusion criteria, underlying diseases, 
co-morbidities, clinical course and treatment prior to inclusion, variety in the control 
groups used for comparison against bacteraemia, department of sample collection, 
and differences in test performance of the various procalcitonin assays. In order to 
reduce the influence of these factors on heterogeneity we performed analyses in the 
supposedly more homogeneous patient subgroups. As to be expected, substantial het-
erogeneity remained in most subgroups. A Funnel plot analysis based on the standard 
error of the lnDOR can be misleading, therefore we evaluated potential publication 
bias using the recommended effective sample size-based funnel plots and associated 
regression tests of asymmetry according to Deeks.51
conclusions
In conclusion, this systematic review and meta-analysis shows that procalcitonin has 
a fair diagnostic accuracy for bacteraemia in adult, hospitalised patients suspected 
of infection or sepsis. In particular low procalcitonin levels can be used to rule out 
the presence of bacteraemia. Further research on the safety and efficacy of using 
procalcitonin as a single diagnostic tool to withhold taking blood cultures remains to 
be proven.
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aBstract
objective Although absolute values for C-reactive protein (CRP) and procalcitonin 
(PCT) are well known to predict sepsis in the critically ill, it remains unclear how changes 
in CRP and PCT compare in predicting evolution of: infectious disease, invasiveness 
and severity (e.g. development of septic shock, organ failure and non-survival) in 
response to treatment. The current study attempts to clarify these aspects.
methods In 72 critically ill patients with new onset fever, CRP and PCT were measured 
on Day 0, 1, 2 and 7 after inclusion, and clinical courses were documented over a week 
with follow up to Day 28. Infection was microbiologically defined, while septic shock 
was defined as infection plus shock. The sequential organ failure assessment (SOFA) 
score was assessed.
results From peak at Day 0-2 to Day 7, CRP decreased when (bloodstream) infection 
and septic shock (Day 0-2) resolved and increased when complications such as a 
new (bloodstream) infection or septic shock (Day 3-7) supervened. PCT decreased 
when septic shock resolved and increased when a new bloodstream infection or septic 
shock supervened. Increased or unchanged SOFA scores were best predicted by PCT 
increases and Day 7 PCT, in turn, was predictive for 28-day outcome.
conclusion The data, obtained during ICU-acquired fever and infections, suggest that 
CRP may be favoured over PCT courses in judging response to antibiotic treatment. 
PCT, however, may better indicate the risk of complications, such as bloodstream 
infection, septic shock, organ failure and mortality, and therefore might help deciding 
on safe discontinuation of antibiotics. The analysis may thus help interpreting current 
literature and design future studies on guiding antibiotic therapy in the ICU.
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introduction
In critically ill patients, new onset fever often prompts clinicians to search for nosoco-
mial microbial infection and to start empiric antibiotics in attempts to diminish morbid-
ity and mortality.1-3 Plasma levels of C-reactive protein (CRP) or procalcitonin (PCT) 
are often used to increase the a priori probability of microbial infection and sepsis in 
the intensive care unit (ICU).2-12.In a previous study on absolute levels within the first 
days after new fever onset in critically ill patients, we found that CRP may particularly 
help in predicting local microbial infection and PCT in predicting bloodstream infec-
tion (BSI) and a downhill clinical course.3 The clinical relevance of changes in the 
markers is less clear, however. Changes in CRP and PCT over 2-7 days have been 
described in non-critically ill patient populations,13-20 in relatively small studies, about 
50 patients or less,4,9,13,15,16,19,21-25 in specific conditions 2,8,10,13,15-17,19,20,22,24,26-29 or in 
heterogeneous conditions in the ICU, 4-7,9,11,21,23,30-32 to judge the course of infection and 
its sequelae. CRP decreases of more than about 25% per day within the first week of 
treatment of (bloodstream) infections or sepsis have been suggested to help predict 
a beneficial response and disease course, while slower decreases or increases have 
been associated with persistent infection, organ failure or mortality, also in the ICU. 
7,8,11,17-19,21-,23,26-29,32 A relatively rapid fall of PCT may be associated with a beneficial 
outcome of pneumonia, meningitis, burn-associated or other infections, whereas a rise 
may be associated with organ failure and mortality and thus might have predictive 
value. 5,6,8-10,15,16,20,24,26,27,30,31 A fall in PCT below 0.5 ng/mL, a threshold suggested in 
studies on non-critically ill patients, has been used to safely and effectively shorten 
the duration of administration of antibiotics for infections in the ICU.33 CRP and PCT 
changes have been compared in their relative ability to detect the evolution of infec-
tion or sepsis, within4-6,10,24-27,30,31 or outside the ICU.8,14,15,18,19 CRP may display slower 
kinetics than PCT and in some, but not all studies, decreases or increases of the latter 
may better predict a beneficial or downhill course with resolving or aggravating organ 
failure, respectively.2,4,6,8,10,14-16,19,24-27,30,31,34 Nevertheless, the relative value of marker 
changes in predicting response to antibiotic treatment of ICU-acquired infections is 
only rarely addressed.10,15,24,26,27,31 Hence, general conclusions on the relative superior-
ity of the markers for specific endpoints in the critically ill are hard to draw from the 
literature and the controversy is ongoing.
In order to further help clinical decision making on the basis of changes in CRP and 
PCT in the ICU, we hypothesised for the current study that, in general critically ill 
patients with new onset fever, the 1-week course of CRP and PCT levels can be used to 
distinguish resolving microbial infection with a beneficial outcome from non-resolving 
or developing infection with a detrimental outcome associated with BSI, septic shock, 
organ failure and death. We also hypothesised that CRP and PCT differ in this respect, 
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so that CRP primarily predicts the course of local infection and PCT that of systemic 
infection and its adverse sequelae. This would also help to define values at which 
antibiotic treatment can be decided as appropriate or to allow safe discontinuation in 
the ICU.
patients and methods
This is a prospective observational study on causes and consequences of ICU-acquired 
fever, approved by the medical ethical committee of the VU University Medical Centre, 
Amsterdam, conducted between 2003 and 2007. All patients or closest relatives gave 
their written informed consent, leading to inclusion of 101 consecutive patients with 
new onset fever, admitted to a mixed medical/surgical ICU, and the complete protocol 
has been described elsewhere.3 The current analysis is on the 72 patients having 
completed a follow up of at least 7 days in the ICU (Consort diagram Figure 1). 
To briefly reiterate, a body temperature >38.3 °C measured rectally was the main 
inclusion criterion, while admitted to the ICU for at least 24 hours without fever (body 
temperature <37.5 °C). Exclusion criteria were: age under 18 years, pregnancy and 
life expectancy of <24 hours. Enrolment had to be completed within 12 hours of meet-
ing inclusion criteria and was marked Day 0 (D0). Demographic data were collected. 
Disease severity was expressed through the simplified acute physiology scores (SAPS) 
II and monitored using sequential organ failures assessment (SOFA)-scores. On Days 
(D) 0, 1, 2 and 7 clinical data were recorded and blood was drawn for determination 
of routine parameters and markers. Antibiotic treatment and changes within the study 
period were recorded.
Routine chest- and sinus-radiographs were taken on D0 and 7, all other diagnostic 
imaging were ordered by treating physicians, blinded to results, as considered neces-
sary. Blood samples for microbiological culture were taken from indwelling arterial 
Assessed	  for	  eligibility	  	  
(N	  =	  388)	   Excluded	  (N	  =	  287)	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  research	  staff	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  not	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  patients	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  101)	  
Excluded	  (N	  =	  29)	  
-­‐	  Not	  in	  ICU	  on	  Day	  7	  
 
Group	  2	  (N	  =	  9)	  
Infection	  presenting	  D0-­‐2	  and	  persisting	  
at	  D3-­‐7	  
Group	  3	  (N	  =	  11)	  
Without	  infection	  between	  	  D0-­‐2	  and	  
presenting	  	  infection	  between	  D	  3-­‐7	  
	  
Group	  4	  (N	  =	  22)	  
Without	  infection	  D0-­‐2	  and	  D3-­‐7	  
Group	  1	  (N	  =	  30)	  
Infection	  presenting	  between	  	  D0-­‐2	  and	  
without	  infection	  between	  D	  3-­‐7	  
figure 1. Consort diagram
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catheters using delayed vial entry bottles for aerobic and anaerobic cultures and 
processed according to protocol. Depending on suspicion of local infection, specimens 
for microbial culture were collected. Investigation of fungal, viral or atypical microor-
ganisms was left at the treating physician’s discretion. All culture and staining results 
from specimens drawn between D0-7 were evaluated. Positive cultures considered to 
represent colonization were not considered to represent infection and microorgan-
isms are grouped according to genus. The presence of infection was determined by 
researchers (SHH and ABJG) blinded to study results and classified by likelihood into 
possible, probable or proven infection, according to criteria defined at the International 
Sepsis Forum Consensus Conference.35 Infections are only considered when probable 
or proven.3 Sepsis was defined as infection in the presence systemic inflammatory 
response syndrome (SIRS) criteria, according to ACCP/SCCM (American Society of 
Chest Physicians/ Society of Critical Care Medicine).36 Criteria of shock criteria were a 
systolic arterial pressure <90 mmHg or a mean arterial pressure (MAP) <70 mmHg for 
at least one hour, despite fluid resuscitation, or need of vasopressor treatment. Shock 
in the presence of sepsis was marked septic shock. Organ failure was assessed by the 
sequential organ failure assessment (SOFA) score on Day 0, 1, 2 and 7.
Patients were divided into four categories of infectious course: Group 1 with infec-
tion presenting at D0-2 and without evidence of infection at D3-7, thus having a 
response to treatment and resolving infection, Group 2 with infection presenting D0-2 
and persisting positive cultures from the same infection site and/or persisting positive 
cultures with the same microorganism at D3-7, thus having treatment failure, Group 
3 without infection D0-2 and with infection D3-7, thus having a new infection, and 
Group 4 without infection D0-2 and D3-7. Complications of infection were considered 
BSI, septic shock and outcome. Therefore a similar division was done for BSI, ir-
respective of local cultures. Group 1a with BSI presenting D0-2 and without BSI D3-7, 
thus resolving BSI in response to treatment. Group 2a with BSI presenting D0-2 and 
with persisting BSI D3-7, i.e. treatment failure, Group 3a without BSI D0-2 and with 
infection D3-7, having a new BSI and Group 4a without BSI D0-2 and D3-7. Septic 
shock was defined by the presence of shock within 12 hours prior or 12 hours after 
the determination of infection in either one of the respective study intervals. Group 1b 
represents presence of septic shock in D0-2 but without septic shock in D3-7, Group 
2b presents septic shock both in D0-2 and D3-7, Group 3b absence of septic shock in 
D0-2 but presence of septic shock D3-7, and Group 4b absence of septic shock in both 
study intervals. Analogously, we divided patients with decreasing SOFA scores (peak 
D0-2 to 7; Group 1c), unchanged SOFA scores (Group 2c) and increasing SOFA scores 
(Group 3c). Outcome is 28-day survival or all-cause mortality.
Routine parameters measured were white blood cell count (WBC) (Sysmex SE-9000 
analyzer, Toa Medical Instruments, Kobe, Japan, normal values 4.5-10 x109/L), lactate 
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(Enzymatic method, Modular analytics <P> Roche diagnostics, Mannheim, Germany, 
normal values <1.8 mmol/L) and C-reactive protein (CRP, Immunoturbidimetric assay, 
Modular analytics <P> Roche diagnostics, Mannheim, Germany, normal values <5 
mg/L). Procalcitonin was measured through the Kryptor compact system (Brahms 
Diagnostica, Henningsdorf, Germany, normal values <0.08 ng/L) using time resolved 
amplified cryptate emission (TRACE) technology.
statistical analysis
CRP and PCT courses were expressed as fractional changes at D7 vs. peak values at 
D0-2. To further separate differences in absolute levels and changes, we used the 
Kruskal-Wallis test to evaluate group differences in the respective values. Area under 
the receiver operating characteristic curves (AUROC) were used to evaluate predictive 
values, such as sensitivity and specificity of optimal cut off values, defined at highest 
combined sensitivity and specificity, and their statistical significance. Exact P values 
are given unless <0.001, and values <0.05 were considered statistically significant. 
Data are expressed as number (percentage) or median (range) in tables and median, 
interquartile range in figure 2.
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figure 2. Evolution of C-reactive protein and procalcitonin according to evolution of 
infection (i) in febrile critically ill patients: CRP and PCT levels presented as median 
(interquartile range). • Group 1=i Day (D)0-2 no i D3-7; ■ Group 2=i D0-2 and i 
D3-7; ▲ Group 3=no i D0-2 but i D3-7; ▼ Group 4=no i D0-2 nor D3-7. For CRP D0-2 
P=0.009, for CRP D7 P=0.002, for change P= 0.004; for PCT D0-2 P=0.054, PCT D7 
P<0.001, for change P=0.23, among groups.
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results
Table 1 represents patient characteristics and Table 2 infection characteristics, grouped 
according to course of infection. Fifty-two patients with new onset fever had resolving 
(Group 1) or no (Group 4) infection and only twenty had non-resolving (Group 2) 
or new (Group 3) infection, but (change of) treatment was mostly successful and 
ultimate mortality did not differ among groups. Most patients with infections had SIRS 
and therefore sepsis. The number of days from ICU admission until study inclusion was 
lowest in Group 2 and 3 and the need for vasopressor and renal replacement therapy 
was highest in Group 3. Infections with yeast were more persistent than infections 
with other microorganisms. 28-Day mortality in BSI was for Group 1a-4a 13, 100, 40 
and 16%, respectively (P=0.02), and in septic shock for Group 1b-4b 19, 40, 20 and 
17%, respectively (P=0.68).
course of infectious disease, crp and pct
Figure 1 shows the differences in marker levels in time for the infection groups. Table 
3 shows that, among changes, those in CRP, rather than PCT, differed between groups 
according to infectious status, with a large decrease in Group 1 and persistently high 
values in Group 2 and 3, whereas absolute values of both CRP and PCT differed among 
groups. Table 4 shows that, among changes, those in PCT best discriminated between 
BSI groups, whereas absolute values of WBC, PCT and lactate at D7 differed among 
groups. Table 5 displays course in time for septic shock showing that, among changes, 
those in PCT better discriminated between groups than changes in CRP, whereas ab-
solute values of WBC (D7), CRP, PCT also differed among groups. Table 6 shows that 
changes in SOFA score were particularly associated with changes in PCT.
predictive values for evolving infectious disease
Table 7 summarises the predictive values of changes in markers for resolving (Group 
1, a, b or c) or new (Group 3, a, b, or c) infection, BSI, septic shock or organ failure 
vs. other groups. Most AUROC’s were above 0.70, with high specificities of optimal 
cut off values. The table shows that CRP changes particularly predict changes in the 
status of infections and their complications knowingly BSI and septic shock, whereas 
PCT changes primarily predict the latter complications and the course of organ failure. 
Optimal cut off values are shown with decreases in markers by 86% or more and 
increases by 23% or more, and higher sensitivities of PCT than of CRP.
d7 values: group differences and outcome prediction
At D7, CRP had a cut off <20.9 mg/L predicting Group 1 (at AUROC 0.67, P=0.01, 
sensitivity 31 and specificity 93%). For PCT, the cut off was <0.18 ng/mL (at AUROC 
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table 1. Patient characteristics.
Group 1 Group 2 Group 3 Group 4 P
N=30 N=9 N=11 N=22
General
Age (year) 62 (19-79)  63 (36-71) 68 (22-76) 66 (26-77) 0.91
Gender (male) 22 (73)  6 (68) 8 (73) 16 (73) 0.98
SAPS II on admission 48 (21-72)  49 (29-78) 50 (24-84) 45 (27-85) 0.99
Peak SOFA at D0-2 8 (3-13)  8 (3-13) 10 (4-14) 8 (3-16) 0.31
SOFA at D7 5 (0-15)  5 (4-14) 7 (5-13) 5 (2-21) 0.28
Temp ºC D0-2 39.2 (38.5-40.8) 39.3 (38.6-40.0) 39.0 (38.7-40.0) 39.0 (35.8-39.8) 0.80
D7 37.6 (36.5-39.0) 39.2 (36.7-40.0) 38.1 (37.3-39.7) 37.8 (36.5-40.0) 0.03
Change 0.96 (0.89-1.00) 1.00 (0.93-1.02) 0.98 (0.94-1.03) 0.96 (0.93-1.00) 0.05
SIRS. D0-2 30 (100) 9 (100) 11 (100) 22 (100) 1.0
D7 23 (85) 9 (100) 9 (82) 17 (90) 0.65
Sepsis, D0-2 30 (100) 9 (100) 0 (0) 0 (0) 1.00
D7 0 (0) 9 (100) 9 (82) 0 (0) 0.19
Septic shock, D0-2 15 (50) 6 (67) 0 (0) 0 (0) 0.39
D7 0 (0) 7 (78) 8 (73) 0 (0) 0.80
Days from admission to D0 7 (1-77) 4 (1-12) 5 (1-16) 12 (2-78) 0.01
Duration mechanical ventilation, days
22 (5-82) 26 (4-42) 16 (11-82) 35 (10-123) 0.15
ICU length of stay, days 28 (10-95) 26 (12-44) 26 (12-85) 37 (11-126) 0.41
28-day mortality 5 (17) 2 (22) 2 (18) 5 (23) 0.95
ICU mortality 7 (23) 1 (11) 2 (18) 5 (23) 0.87
admission category
Trauma 4 (13) 1 (11) 2 (18) 4 (18) 0.94
Surgery
 general 17 (57) 6 (67) 9 (82) 13 (59) 0.50
 cardiac 1 (3) 1 (11) 1 (9) 3 (14) 0.60
 vascular 2 (7) 1 (11) 4 (36) 9 (2) 0.08
Neurologic 5 (17) 2 (22) 1 (9) 3 (14) 0.86
Respiratory insufficiency 17 (57) 2 (22) 4 (36) 7 (32) 0.16
post CPR 3 (10) 0 (0) 2 (18) 0 (0) 0.18
Sepsis 12 (40) 3 (33) 1 (9) 7 (32) 0.32
Shock 9 (30) 1 (11) 0 (0) 7 (32) 0.13
treatment up to 7 days prior to inclusion
Corticosteroids 14 (47) 3 (33) 4 (36) 12 (55) 0.65
SDD 8 (27) 2 (22) 4 (36) 12 (55) 0.65
Surgery 4 (13) 2 (22) 1 (9) 2 (9) 0.77
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0.76, P<0.001, sensitivity 63 and specificity 93%). For a PCT cut off <0.5 ng/mL 
sensitivity was 87 and specificity 45%. PCT at D7 also predicted, at a cut off >7.8 ng/
mL (AUROC 0.67, P=0.03, sensitivity 13 and specificity 96%), no decrease in SOFA 
score (Group 3c+2c). On D7, only WBC and PCT were lower in 28-day survivors than 
in non-survivors (P=0.003 and 0.02, respectively). The AUROC for non-survival for 
WBC at D7, at an optimal cut off >33.1 x109/L, was 0.76 (P<0.001, with sensitivity of 
0 and specificity of 100%) and for PCT at D7 0.70 (P=0.005, with sensitivity 29 and 
specificity 95%), at an optimal cut off >2.6 ng/mL.
discussion
This prospective, medium-sized study shows that changes in CRP and PCT, rather than 
changes in WBC, in general critically ill patients with new onset fever predict infectious 
courses in response to treatment, but in a different manner. CRP changes appear most 
predictive for changes in infectious status and complications such as BSI and develop-
ment of septic shock. Whereas PCT changes primarily appear predictive for infectious 
complications BSI, development of septic shock, associated organ failure and death.
Our study is the third one comparing CRP and PCT and the second one compar-
ing their courses in the evolution of nosocomial infection in the general critically ill 
patient with new onset fever.9,12 Our data do not suggest different kinetics per se 
over a 5-7 day course, in contrast to the slower kinetics of CRP than of PCT in the 
critically ill suggested by others.4,6,8,10,12,15,27,31,34 This study however, suggests that CRP 
table 1. Patient characteristics. (Continued)
Group 1 Group 2 Group 3 Group 4 P
N=30 N=9 N=11 N=22
treatment during study d0-7
Antibiotics 30 (100) 9 (100) 11 (100) 19 (86) 0.07
Change in antibiotics 20 (67) 8 (89) 7 (64) 13 (59) 0.46
Corticosteroids 19 (63) 4 (44) 4 (36) 12 (55) 0.65
SDD 8 (27) 2 (22) 4 (36) 12 (55) 0.65
Mechanical ventilation 29 (97) 8 (89) 11 (100) 22 (100) 0.35
Inotropic/vasopressors 16 (57) 8 (89) 11 (100) 13 (59) 0.03
Renal replacement therapy 1 (3) 0 (0) 4 (36) 2 (9) 0.01
Surgery 3 (10) 1 (11) 2 (18) 3 (14) 0.91
Median (range), or number (percentage); SAPS=simplified acute physiology score; 
SOFA=sequential organ failure assessment score; ICU=intensive care unit; CPR=cardiopulmonary 
resuscitation; SDD=selective decontamination of the digestive tract. Group 1= infection (I) Day 
(D)0-2 not D3-7; Group 2= I D02 and I D3-7; Group 3=no I D0-2 but D3-7; Group 4=no I D0-2 
nor D3-7.
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table 2. Infection characteristics.
Group 1 Group 2 Group 3 P
 N=30 N=9 N=11  
infection d0-2
Tracheobronchitis 8 (27) 5 (55) - 0.11
CAP 1 (3) 0 (0) - 0.58
VAP 6 (20) 1 (11) - 0.54
Aspiration pneumonia 1 (3) 0 (0) - 0.58
Pleurisy/empyema 1 (3) 1 (11) - 0.35
Sinusitis 5 (17) 1 (11) - 0.19
Catheter infection 2 (7) 2 (22) - 0.18
Peritonitis 2 (7) 1 (11) - 0.43
Pancreatitis 2 (7) 0 (0) - 0.43
Skin and soft tissue 7 (23) 0 (0) - 0.15
infection d3-7
Tracheobronchitis - 3 (33) 2 (18) 0.44
VAP - 1 (11) 4 (36) 0.19
Aspiration pneumonia - 0 (0) 0 (0) 1.0
Pleurisy/empyema - 1 (11) 0 (0) 0.26
Sinusitis - 1 (11) 2 (18) 0.66
Catheter infection - 1 (11) 1 (9) 0.88
Peritonitis - 1 (11) 0 (0) 0.26
Skin and soft tissue - 0 (0) 4 (36) 0.04
Meningitis - 1 (11) 0 (0) 0.26
local microbiology d0-2
Enterobacteriaceae 9 (30) 4 (44) - 0.85
Staphylococci 10 (33) 3 (33) - 1.00
Pseudomonadaceae 5 (17) 0 (0) - 0.19
Enterococci 4 (13) 0 (0) - 0.25
Xantomonadaceae 3 (10) 2 (22) - 0.34
Yeasts 5 (17) 3 (33) - 0.28
Miscellaneous 12 (40) 3 (33) - 0.72
local microbiology d3-7
Enterobacteriaceae - 4 (44) 4 (36) 0.71
Staphylococci - 3 (33) 3 (27) 0.80
Pseudomonadaceae - 0 (0) 1 (9) 0.35
Enterococci - 0 (0) 2 (18) 0.18
Xantomonadaceae - 2 (2) 2 (18) 0.82
Yeasts - 3 (33) - 0.04
Miscellaneous - 3 (33) 2 (18) 0.82
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changes are more associated with evolution of infection and PCT more with evolution 
of adverse infectious sequelae. Although the AUROC’s of changes in markers seem 
higher than those for absolute levels, our current findings on absolute levels are in line 
with those reported earlier3, suggesting that during nosocomial fever in the critically 
ill CRP is more likely to contribute to infection diagnosis whereas PCT has better 
table 2. Infection characteristics. (Continued)
Group 1 Group 2 Group 3 P
N=30 N=9 N=11
Blood stream infection d0-2
Enterobacteriaceae 1 (3) 1 (11) - 0.35
Staphylococci 4 (13) 0 (0) - 0.25
Enterococci 1 (3) 1 (11) - 0.35
Yeasts 0 (0) 2 (22) - 0.008
Miscellaneous 1 (3) 0 (0) - 0.58
Blood stream infection d3-7
Enterobacteriaceae - 1 (11) 1 (9) 0.88
Staphylococci - 0 (0) 2 (18) 0.18
Enterococci - 1( 11) 2 (18) 0.66
Yeasts - 2 (22) 0 (0) 0.10
Number (percentage); CAP=community-acquired pneumonia; VAP=ventilator-acquired pneumo-
nia; Group 1= infection (I) Day (D)0-2 not D3-7; Group 2= I D0-2 and I D3-7; Group 3= no I 
D0-2 but D3-7.
table 3. Evolution of infection.
Group 1 Group 2 Group 3 Group 4 p
 N= 30 N = 9 N = 11 N = 22  
WBC D0-2, x109/L 13.9 (2.5-24.4) 12.8 (7.9-81.7) 16.2 (9.0-24.8) 11.6 (7.8-23.9) 0.22
WBC D7, x109/L 11.5 (4.9-23.2) 16.9 (8.3-30.2) 16.2(6.4-33.0) 11.9 (5.3-29.2) 0.06
WBC change 0.80 (0.47-3.20) 0.75 (0.37-1.41) 1.16 (0.40-2.95) 0.94 (0.50-1.65) 0.55
CRP D0-2, mg/L 210 (5-397) 303 (102-421) 145 (38- 440) 137 (27-248) 0.009
CRP D7, mg/L 57 (2-267) 182 (22-416) 156 (49-304) 62 (6-265) 0.002
CRP change 0.40 (0.02-1.15) 0.68 (0.07-1.82) 0.93 (0.44-6.97) 0.58 (0.11-2.58) 0.004
PCT D0-2, ng/mL 0.5 (0.08-45.1) 2.6 (0.08-75.3) 1.7(0.3-6.3) 0.8 (0.1-2.8) 0.054
PCT D7, ng/mL 0.1 (0.06-38.5) 0.6 (0.1-24.3) 1.3 (0.3-20.8) 0.2 (0.08-4.3) <0.001
PCT change 0.30 (0.05-1.57) 0.42 (0.04-2.97) 0.52 (0.08-68.3) 0.44 (0.11-5.88) 0.23
Lactate D0-2, mmol/L 1.6 (0.5-3.5) 1.5 (0.9-3.5) 1.3 (1.0-2.3) 1.4 (0.5-2.0) 0.60
Lactate D7 mmol/L 1.1 (0-4.3) 1.1 (0.9-3.1) 1.1 (0.7-1.8) 1.0 (0.5-2.2) 0.67
Lactate change 0.77 (0-2.08) 0.95 (0.48-1.72) 0.85 (0.43-1.60) 1.06 (0.42-1.50) 0.32
Median (range) for WBC=white blood cell count; CRP=C-reactive protein; PCT=procalcitonin; 
Group 1=infection (I) Day (D)0-2 not D3-7; Group 2=I D0-2 and I D3-7; Group 3=no I D0-2 but 
D3-7; Group 4=no I D0-2 nor D3-7.
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capability of predicting risks of infections. PCT has also been reported to be capable, 
more than CRP, of early discrimination between severe infection or sepsis on the one 
hand and non-infectious SIRS or uncomplicated infection on the other.2,4-6,8-10,12 PCT 
increases predicted bloodstream invasion, septic shock and organ failure and carried 
greater prognostic significance in the course of infectious disease than CRP on D7 
thus supporting that PCT is more useful in predicting infectious complications, also in 
table 4. Evolution of bloodstream infection.
Group 1a Group 2a Group 3a Group 4a p
N=8 N=2 N=5 N=57  
WBC D0-2, x109/L 18.2 (2.5-27.5) 53.2 (24.7-81.7) 13.9 (9.0-19.8) 12.8 (7.8-24.8) 0.08
WBC D7, x109/L 15.5 (8.0-23.2) 24.2 (18.3-30.2) 23.1 (10.5-33.0) 12.3(4.9-29.2) 0.007
WBC change 0.76 (0.55-3.20) 0.56 (0.37-0.74) 1.17 (1.14-2.95) 0.88(0.40-2.33) 0.02
CRP D0-2, mg/L 220 (71-397) 362 (303-421) 139 (38-257) 183 (5-440) 0.07
CRP D7, mg/L 57 (3-267) 205 (22-389) 54 (101-304) 85 (2-416) 0.20
CRP change 0.14 (0.04-1.01) 0.50 (0.07- 0.92) 1.07 (0.73-6.97) 0.55 (0.02-2.93) 0.02
PCT D0-2, ng/mL 1.6 (0.09-45.1) 74.2 (73.2-75.3) 0.8 (0.3-3.4) 0.6 (0.08-37.2) 0.07
PCT D7, ng/mL 0.2 (0.06-7.8) 13.6 (2.9-24.3) 2.1 (1.3-20.8) 0.2 (0.06-38.5) 0.002
PCT change 0.32 (0.05-2.97) 0.19 (0.04-0.33) 2.80 (0.45-68.3) 0.43 (0.05-5.88) 0.01
Lactate D0-2, mmol/L 1.7 (1.1-3.5) 2.6 (1.8-3.5) 1.2 (1.0-1.5) 1.4 (0.5-2.3) 0.05
Lactate D7, mmol/L 2.1 (1.2-4.3) 2.5 (1.8-3.1) 1.3 (1.1-1.6) 1.0 (0 -2.2) 0.002
Lactate change 1.15 (0.50-2.08) 1.12 (0.51-1.72) 1.01(0.73-1.60) 0.79 (0-1.50) 0.20
Median (range) for WBC=white blood cell count; CRP=C-reactive protein; PCT=procalcitonin. 
Group 1b=septic shock (SS) Day (D) 0-2 not D3-7; Group 2b= SS D0-2 and SS D3-7; Group 3b= 
no SS D0-2 but D3-7; Group 4b=no SS D0-2 nor D3-7.
table 5. Evolution of septic shock.
Group 1b Group 2b Group 3b Group 4b p
 N = 16 N = 5 N = 10 N = 41  
WBC D0-2, x109/L 13.9 (2.5-24.4) 19.8 (7.9-81.7) 17.5 (9.0-27.5) 12.3 (7.8-23.9) 0.17
WBC D7, x109/L 14.5 (4.9-23.2) 17.1 (9.3-30.2) 19.0 (10.5-33.0) 10.7 (5.3-29.2) 0.001
WBC change 0.93 (0.47-3.20) 0.74 (0.37-1.34) 1.14 (0.60-2.95) 0.81(0.40-2.33) 0.25
CRP D0-2, mg/L 243 (5.0-397) 306 (102-421) 142 (38-257) 181 (5-440) 0.004
CRP D7, mg/L 57 (3.0-416) 182 (22-389) 156 (101-304) 61 (2-265) 0.01
CRP change 0.31 (0.04-1.12) 0.56 (0.07-1.82) 1.03 (0.48-6.97) 0.51 (0.02-2.58) 0.003
PCT D0-2, ng/mL 1.1 (0.08-45.1) 8.2 (0.3-75.3) 1.3 (0.08-6.3) 0.5 (0.09-37.1) 0.02
PCT D7, ng/mL 0.2 (0.06-2.6) 0.6 (0.2-24.3) 1.6 (0.2-20.8) 0.2 (0.06-3.5) 0.001
PCT change 0.18 (0.05-2.00) 0.18 (0.04-0.64) 1.73 (0.19-68.3) 0.43 (0.08-5.88) <0.001
Lactate D0-2, mmol/L 1.6 (1.0-3.5) 1.5 (1.0-3.5) 1.2 (0.9-2.3) 1.4 (0.5-2.2) 0.32
Lactate D7, mmol/L 1.2 (0-4.3) 1.3 (0.9-3.1) 1.1 (0.7-2.4) 1.0 (0.5-2.7) 0.21
Lactate change 0.86 (0-1.23) 0.83 (0.51-1.72) 1.00 (0.43-1.60) 0.80 (0.38-2.08) 0.69
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the ICU, even when not predicting new BSI.2,4-6,8-10,12,14,20,24-27,30,31 In leptospirosis, PCT 
normalises upon treatment in 4 days and CRP within 7 days in non-severe cases and 
both return to normal in 7 days in severe infections19, suggesting greater sensitivity of 
PCT than of CRP to infection severity, in line with our data. Conversely, we can assume 
in line with others,10,15,17,21-23,28,29,31,32 that the decrease in CRP in Group 1 with resolving 
infection resulted from appropriate antibiotic treatment, so that we cannot exclude 
that the persistent infection in Group 2 with less decreases was caused by treatment 
failure or slow response, even though not associated with increased mortality. The 
threshold for CRP at D7 to decide on the resolution of infection only is about 21 mg/L. 
Our study does not agree with the relation between rate of decline in CRP up to D7 
during treatment for infection in the ICU and survival,22,24,26-29,31 since the change of 
CRP did not predict outcome. The difference with our study may relate to differences 
in inclusion criteria, among others. Our study suggesting greater value of decreases 
in CRP than of PCT in resolving nosocomial infection in the ICU, does also not agree 
with the reported superior value of PCT decreases in predicting response of infections 
to treatment.10,15,26,31 A decrease of PCT to 0.5-1.0 ng/mL or lower has otherwise 
been used for allegedly safe discontinuation of antibiotics in patients with presumed 
infection given antibiotics with high likelihood for survival in the ICU.8-10,12,16,24,26,27,31,33 
However, our data are not in line with this threshold and suggest a lower value of 
about 0.2 ng/mL, after one week treatment, since the values associated with non-
resolving infection, increasing SOFA and mortality are higher.
table 6. Evolution of SOFA scores.
Group 1c Group 2c Group 3c p
 N = 52 N = 8 N = 8  
WBC D0-2, x109/L 13.5 (2.5-27.5) 13.2 (9.2-19.8) 16.1(8.0-81.7) 0.76
WBC D7, x109/L 13.0 (4.9-33.0) 13.2 (8.5-27.2) 15.5 (6.9-30.2) 0.37
WBC change 0.83 (0.40-3.20) 1.09 (0.67-1.96) 0.82 (0.37-2.56) 0.30
CRP D0-2, mg/L 202 (5-440) 173 (38-290) 157 (59-421) 0.87
CRP D7, mg/L 85 (2-416) 160 (41-304) 92 (18-389) 0.13
CRP change 0.51 (0.02-2.93) 0.95 (0.20-6.97) 0.72 (0.17-1.03) 0.11
PCT D0-2, ng/mL 0.67 (0.08-75.3) 0.68 (0.08-1.98) 1.42 (0.14-73.2) 0.37
PCT D7, ng/mL 0.23 (0.06-38.5) 0.49 (0.15-10.4 1.36 (0.12-24.3) 0.13
PCT change 0.39 (0.04-68.3) 1.73 (0.18-5.88) 0.67 (0.18-1.79) 0.01
Lactate D0-2, mmol/L 1.4 (0.5-3.5) 1.2 (0.50-1.8) 1.7 (1.2-3.5) 0.03
Lactate D7, mmol/L 1.1 (0.5-2.7) 1.1 (0.7-1.9) 1.0 (0.6-4.3) 0.96
Lactate change 0.80 (0.38-2.08) 1.17 (0.77-1.40) 0.63 (0.38-1.72) 0.15
Median (range) for WBC=white blood cell count; CRP=C-reactive protein; PCT=procalcitonin. 
Group 1c decreasing SOFA scores between D0-2 and D7. Group 2c unchanged SOFA scores, 
Group 3c increase in SOFA scores.
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Some limitations of this study should be addressed. A fair number of patients re-
ceived corticosteroids, including so called low dose steroids for treatment of relative 
adrenal insufficiency during sepsis, prior and during inclusion, but this may hardly 
affect marker levels as related to the course of infection as our data in line with those 
of others suggest.13,17,37 We used selective decontamination of the digestive tract by 
non-absorbable antibiotics for infection prevention in many of our patients but the use 
apparently did not confound the value of CRP and PCT changes. We cannot exclude 
that Group 4 patients without infections had benefited from this type of infection 
prevention and had received overtreatment by empiric antibiotics, in the absence of 
demonstrable microbial infection. We chose to classify all groups similar to our primary 
outcome variable: course of infectious disease, thus always entailing four groups per 
outcome measure, except for SOFA score. This resulted in uneven numbers per patient 
group, and the small number of patients in group 2a is a consequence of this uniform 
categorisation. However, small groups may not invalidate statistical significance. The 
study carries the advantage over many others2,4-7,17,30-32 of documentation of microbial 
infection and definitions of infectious complications rather than stages of ‘sepsis’ in 
the critically ill. Finally, our study lacks daily measurements, as other have done in 
spite of increasing costs,2,5-11,14,15,18,20,21-23,25,31,32 so that we cannot conclude on rapid 
time courses of the infection markers. However, our data suggest clinical usefulness of 
the sampling regimen followed. We did not evaluate biomarker changes over shorter 
periods since the kinetics of resolving and developing infections may differ according 
to infectious focus and causative microorganism, among others.
conclusions
In conclusion, our study on ICU-acquired fever and infections suggests that CRP may 
be favoured over PCT courses over 5-7 days in judging response to antibiotic treat-
ment, whereas the latter may better indicate the risk of complications, such as blood-
stream infection, septic shock, organ failure and mortality, which may help deciding 
on safe discontinuation of antibiotics. The analysis may thus help interpreting current 
literature and design future studies on guiding antibiotic therapy in the ICU.
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aBstract
objective We studied the value of routine biochemical variables albumin, C-reactive 
protein (CRP) and lactate dehydrogenase (LDH) to improve prediction and monitoring 
of acute respiratory distress syndrome (ARDS) severity in the intensive care unit.
methods In 101 critically ill patients, with or at risk for ARDS after new onset fever, 
data were collected on days (D) 0, 1, 2, and 7 after inclusion. ARDS was defined by 
the Berlin definition and lung injury score (LIS).
results At baseline, 48 patients had mild to severe ARDS according to Berlin and 87 
according to LIS (Rs=0.54, P<0.001). Low baseline albumin levels were moderately 
associated with maximum Berlin and LIS categories within 7 days; an elevated CRP 
level was moderately associated with maximum Berlin categories only. The day-by-
day Berlin and LIS categories were inversely associated with albumin levels (P=0.01, 
P<0.001) and directly with CRP levels (P=0.02, P=0.04, respectively). Low albumin 
levels had monitoring value for ARDS severity on all study days (area under the 
receiver operating characteristic curve, AUROC, 0.62-0.82, P<0.001-0.03), whereas 
supranormal CRP levels performed less . When the Berlin or LIS category increased, 
albumin levels decreased ≥1 g/L (AUROC 0.72-0.77, P=0.001) and CRP increased 
≥104 mg/L (only significant for Berlin, AUROC 0.69, P=0.04). When the LIS decreased, 
albumin levels increased ≥1 g/L (AUROC 0.68, P=0.02). LDH was higher in 28-day 
non-survivors than survivors (P=0.007).
conclusions Overall, albumin may be of greater value than CRP in predicting and 
monitoring the severity and course of ARDS in critically patients with or at risk for the 
syndrome after new onset fever. Albumin levels below 20 g/L as well as a decline over 
a week are associated with ARDS of increasing severity, irrespective of its definition. 
LDH levels predicted 28-day mortality.
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introduction
The acute respiratory distress syndrome (ARDS) is caused by alveolocapillary inflam-
mation and increased permeability following a direct pulmonary or extrapulmonary 
insult. Many conditions, such as sepsis and trauma, which increase the risk for 
developing or worsening of ARDS are associated with fever. Fever , in turn, may ag-
gravate alveolocapillary inflammation.1,2 The recent Berlin definition and the old, more 
elaborate lung injury score (LIS)2-8 are used to diagnose and classify ARDS. One of the 
drawbacks of the Berlin definition, even though moderately relating to lung edema,9 is 
its dependency on ventilator settings in mechanically ventilated patients (with positive 
end-expiratory pressure, PEEP, affecting the oxygenation ratio) and lack of a specific 
index of severity as the total respiratory compliance.5,7 PEEP and compliance are 
incorporated in the LIS,3 which may therefore constitute a refined but more complex 
measure of clinical severity that correlates with alveolocapillary permeability and can 
be assessed at the bedside if the measurement technique is available.10,11 The Berlin 
definition further includes preconditions and bilateral consolidations, even in the low-
est class, while the lowest class of LIS may contain unilateral consolidation. Another 
limitation of these clinical classifications systems is their use of chest radiographs in 
the diagnostic work up. Interobserver agreement on chest imaging is poor, leading 
to frequent false positives and false negatives.12,13 The systems have been compared 
and only partial overlap has been acknowledged.1,4 Notably, agreement between clini-
cal ARDS definitions and autopsy findings of diffuse alveolar damage is moderate.4,8 
Moreover, clinicians may underdiagnose ARDS, particularly when occurring late in the 
intensive care unit (ICU), and may be poorly able to quantify its severity and course, 
particularly when clinical classification systems are not commonly used.4,6-8,14
Therefore, the search for accurate biomarkers reflecting the severity and course 
of alveolocapillary inflammation and increased permeability underlying the non-
cardiogenic pulmonary edema of ARDS is ongoing.6,15 We and others described that 
circulating albumin levels, in cross-sectional studies, inversely relates to increased 
alveolocapillary permeability and that hypoalbuminemia predict ARDS and oedema 
formation in at risk patients.9,11,16-19 Extravasation of albumin following increased per-
meability lowers albumin levels and the resultant low plasma colloid osmotic pressure 
promotes oedema formation. Inflammation and injury markers such as C-reactive 
protein (CRP)18,20-25 and lactate dehydrogenase (LDH)24,26 have been suggested to help 
predict early onset ARDS and its outcome in cross-sectional studies. Since both clinical 
classifications systems allow coincident ARDS and hydrostatic oedema, inflammatory 
markers such as CRP may be of value in separating non-hydrostatic from hydrostatic 
edema.15,23 Meduri et al.20 showed a decline in CRP and LIS in early ARDS patients 
responding to corticosteroids. However, the ARDS monitoring value of these routine 
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biochemical markers, often available on a daily basis in the intensive care unit (ICU), 
is unknown. Associations with the severity and course of ARDS, if any, could be of 
value in monitoring and therefore in the management of the syndrome at the bedside.
The aim of the present study is to determine whether albumin, CRP and LDH levels 
are associated with the severity and course of ARDS in critically ill patients after new 
onset fever with or considered at risk for the syndrome defined by the Berlin and the 
LIS criteria. The hypothesis was that decreasing albumin and increasing CRP and LDH 
reflect, accurately enough for clinical use, increasing severity of ARDS if judged by 
both clinical classification systems. Indeed, we reasoned that the overlap of systems 
would be a better reference standard for potential biomarkers than either system 
alone.
patients and methods
This was a prospective observational cohort study on the predictive and monitoring 
value of routine biochemical parameters for ARDS severity. The study was subsidiary 
to the original study on biomarkers of infection and subsequent organ failure in 101 
consecutive critically ill patients with ICU-acquired fever.27 Fever is a warning sign of 
inflammation. Many conditions associated with the development of ARDS, i,e, sepsis, 
trauma, burn injury, transfusion related lung injury amongst others, are accompanied 
by fever due to inflammation. The study was approved by the local Ethical Committee 
of the VU University Medical Centre, Amsterdam. All patients or closest relatives gave 
written informed consent and a full description of the protocol can be found in a previ-
ous publication on this cohort evaluating biomarkers of infection only.27 To briefly sum-
marise: the main inclusion criterion was new onset fever: a body temperature >38.3 
°C measured rectally, while body temperature in the first 24 hrs of ICU stay was <37.5 
°C. Exclusion criteria were: age under 18 years, pregnancy, and life expectancy of <24 
hours. Patients were taken care of by intensivists unaware of test results according to 
international and local standards. Albumin infusion was no part of standard treatment.
protocol
The day of new onset fever was marked day 0 (D0). Within 12 hours of meeting inclusion 
criteria we recorded: demographic variables, risk factors, and baseline characteristics. 
Disease severity was expressed by the simplified acute physiology score (SAPS) II on 
admission. The sequential organ failure assessment (SOFA) scores were used to moni-
tor organ failure. Mechanical ventilation was pressure guided (control or support) and 
protective according to standard of care in our hospital. Chest radiographs collected 
on study days were reviewed by two authors (SHH and ABJG) blinded to the study 
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results in an effort to exclude severe fluid overload or signs of congestive heart failure 
in classifying alveolar consolidations, In addition to the chest radiographs we used the 
central venous pressure (CVP), which was routinely measured in 83% of patients, to 
rule out severe fluid overload. The routine biochemical variables, albumin, CRP, LDH, 
and respiratory parameters like ventilator settings and daily chest radiographs were 
collected on D0, 1, 2, and 7. Total respiratory dynamic compliance was calculated from 
tidal volume/(plateau pressure-positive end-expiratory pressure), mL/cmH2O. The 
need for additional imaging and collection of specimen for cultures was decided upon 
by treating physicians blinded to study results. In case culture and/or imaging results 
were positive we considered the day of their collection the day of diagnosis. Sepsis is 
the simultaneous presence of either clinically suspected or proven infection and the 
systemic inflammatory response syndrome. Patients were considered suffering shock 
when a systolic arterial pressure <90 mmHg or a mean arterial pressure (MAP) <65 
mmHg was observed for at least one hour despite adequate fluid resuscitation and/or 
need of vasopressor administration. All definitions, including infections, are in line with 
American Society of Chest Physicians/ Society of Crit Care Med criteria.28,29 For the 
sake of clarity, pneumonia is either community-, hospital- or ventilator-acquired. To 
define ARDS severity on study days, both the Berlin definition and the LIS were used. 
The Berlin definition divides patients into 4 categories that reflect the severity of the 
syndrome: no ARDS (Berlin 0, not fulfilling preconditions or PaO2/FIO2 >300 mmHg), 
mild ARDS (Berlin 1, 200 mmHg< PaO2/FIO2 ≤300 mmHg), moderate ARDS (Berlin 2, 
100 mm Hg< PaO2/FIO2 ≤200 mm Hg), and severe ARDS (Berlin 3, PaO2/FIO2 ≤100 
mmHg). Patients suffer from ARDS if its onset is within 1 week of a known clinical 
insult or worsening of respiratory symptoms, there are bilateral opacities on chest 
radiograph not fully explained by cardiac failure of fluid overload, and the PEEP level is 
≥5 cmH2O.7 We also calculated the LIS [3]; an average based on classification of pa-
tients by the number of quadrants with alveolar consolidation on the anterior-posterior 
chest radiograph, severity of hypoxemia, pulmonary compliance (tidal volume/(peak 
inspiratory pressure-PEEP)), and PEEP level. We used the lowest PaO2/FIO2 measured 
on study days and recorded the corresponding PEEP levels and compliance at the time 
of sampling. Based on their LIS, patients were divided into three categories that reflect 
disease severity: no lung injury (LIS ≤1), mild ARDS (LIS 1-2.5), and severe ARDS 
(LIS >2.5).6 Follow up was until day 28 and we checked the clinical state or date of 
death for all patients.
Biochemistry
Albumin was measured by using Albumin/BCP (Roche Diagnostics, Mannheim, Germa-
ny); normal values are 35-47 g/L. CRP was measured using an immunoturbidimetric 
assay by Modular analytics <P> Roche diagnostics (Mannheim, Germany) and normal 
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values are <5 mg/L. LDH was measured using lactate dehydrogenase optimised (Roche 
diagnostics, Mannheim, Germany); the normal range is 240- 480 U/L.
statistical analysis
Data are expressed as median (interquartile range) or number (percentage) where 
appropriate. Non-normally distributed data were logarithmically transformed where 
appropriate. To study group differences in continuous variables we performed the 
Kruskal-Wallis test followed by a Mann-Whitney U test and for categorical variables we 
used the X2 test. We used the Spearman’s rank correlation for non-normally distributed 
data to indicate any overlap between the Berlin and LIS categories. First, to evaluate 
the diagnostic value of day 0 routine biochemical variable levels for the maximum ARDS 
severity within one week after inclusion, we calculated the area under the receiver 
operating characteristic curve (AUROC) and associated statistical predictive variables, 
such as optimal cutoff values, sensitivity, specificity, positive and negative predictive 
values. We performed the AUROC analyses using MedCalc for Windows, version 13 
(MedCalc Software, Ostend, Belgium). The optimal diagnostic cutoff value was derived 
from the optimal Youden’s index ( J= sensitivity + specificity-1; were J=1 represents 
perfect diagnostic test accuracy).30 Prior to data-analysis and in line with the literature 
we decided that an AUROC >0.65 was clinically relevant and >0.70 of good discrimina-
tive value. Subsequently, to study the monitoring value of routine biochemical markers 
for ARDS longitudinally, we performed generalised estimating equations (GEE), taking 
repeated measures in the same patient and first order interactions into account. To 
further study the monitoring value of the biochemical markers for ARDS severity, we 
calculated the AUROCs on individual study days. Finally, we compared the change in 
biomarker levels (increase or decrease) over 7 days between patients with increasing, 
equal or decreasing ARDS severity. To study this association we calculated the day 0 
to day 7 change in routine biochemical variables (∆=D0-7) and the change in Berlin 
and LIS category and tested for differences between groups. We compared routine 
biochemical variable levels between 28-day survivors and non-survivors and between 
28-day survivors and non-survivors with a maximum Berlin ≥1 or maximum LIS >1. 
Since LDH did not appear useful in diagnosing ARDS severity and course, associations 
with outcome are reported only. All tests were two-sided and P-values ≤0.05 were 
considered statistically significant. Exact P values are given, unless <0.001.
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results
patients
Baseline patient characteristics according to Berlin categories are presented in Table 
1. Of the 101 patients, 53 (52%) had no ARDS on D0, 9 (9%) mild ARDS, 32 (32%) 
moderate, and 7 (7%) severe ARDS. In patients with severe ARDS (Berlin 3), SOFA 
scores were higher than in those without ARDS (Berlin 0, P= 0.02). The PaO2/FIO2 ratio 
in patients without ARDS (Berlin 0) was lower than in those with mild ARDS (Berlin 1, 
P=0.001), but higher than in Berlin categories 2 (P=0.05) and 3 (P<0.001) (Table 2). 
Despite the relatively low PaO2/FIO2 ratio in the Berlin 0 category these patients did 
not fulfil the other prerequisites for ARDS. Similar variables are presented for the LIS 
categories on D0 in Table 1. According to the LIS, 14 (14%) patients had no ARDS on 
D0, 69 (68%) mild, and 18 (18%) severe ARDS. In comparison to patients without 
lung injury, patients with mild (LIS >1.0) or severe ARDS (LIS >2.5) were more likely 
to need mechanical ventilation (P=0.001 and P=0.02), required more ventilator days 
(P=0.04 and P=0.03), and had a higher D0 SOFA score (P=0.02 and P= 0.001; Table 
2). On the day of inclusion an ARDS risk factor (Table 3) was present in 93% of Berlin 
ARDS patients and 96% of LIS ARDS patients, while some patients suffered from 
more than one risk factor. The correlation between the Berlin and LIS categories was 
moderate (Rs=0.54, P<0.001) (Figure 1). Forty-one patients had a Berlin category <1 
and 6 patients had a LIS ≤1 throughout the study.
Association with ARDS severity
Table 4 shows some associative values of D0 albumin and CRP for the maximum Berlin 
and LIS categories within one week after inclusion. During the week, 42 patients 
reached a maximum Berlin <1 and 59 patients a maximum Berlin ≥1, whereas 6 
patients reached a maximum LIS ≤1 and 95 patients a maximum LIS >1. Patients 
with a maximum Berlin ≥1 reached their maximum Berlin score after day 0 in 30% of 
cases. Patients with a maximum LIS >1 reached their maximum LIS score after day 
0 in 26% of cases. The associative values of albumin ranged between (AUROC) 0.62 
to 0.65 (P=0.04 or lower). An albumin level <20 g/L was associated with a maximum 
Berlin category ≥1 and albumin <22 g/L was associated with a maximum LIS >2.5. In 
contrast, CRP levels >138 mg/L were associated with a maximum Berlin category ≥2 
while CRP levels >81 mg/L were associated with a maximum LIS >1.
monitoring ards severity
Figure 2 presents values according to Berlin categories and Figure 3 according to LIS 
categories in the course of time. Of note, changing numbers per day indicate that ARDS 
was deteriorating or improving over time in some patients. Albumin levels were lower 
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table 1. Patient characteristics according to Berlin and LIS categories of ARDS at 
baseline.
Berlin category 0 1 2 3
P-valueN = 53 N = 9 N = 32 N = 7
Age, years 61 (30) 71 (22) 63 (24) 69 (29) 0.21
Sex, male 39 (74) 5 (56) 20 (63) 5 (71) 0.60
SAPS II admission 46 (20) 59 (24) 49 (16) 44 (57) 0.39
SOFA D0 7 (4) 8 (5) 9 (5) 10 (5) 0.06
ICU days until inclusion 6 (12) 7 (19) 8 (12) 9 (32) 0.98
CVP D0, mmHg 9 (5) 5 (2) 6 (6) 7 (3) 0.26
CVP D1, mmHg 8 (5) 6 (5) 7 (4) 6 (0) 0.83
CVP D2, mmHg 7 (4) 9 (2) 6 (4) 5 (0) 0.25
CVP D7, mmHg 7 (4) 9 (4) 7 (5) 9 (1) 0.49
Vasopressor use D0-7 28 (53) 6 (67) 23 (72) 5 (71) 0.20
Renal replacement therapy D0-7 3 (6) 1 (11) 4 (13) 0 0.57
Albumin 20% administration
(100 mL) D0-7 3 (6) 2 (22) 8 (25) 0 0.03
Corticosteroids use D -7-0 23 (43) 5 (56) 14 (44) 3 (43) 0.92
Corticosteroid use D 0-7 23 (43) 7 (78) 16 (50) 4 (57) 0.28
28-day mortality 9 (17) 4 (44) 10 (31) 3 (43) 0.15
LIS category LIS <1 LIS 1.0-2.5 LIS >2.5
N =14 N = 69 N =18 P-value
Age, years 62 (28) 63 (24) 59 (28) 0.92
Sex, man 10 (71) 47 (68) 12 (67) 0.96
SAPS II at admission 49 (20) 47 (20) 45 (23) 0.35
SOFA D0 5 (2) 8 (5) 10 (3) 0.004
ICU days until inclusion 6 (14) 7 (9) 6 (12) 0.85
CVP D0, mmHg 8 (6) 7 (5) 8 (5) 0.79
CVP D1, mmHg 7 (4) 7 (6) 7 (4) 0.50
CVP D2, mmHg 3 (0) 7 (3) 7 (6) 0.32
CVP D7, mmHg 6 (7) 7 (5) 8 (3) 0.61
Vasopressor use D0-7 5 (39) 4 (63) 14 (82) 0.05
Renal replacement therapy D0-7 0 7 (10) 1 (6) 0.40
Albumin 20% administration
(100 mL) D 0-7 0 12 (17) 1 (6) 0.12
Corticosteroids use D -7-0 6 (43) 31 (45) 8 (44) 0.99
Corticosteroid use D 0-7 4 (29) 35 (51) 11 (61) 0.18
28-day mortality 2 (14) 18 (26) 6 (33) 0.47
Median (inter quartile range) or number (percentage), where appropriate. Abbreviations: ARDS- 
acute respiratory distress syndrome; CPR- cardiopulmonary resuscitation; CVP- central venous 
pressure; D- day; ICU- intensive care unit; PaO2/FIO2- arterial O2 pressure over inspiratory O2 
fraction; PEEP- positive end-expiratory pressure; SAPS- simplified acute physiology score; SOFA- 
sequential organ failure assessment.
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table 2. Ventilator course between days 0 and 7 according to Berlin and LIS cat-
egories of ARDS.
Berlin category 0 1 2 3
P-valueN = 53 N = 9 N = 32 N = 7
Ventilator course d0-7
Mechanical ventilation D0 47 (89) 9 (100) 32 (100) 7 (100) 0.12
duration, days 22 (30) 23 (27) 22 (25) 16 (26) 0.85
PaO2/FIO2 ratio D0 180 (76) 226 (60) 155 (49) 89 (32) <0.001
PaO2/FIO2 ratio D1 191 (66) 208 (64) 156 (34) 91 (0) <0.001
PaO2/FIO2 ratio D2 194 (105) 252 (41) 168 (35) 68 (0) <0.001
PaO2/FIO2 ratio D7 189 (110) 239 (23) 161 (48) 73 (21) <0.001
PEEP D0, cmH20 8 (7) 8 (4) 10 (4) 10 (2) 0.10
PEEP D1, cmH20 8 (7) 8 (6) 10 (4) 13 (0) 0.13
PEEP D2, cmH20 8 (7) 10 (6) 10 (4) 8 (0) 0.40
PEEP D7, cmH20 6 (6) 11 (7) 9 (4) 13 (8) 0.001
Compliance D0, mL/cmH20 32 (23) 39 (13) 38 (23) 36 (27) 0.88
Compliance D1, mL/cmH20 39 (18) 35 (24) 35 (18) 21 (0) 0.24
Compliance D2, mL/cmH20 35 (20) 40 (30) 35 (20) 33 (0) 0.78
Compliance D7, mL/cmH20 47 (34) 31 (12) 37 (24) 19 (9) 0.11
Tidal volume D0, mL 500 (217) 500 (116) 520 (206) 530 (256) 0.92
Tidal volume D1, mL 520 (120) 500 (140) 500 (210) 530 (150) 0.68
Tidal volume D2, mL 520 (123) 500 (147) 505 (250) 550 (300) 0.78
Tidal volume D7, mL 530 (192) 463 (216) 500 (150) 450 (250) 0.17
Chest radiograph D0, quadrants 1 (1) 2 (0) 2 (1) 2 (1) <0.001
Chest radiograph D1, quadrants 1 (1) 2 (0) 2 (1) 2 <0.001
Chest radiograph D2, quadrants 1 (1) 2 (1) 2 (1) 3 <0.001
Chest radiograph D7, quadrants 0 (1) 2 (0) 2 (2) 3 (1) <0.001
LIS category LIS <1 LIS 1.0-2.5 LIS >2.5
N =14 N = 69 N =18 P-value
Ventilator course d0-7
Mechanical ventilation D0 10 (71) 67 (97) 18 (100) 0.001
duration, days 11 (20) 22 (27) 28 (21) 0.07
PaO2/FIO2 ratio D0 214 (130) 174 (68) 112 (70) <0.001
PaO2/FIO2 ratio D1 238 (157) 184 (60) 149 (40) <0.001
PaO2/FIO2 ratio D2 284 (111) 181 (72) 156 (48) <0.001
PaO2/FIO2 ratio D7 269 (162) 177 (79) 102 (78) <0.001
PEEP D0, cmH20 5 (2) 9 (6) 14 (3) <0.001
PEEP D1, cmH20 5 (1) 9 (4) 13 (4) <0.001
PEEP D2, cmH20 5 (1) 9 (5) 12 (6) <0.001
PEEP D7, cmH20 4 (3) 8 (6) 14 (5) <0.001
Compliance D0, mL/cmH20 44 (57) 39 (20) 27 (18) <0.001
Compliance D1, mL/cmH20 51 (25) 37 (18) 28 (21) <0.001
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table 2. Ventilator course between days 0 and 7 according to Berlin and LIS catego-
ries of ARDS. (continued)
LIS category LIS <1 LIS 1.0-2.5 LIS >2.5
N =14 N = 69 N =18 P-value
Compliance D2, mL/cmH20 61 (105) 35 (19) 31 (21) 0.01
Compliance D7, mL/cmH20 65 (75) 37 (24) 20 (11) 0.007
Tidal volume D0, mL 409 (268) 500 (176) 550 (154) 0.39
Tidal volume D1, mL 523 (177) 500 (166) 523 (95) 0.92
Tidal volume D2, mL 490 (138) 525 (133) 535 (194) 0.43
Tidal volume D7, mL 450 (150) 500 (213) 500 (138) 0.71
Chest radiograph D0, no quadrants 0 (1) 2 (1) 2 (3) <0.001
Chest radiograph D1, no quadrants 1 (1) 1 (1) 2 (2) <0.001
Chest radiograph D2, no quadrants 0 (1) 2 (1) 2 (3) <0.001
Chest radiograph D7, no quadrants 1 (0) 2 (1) 2 (1) 0.005
Median (interquartile range) or number (percentage), where appropriate. Abbreviations: ARDS- 
acute respiratory distress syndrome; D- day; ICU- intensive care unit; PaO2/FIO2- arterial O2 
pressure over inspiratory O2 fraction; PEEP- positive end-expiratory pressure.
figure 1. Scatterplot of the Berlin definition categories vs. the lung injury score of 
ARDS (Rs=0.54, P<0.001).
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table 3. ARDS risk factors on ICU admission and on study inclusion.
Berlin category 0 1 2 3
P-valueN = 53 N = 9 N = 32 N = 7
ards risk factors on icu admission
Sepsis 14 (26) 4 (44) 12 (38) 1 (14) 0.42
Shock 8 (15) 3 (33) 9 (28) 0 0.18
Trauma 11 (21) 0 2 (6) 0 0.09
General surgery 30 (57) 3 (33) 16 (50) 5 (71) 0.43
Vascular surgery 4 (8) 1 (1) 3 (9) 2 (29) 0.38
Cardiac surgery 3 (6) 0 2 (6) 1 (14) 0.69
Intracranial bleeding 10 (19) 2 (22) 1 (3) 1 (14) 0.19
CPR 6 (11) 1 (11) 2 (6) 1 (14) 0.86
Other 7 (13) 0 2 (6) 0 0.38
ards risk factors on d0
Sepsis 29 (56) 4 (44) 13 (41) 4 (57) 0.66
Shock 14 (26) 5 (56) 14 (44) 4 (57) 0.13
Pneumonia 3 (6) 0 4 (13) 2 (29) 0.14
Aspiration pneumonia 3 (6) 0 0 0 0.43
Peritonitis 3 (6) 1 (11) 1 (3) 0 0.71
Infected pancreatitis 2 (4) 0 1 (3) 0 0.89
Miscellaneous infection 20 (38) 2 (22) 10 (31) 3 (43) 0.75
Surgery within 48 hrs prior to inclusion 8 (15) 1 (11) 4 (13) 0 0.73
LIS category LIS ≤1.0 LIS 1.0-2.5 LIS >2.5
P-valueN =14 N = 69 N =18
ards risk factors on icu admission
Sepsis 3 (21) 22 (32) 6 (33) 0.72
Shock 2 (14) 17 (25) 1 (6) 0.17
Trauma 1 (7) 10 (15) 2 (11) 0.73
General surgery 8 (57) 37 (54) 9 (50) 0.92
Vascular surgery 0 8 (11) 2 (11) 0.41
Cardiac surgery 0 4 (6) 2 (11) 0.42
Intracranial bleeding 5 (36) 7 (10) 2 (11) 0.04
CPR 1 (7) 7 (10) 2 (11) 0.93
Other 3 (21) 5 (7) 1 (6) 0.20
ards risk factors on d0
Sepsis 9 (64) 34 (49) 7 (39) 0.36
Shock 2 (14) 27 (39) 8 (44) 0.16
Pneumonia 1 (7) 6 (9) 2 (11) 0.92
Aspiration pneumonia 1 (7) 1 (2) 1 (6) 0.41
Peritonitis 1 (7) 3 (4) 1 (6) 0.90
Infected pancreatitis 2 (14) 1 (1) 0 0.03
Miscellaneous infection 7 (50) 25 (36) 3 (17) 0.13
Surgery within 48 hrs prior to inclusion 1 (7) 9 (13) 3 (17) 0.73
Number (percentage). Abbreviations: ARDS- acute respiratory distress syndrome; CPR- cardio-
pulmonary resuscitation; ICU- intensive care unit; hrs- hours; LIS- lung injury.
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and CRP levels were higher with increasing Berlin and LIS category. The albumin levels 
had a monitoring value, albeit moderate, on all study days and cutoff values generally 
decreased with increasing ARDS severity (AUROC between 0.62-0.82, P<0.001-0.03, 
Table 5). CRP levels had less frequent monitoring value for ARDS severity. Figure 4 
depicts the change in albumin and CRP levels between D0 and 7 (∆D0-7) in relation 
to the change in Berlin and LIS category: albumin levels inversely related to change 
in ARDS severity regardless of definition. Increasing CRP levels were associated with 
increasing Berlin definition only. A decrease in albumin of ≥1 g/L and an increase of 
table 4. Diagnostic values of D0 albumin and CRP for maximum Berlin and LIS cat-
egories within one week after new onset fever in critically ill patients.
auroc 95% CI p-value
optimal 
cutoff sn sp ppV npV
Maximum Berlin ≥1 (N=59)
 Albumin 0.65 0.53-0.76 0.01 <20 g/L 71 58 71 58
Maximum Berlin ≥2 (N=50)
 Albumin 0.63 0.52-0.74 0.02 <20 g/L 72 53 61 65
 CRP 0.62 0.51-0.74 0.03 >138 mg/L 54 76 69 62
Maximum LIS >1.0 (N=95)
 CRP 0.82 0.64-1.00 0.002 >81 mg/L 77 80 99 15
Maximum LIS >2.5 (N=34)
 Albumin 0.62 0.51-0.73 0.04 <22 g/L 91 31 41 87
Abbreviations: AUROC- area under the curve; ARDS- acute respiratory distress syndrome; CI 
- confidence interval; CRP- C-reactive protein; LIS- lung injury score; NPV- negative predictive 
value; PPV- positive predictive value; SN- sensitivity; SP- specificity.
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figure 2. Median and interquartile range of albumin and C-reactive protein (CRP) for 
the Berlin definition on ARDS.
The Berlin categories are inversely associated with albumin levels (P=0.05) and directly with CRP 
levels (P=0.02) in generalized estimating equations. ● no acute respiratory distress syndrome 
(ARDS, Berlin 0), ■ mild ARDS (Berlin 1), ▲ moderate ARDS (Berlin 2) ▼ severe ARDS (Berlin 
3). Numbers refer to numbers of patients.
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figure 3. Median and interquartile range of albumin and C-reactive protein (CRP) for 
the lung injury score (LIS).
The LIS categories are inversely associated with albumin (P<0.001) and directly with CRP 
(P=0.04) in generalized estimating equations. ● no lung injury (LIS ≤1.0), ■ mild acute re-
spiratory distress syndrome ARDS (LIS 1.0-2.5), ▲ severe ARDS (LIS >2.5). Numbers refer to 
numbers of patients.
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figure 4. Changes of albumin and C-reactive protein (CRP) levels for changes in 
Berlin and lung injury score (LIS) categories between D0-7.
The change in albumin levels is associated with a change in Berlin and LIS category (P=0.05 and 
P=0.03, respectively). A change in CRP levels is associated with a change in LIS category only 
(P=0.03).
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CRP ≥104 mg/L were associated with an increase in ARDS severity by Berlin category 
(AUROC 0.72, P=0.001 with sensitivity 100, specificity (SP) 42, positive predictive 
value (PPV) 23 and negative predictive value (NPV) 100 %; AUROC 0.69, P=0.04, SN 
27, SP 98, PPV 78 and NPV 88%, respectively). A decrease in albumin ≥1 g/L was 
table 5. Monitoring values for ARDS severity on study days.
auroc 95% CI p-value
optimal 
cutoff sn sp ppV npV
Berlin ≥1 day 0
Albumin 0.62 0.52-0.72 0.03 <20 g/L 71 51 58 65
day 1
Albumin 0.66 0.56-0.77 0.003 <20 g/L 84 44 55 77
day 2
Albumin 0.67 0.56-0.78 0.002 <17 g/L 67 65 58 73
day 7
Albumin 0.71 0.59-0.81 <0.001 <14 g/L 38 92 81 63
Berlin ≥2 day 1
Albumin 0.67 0.57-0.76 0.002 <18 g/L 73 54 44 80
day 2
Albumin 0.68 0.58-0.77 <0.001 <17 g/L 73 62 46 84
day 7
CRP 0.65 0.53-0.76 0.045 >105 mg/L 67 64 47 80
Berlin ≥3 day 7
Albumin 0.77 0.65-0.86 0.01 <18 g/L 100 49 10 100
CRP 0.91 0.82-0.97 <0.001 >162 mg/L 100 73 19 100
lis >1 day 0
CRP 0.70 0.60-0.79 0.01 >81 mg/L 78 54 92 27
day 1
CRP 0.65 0.55-0.75 0.04 >182 mg/L 42 92 97 20
day 2
Albumin 0.82 0.73-0.89 <0.001 <21 g/L 86 64 94 43
day 7
Albumin 0.81 0.70-0.89 <0.001 <17 g/L 56 92 97 31
CRP 0.79 0.68-0.87 <0.001 >60 mg/L 68 79 93 36
lis >2.5 day 1
Albumin 0.69 0.56-0.78 0.02 <11 g/L 39 96 70 88
day 7
Albumin 0.72 0.60-0.82 0.004 <18 g/L 83 53 26 94
CRP 0.83 0.73-0.91 <0.001 >158 mg/L 75 80 41 94
Abbreviations: AUROC- area under the receiver operating characteristics curve; CI - confidence 
interval; CRP- C-reactive protein; LIS- lung injury score; NPV- negative predictive value; PPV- 
positive predictive value; SN- sensitivity- SP- specificity.
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associated with an increase in LIS category (AUROC 0.77, P<0.001, SN 91, SP 54, 
PPV 26, NPV 97), and an increase in albumin ≥1 g/L with a decrease in LIS category 
(AUROC 0.68, P=0.02, SN 61, SP 73, PPV 42, NPV 85).
mortality
In 28-day non-survivors, D2 and peak LDH levels were higher (647 (5005) and 756 
(409) U/L, respectively, P=0.003) than in survivors (435 (199) and 543 (362) U/L, 
respectively, P=0.007). In patients with ARDS according to the Berlin definition, LDH 
levels were higher in non-survivors (665 (421) U/L) than in survivors (458 (243) U/L) 
on D1 (P=0.03), in non-survivors (706 (621) U/L) than in survivors (452 (225) U/L) on 
D2 (P<0.001), and in non-survivors (618 (364) U/L) than in survivors (454 (258) U/L) 
on D7 (P=0.02). Peak LDH levels in non-survivors (876 (653) U/L) were higher than in 
survivors (581 (347) U/L, P=0.002). In patients with ARDS according to the LIS, peak 
LDH levels in non-survivors (756 (409) U/L) were higher than in survivors (548 (359) 
U/L, P=0.009). Albumin and CRP did not have prognostic significance.
discussion
This longitudinal study in critically ill patients with or at risk for ARDS with new onset 
fever suggests that albumin rather than CRP levels are valuable in daily monitoring of 
ARDS severity and course at the bedside. Although the associative values were only 
moderate, a low albumin was a useful indicator on all study days, while a supranormal 
CRP cutoff was less frequently associated with ARDS severity. During the week, a 
change in albumin levels was inversely related to a change in ARDS severity regardless 
of definition. In contrast, increasing CRP levels were associated with increasing Berlin 
categories only. The LDH levels only predicted 28-day mortality.
Only partial overlap between Berlin and LIS categories has been observed before.1,4 
In the absence of a reference standard like autopsy or measurement of alveolar-
capillary permeability, we cannot determine whether the Berlin categories underesti-
mated or the LIS overestimated the severity of ARDS. A relatively high PaO2/FIO2 ratio, 
in the presence of relatively high PEEP, may not meet Berlin criteria if preconditions 
and bilaterality are absent, whereas PEEP adds to the LIS score.3 The sensitivity of 
compliance, which is often the first parameter to deteriorate after initiation of lung 
injury, even before onset of edema, could also explain the higher frequency of ARDS 
by LIS than Berlin definitions.31 The Berlin definition includes bilateral chest radiograph 
abnormalities, while the LIS includes quadrants. However, chest radiographs have 
high interobserver variability, leading to frequent false positives and negatives.12,13 As 
such the LIS may constitute a more sensitive measure of the clinical severity of ARDS 
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correlating with alveolocapillary permeability than the Berlin definition, but thereby 
carries the risk of oversensitivity and overestimation,1,5 In any case, the CVP was 
comparable between Berlin and LIS categories, so it is less likely that severe fluid 
overload explains the difference in ARDS rating between definitions. Otherwise, the 
rate and distribution of risk factors in this population with or at risk for late ARDS in 
the ICU is in agreement with the literature, showing ICU-acquired sepsis as the lead-
ing cause (Table 3).1,14 The relatively high ARDS prevalence reflects the selection of 
critically ill patients with new onset fever, suggesting new onset sepsis or inflammation 
both important ARDS risk factors.
We reasoned that an association with both ARDS severity classifications would render 
a potential biomarker clinically valuable, in the absence of a true reference standard 
of ARDS. Albumin levels had monitoring value for ARDS defined by the Berlin defini-
tion and the LIS on all study days and cutoff values in AUROC’s declined as disease 
severity increased. This agrees with the idea that a low albumin is indeed involved in 
ARDS pathogenesis, i.e. increased permeability oedema, as suggested before in cross-
sectional studies.9,11,16-19 Albumin levels did not prognosticate outcome as in other 
studies.18 CRP levels had no consistent monitoring ability for ARDS. A supranormal 
CRP was mainly associated with severe ARDS on D7. Our data suggest that CRP is 
not useful as a marker of ARDS severity and course, in line with some studies .22,24 
However, in previous studies CRP had value in differentiating ARDS from cardiogenic 
pulmonary edema23 and the CRP and LIS decline upon successful ARDS treatment by 
corticosteroids.20 In our study, patients with cardiogenic oedema were excluded. The 
use of corticosteroids on clinical indication could have been a confounder but distri-
bution between ARDS categories was comparable. CRP levels did not prognosticate 
outcome in our study in line with some,22 but in contrast to reports on the association 
between elevated CRP levels and survival21 or non-survival.25 Even though ARDS can 
be considered an inflammatory response of the lung, numerous other factors can be 
responsible for elevated CRP levels in critically ill patients. The levels of LDH, a marker 
of cell damage, were not diagnostic of ARDS severity and course in line with some,24 
but in contrast to other observations suggesting elevated levels in sepsis patients 
progressing to ARDS.26 The LDH levels were however associated with 28-day mortality, 
which has not been reported before.
A limitation of this study is its relatively small sample size and heterogeneous popu-
lation. Considering generalisabilty of the results the latter might be an advantage as 
well. We included patients with the symptom fever rather than with specific conditions 
to focus on an inflammatory response as a major risk factor for developing or worsen-
ing ARDS. Few patients received corticosteroids or albumin as part of their treat-
ment, but their distribution was equal between ARDS categories and therefore do not 
invalidate our conclusions. With exceptions, the AUROC’s were generally not >0.75. 
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Low predictive capacity could also be related to the inclusion of high risk patients only. 
This must be weighed against the accessibility of these variables which are collected 
almost daily and routinely in many ICU’s. Nevertheless, even though the associations 
between albumin levels and ARDS were modest, they were present on all individual 
study days and over the course of a week. Furthermore, albumin was inversely re-
lated to disease severity regardless of the clinical definition and its course predicted 
disease course (AUROC 0.68-0.77 respectively), while neither albumin nor CRP had 
any predictive value for 28-day mortality, possibly due to the limited power of this 
study. Our study suggests that albumin levels may have practical value in monitoring 
the severity of ARDS at the bedside of critically ill patients without the need for LIS 
calculations which are hardly done routinely. Assessing the PaO2/FIO2 ratio and chest 
radiograph may be insufficient to monitor ARDS, since both are treatment-dependent, 
for instance with higher PaO2/FIO2 ratios and more aerated chest radiographs with 
higher PEEP. Even though two authors reviewed clinical history, chest radiographs, and 
CVP to exclude severe fluid overload or congestive heart failure in classifying alveolar 
consolidations we cannot fully exclude a a component of hydrostatic oedema in some 
of our ARDS patients. Nevertheless, even when there is dilution due to fluid admin-
istration hypoalbuminemia leads to lowered oncotic pressure and in the presence of 
increased vascular permeability this leads to pulmonary oedema and ARDS. As shown 
by others low total protein and albumin levels, regardless of fluid state, are associated 
with the presence and development of ARDS.11,16,17 Our study adds to the latter studies 
by focusing on the value of albumin in late ARDS (85-90% after 48 hours, depending 
on definition) in the ICU, a commonly underdiagnosed condition.14
conclusions
Overall, albumin rather than CRP may be valuable in predicting and monitoring the se-
verity and course of ARDS in febrile critically patients with or at risk for the syndrome. 
Albumin levels below 20 g/L as well as a decline in albumin levels are associated with 
ARDS of increasing severity, irrespective of definition. LDH levels predicted 28-day 
mortality but had no monitoring value for ARDS severity.
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aBstract
objective Accurate biomarkers of the acute respiratory distress syndrome (ARDS) 
may help risk stratification and management. We assessed the relation between 
several biomarkers and the severity, course and outcome of late onset ARDS in 101 
consecutive critically ill patients with new onset fever.
methods On study days 0, 1, 2 and 7 we measured angiopoietin-2 (ANG2), pen-
traxin-3, interleukin-6 (IL6), procalcitonin (PCT), and midregional pro-adrenomedullin 
(proADM). ARDS was defined by the Berlin definition and by the lung injury score 
(LIS).
results At baseline, 48% had ARDS according to the Berlin definition and 86% ac-
cording to the LIS. Baseline markers poorly predicted maximum Berlin categories 
attained within 7 days, whereas ANG2 best predicted maximum LIS. Depending on 
the ARDS definition, the day-by-day area under the receiver operating characteristic 
curves suggested greatest monitoring value for IL6 and PCT, followed by ANG2. ANG2 
and proADM predicted outcome, independently of disease severity.
conclusions Whereas IL6 and PCT had some disease monitoring value, ANG2 was 
the only biomarker capable of both predicting the severity, monitoring the course and 
predicting the outcome of late onset ARDS in febrile critically ill patients, irrespective 
of underlying risk factor, thereby yielding the most specific ARDS biomarker among 
those studied.
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introduction
The acute respiratory distress syndrome (ARDS) following sepsis, trauma, pancreatitis 
and other insults is caused by alveolocapillary inflammation and increased permeabil-
ity and is frequently underdiagnosed, particularly when developing late (≥48 hours) 
in the intensive care unit (ICU).1-3 Many underlying conditions of ARDS are associated 
with fever, such as sepsis, and fever itself may also aggravate alveolocapillary inflam-
mation4; fever therefore denotes a risk factor. There are various clinical classification 
systems for ARDS, including the recent Berlin definition and the old, more elaborate 
table 1. Clinical classification systems of the Acute Respiratory Distress Syndrome.
Berlin definition of ARDS6
Preconditions:
Timing Onset within 1 week of a known clinical insult or worsening of respiratory 
symptoms.
Imaging Bilateral opacities on chest radiograph or computed tomography not fully 
explained by effusions, lobar/lung collapse, or nodules.
Origin of oedema Respiratory failure not fully explained by cardiac failure of fluid overload (Need 
objective assessment to exclude hydrostatic oedema if no risk factor present 
(e.g. echocardiography).
Oxygenation Berlin 1: Mild ARDS: 200 < PaO2/FiO2 mmHg ≤300 with PEEP or CPAP ≥5 cmH2O
Berlin 2: Moderate ARDS: 100 < PaO2/FiO2 mm Hg ≤200 with PEEP ≥5 cmH2O
Berlin 3: Severe ARDS: PaO2/FiO2 ≤100 mmHg with PEEP ≥5 cmH2O
lung injury score5
Anterior-posterior chest radiograph score Hypoxemia severity score
0= no alveolar consolidations 0= PaO2/FiO2 = >300 mmHg
1= alveolar consolidations in 1 quadrant 1= PaO2/FiO2 = 225-299 mmHg
2= alveolar consolidations in 2 quadrants 2= PaO2/FiO2 = 175-224 mmHg
3= alveolar consolidations in 3 quadrants 3= PaO2/FiO2 = 100-174 mmHg
4= alveolar consolidations in all quadrants 4= PaO2/FiO2 = <100 mmHg
PEEP score (when ventilated) Pulmonary compliance score
0= PEEP ≤5 cmH2O 0= Compliance ≥80 mL/cmH2O
1= PEEP 6-8 cmH2O 1= Compliance 60-79 mL/cmH2O
2= PEEP 9-11 cmH2O 2= Compliance 40-59 mL/cmH2O
3= PEEP 12-14 cmH2O 3= Compliance 20-39 mL/cmH2O
4= PEEP >15 cmH2O 4= Compliance ≤19 mL/cmH2O
The final lung injury score is obtained by calculating the average of all four categories.
No lung injury ≤1 mild ARDS 1-2.5 severe ARDS >2.5 
Abbreviations: ARDS- acute respiratory distress syndrome, PaO2/FiO2 - arterial O2 pressure over 
inspiratory O2 fraction, PEEP- positive end-expiratory pressure; pulmonary compliance = (tidal 
volume / (peak inspiratory pressure - PEEP).
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lung injury score (LIS, Table 1).1,5-7 Although used as a clinical standard for diagnosis, 
the limitation of the Berlin definition is its dependency on ventilator treatment (with 
positive end-expiratory pressure affecting the oxygenation ratio and chest radiography 
in mechanically ventilated patients) and lack of a specific index of severity such as 
the total respiratory compliance, that is incorporated in the LIS.5-8 The LIS score, 
however, does not include bilateral consolidations as a criterion. The LIS may therefore 
constitute a more refined but complex and not routine measure of the clinical severity 
of ARDS correlating with alveolocapillary permeability.1,9 Nevertheless, the agreement 
of both classification systems with diffuse alveolar damage at autopsy is limited1,10,11 
and apart from the laborious direct measurement of alveolocapillary permeability, if 
available,9 there is no in vivo reference standard for diagnostics and monitoring.12 
Moreover, two phenotypes of ARDS may prevail: one with hyperinflammatory sepsis, 
shock and a poor outcome and the other without such abnormalities.13
Because of clinical classification problems, amongst others, there is an active search 
for biomarkers that may accurately predict the development or presence of alveolo-
capillary inflammation of ARDS and would help in risk stratification and management in 
future studies.14-16 We and others previously described that circulating angiopoietin-2, 
possibly derived from the pulmonary vessel wall, is associated with alveolocapillary 
permeability, development of clinical ARDS, positive fluid balance and mortality in the 
critically ill sepsis or trauma patients, even though sepsis and trauma may predispose 
to different ARDS phenotypes.12,13,16,17-24 The biomarker value for ARDS of alternative 
molecules such as pentraxin-3, a pro-inflammatory acute phase mediator,25-27 interleu-
kin-6, a cytokine with both pro- and anti-inflammatory properties,14-16,19,25,28-33 procalci-
tonin, a marker of inflammation,15,16,34,35 and midregional pro-adrenomedullin, a stable 
fragment of adrenomedullin with immune modulating, metabolic and vasodilator actions 
and prognostic properties in pneumonia and sepsis,36-39 remains unclear up till now. 
The literature on foregoing biomarkers reported on less than 60 patients13,17,20,26,28,32,35 
or on only one single marker or clinical classification system for ARDS.14,15,17-24,26,28,31-35 
Moreover, many studies were cross-sectional.11,12,14,15,17-19,21,23,24,30-39 Since these stud-
ies focused mostly on early ARDS development or its outcome, the value of biomarkers 
in reflecting severity and course of late onset ARDS regardless of risk factors is largely 
unknown. Therefore, the goal of the present, longitudinal study was to investigate 
which biomarker would be most accurate in predicting and monitoring the severity, 
course and outcome of ARDS in critically ill patients after new onset fever who are at 
risk for the syndrome. The hypothesis was that biomarkers directly associated with 
inflammation, such as angiopoietin-2, interleukin-6 and procalcitonin would be more 
accurate than those indirectly associated with inflammation, such as pentraxin-3 and 
proadrenomedullin, independent of underlying ARDS risk factor.13,15,16,18,29
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patients and methods
This was a prospective observational study on the accuracy of biomarkers to predict 
and monitor ARDS severity in critically ill patients with new onset fever. This study 
was ancillary to the original one evaluating the role of biomarkers to predict infection 
and resultant organ failure.40 The original study was approved by the VU University 
Medical Ethical Committee, Amsterdam, the Netherlands. All patients or closest rela-
tives gave their written informed consent prior to inclusion. For the original study we 
consecutively included 101 critically ill patients whom developed new-onset fever in 
the ICU. New onset fever was defined as a rectal temperature >38.3 °C while rectal 
temperature in the preceding 24 hours was <37.5 °C. Due to limited availability of the 
research staff and competing studies we only included during office hours. The main 
exclusion criteria were: lack of informed consent, age <18 years, pregnancy, or life 
expectancy of <24 hours. All patients were taken care of according to local guidelines 
by certified intensivists unaware of biomarker levels. Need of diagnostic imaging and 
sampling of specimen for culture was left at the treating physician’s discretion, who 
was unaware of biomarker results.
study protocol
Day 0 (baseline) was the day of new onset fever. Demographic variables, potential 
ARDS risk factor on ICU admission and baseline characteristics were recorded within 
12 hours of presenting new onset fever. To express disease severity, we used the 
simplified acute physiology score (SAPS) II on admission and the sequential organ 
failure assessment (SOFA) score on study days. In addition to clinical and radiological 
assessment, the central venous pressure (CVP, mmHg), which was routinely measured 
in 83% of patients, was registered to exclude severe fluid overload and severe heart 
failure. On study days 0, 1, 2, and 7 respiratory parameters, chest radiographs, and 
blood samples for biomarker measurement were collected.
definitions
The Berlin definition and LIS were used to diagnose ARDS and classify ARDS severity 
on study days. We reviewed all chest radiographs collected on study days unaware of 
biomarker results and attempted to exclude gross overhydration or signs of conges-
tive heart failure in classifying alveolar consolidations, heart size, vascular pedicle, 
vessel distribution Kerley lines and pleural effusion. The Berlin definition consists of 
4 categories that reflect ARDS severity: no ARDS (Berlin 0), mild ARDS (Berlin 1), 
moderate ARDS (Berlin 2), and severe ARDS (Berlin 3) according to the PaO2/FIO2 ratio, 
regardless of positive end-expiratory pressure, and fulfillment of other preconditions, 
such as a known clinical etiology, bilateral chest radiograph abnormalities and ab-
140 Chapter 7
sence of a hydrostatic cause.6 In contrast, the LIS consists of 3 categories that reflect 
ARDS severity: no lung injury/ARDS (LIS ≤1), mild (LIS 1-2.5) and severe ARDS (LIS 
>2.5).5 The ratio incorporates the PaO2/FIO2 ratio, the PEEP, total respiratory dynamic 
compliance and number of quadrants with alveolar consolidations on chest radiogra-
phy, in the presence of a known clinical etiology. Compliance is calculated from plateau 
inspiratory pressure-PEEP/tidal volume, in pressure-guided mechanically ventilated 
patients. In addition, the maximum Berlin category and maximum LIS during the 7-day 
course were registered. We used the lowest PaO2/FIO2 ratio per day and corresponding 
PEEP levels and compliance. Sepsis was defined according to American Society of 
Chest Physicians/ Society of Crit Care Med criteria41 as the presence of either clinically 
suspected or proven infection and the systemic inflammatory response syndrome. We 
considered the day of specimen collection and/or imaging the day of diagnosis when 
results were positive. Shock was diagnosed when the systolic arterial pressure was 
<90 mmHg or the mean arterial pressure (MAP) was <65 mmHg for ≥1 hour in spite of 
adequate fluid resuscitation and/or need of vasopressor administration.42 Septic shock 
was the presence of sepsis and shock. Mortality is 28-day mortality.
Biomarker assay test specifics
Angiopoietin 2 (ANG2) and pentraxin 3 (PTX3) were measured using the Quantikine 
Enzyme-Linked Immunosorbent Assay (ELISA) Kit (R&D systems Inc. Minneapolis, 
United States). Test specifics for ANG2: lower detection limit 0.05 ng/mL, upper detec-
tion limit 3 ng/mL, normal value in healthy subjects around 0.1 ng/mL with an upper 
limit of 1.2 ng/mL [7,12]. The intra-assay coefficient of variation (CV) is 6.5% and 
inter-assay CV 10%, while the average recovery in serum is 100%. Test specifics for 
PTX3: lower detection limit 0.31 ng/mL, upper detection limit 20 ng/mL with an upper 
limit in healthy subjects <2 ng/mL. The intra-assay CV is <4.5% and inter-assay 
CV 6%, with average recovery in serum of 99%. Interleukin-6 (IL6) was measured 
using the Luminex performance Assay Fluorokine MAP (R&D systems Inc. Minneapo-
lis, United States): lower detection limit 0.36 pg/mL, normal value of IL6 in healthy 
subjects around 1 pg/mL, intra-assay CV <5%, inter-assay CV <9%, and average 
recovery in serum 108%. Procalcitonin (PCT) and midregional pro-adrenomedullin 
(proADM) were measured using the Kryptor compact system (Brahms Diagnostica, 
Henningsdorf, Germany). For PCT: lower detection limit 0.02 ng/mL, upper limit in 
healthy subjects 0.05 ng/mL, and intra-assay and inter-assay CV <6%. Test specifics 
of pro-adrenomedullin (proADM): lower detection limit 0.05 nmol/L, upper limit in 
healthy subjects 0.55 nmol/L, intra-assay CV <4% and inter-assay CV <11%.
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statistical analysis
Since biomarker values were distributed non-normally (Kolmogorov-Smirnov P<0.05), 
data are expressed as median (interquartile range) or number (percentage) where 
appropriate. To determine group differences at baseline we used the Kruskal-Wallis 
test for non-parametric continuous variables and for categorical variables the X2 or 
Fisher exact test where appropriate. In order to perform generalized estimating equa-
tions (GEE), taking repeated measurements into account, non-normally distributed 
data where logarithmically transformed where appropriate. GEE was used to evalu-
ate associations between biomarker levels with ARDS severity throughout the 7-day 
course. Furthermore, GEE were used to compare biomarker levels throughout the 
7-day course between survivors and non-survivors. To study the diagnostic, monitor-
ing and predictive value of baseline biomarkers for maximum ARDS categories, of 
day-to-day values of severity of ARDS and of both baseline and day-to-day values 
for mortality, the area under the receiver operating characteristic curve (AUROC) 
was calculated, after logarithmic transformation of biomarker values, optimal cut-off, 
sensitivity, specificity, positive and negative predictive values were calculated. The 
AUROC analyses were performed using MedCalc for Windows, version 13 (MedCalc 
Software, Ostend, Belgium). We considered an AUROC <0.70 poor, 0.70-0.80 fair, 
0.80-0.90 good, and >0.90 excellent. The optimal diagnostic cutoff value was derived 
from the optimal Youden’s index (J= sensitivity + specificity-1; were J=1 represents 
perfect diagnostic test accuracy).43 To study the predictive value and interdependency 
of baseline biomarker levels, sepsis and SAPS II for 28-day mortality multivariate 
logistic regression was performed, with the Hosmer-Lemeshow test for goodness of 
fit, using stepwise backward elimination of predictors based on the likelihood ratio. 
Two sided P-values <0.05 were considered statistically significant unless specified 
otherwise; P-values are exact unless P<0.001. To correct for multiple testing only 
P-values ≤0.01 were considered statistically significant in the tables with AUROC’s.
results
patient characteristics
According to the Berlin definition, 53% had no ARDS (Berlin 0) at baseline, 9% mild 
(Berlin 1), 32% moderate (Berlin 2), and 7% severe ARDS (Berlin 3). In 90% of 
patients ARDS according to the Berlin definition developed 48 hours after ICU admis-
sion. Compared to patients without ARDS (Berlin 0), patients with ARDS (Berlin ≥1) 
had higher day 0 SOFA scores, more often suffered from shock, more likely needed 
vasopressors and had a higher 28-day mortality rate. The day 0 PaO2/FIO2 ratio in 
patients without ARDS (Berlin 0) was lower than in those with mild ARDS (Berlin 1, 
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P=0.001), but higher than in Berlin categories 2 (P=0.05), and 3 (P<0.001). Accord-
ing to the LIS categories 14% of patients had no ARDS (LIS ≤1) at baseline, 68% mild 
and 18% severe ARDS (Table 2). In 85.% of patients ARDS according to LIS developed 
48 hours after ICU admission. Patients with ARDS according to LIS had higher day 0 
table 2. Patient characteristics by Berlin definition and LIS at baseline.
Berlin 0 Berlin ≥1
p
LIS ≤1 lis >1
 pN=53 N=48 N=14 N=87
General characteristics
Age, years 61 (40-70) 67 (52-75) 0.04 62 (42-70) 63 (48-73) 0.70
Sex, man 39 (74) 30 (63) 0.23 10 (71) 59 (68) 0.79
ICU days until inclusion 6 (4-16) 8 (3-15) 0.69 6 (4-18) 7 (3-15) 0.93
SAPS II 46 (46-55) 50 (38-57) 0.22 49 (41-61) 47 (35-55) 0.16
SOFA day 0 7 (5-9) 9 (5-10) 0.03 5 (5-7) 8 (5-10 0.008
SOFA day 1 6 (4-9) 8 (7-10) 0.01 5 (4-7) 8 (5-10) 0.02
SOFA day 2 5 (4-9) 8 (5-10) 0.11 4 (3-6) 7 (4-10) 0.18
SOFA day 7 5 (4-8) 6 (4-9) 0.60 5 (2-7) 6 (4-8) 0.28
Shock day 1 14 (26) 23 (48) 0.04 3 (21) 34 (39) 0.25
Shock day 2 12 (23) 22 (46) 0.02 3 (23) 31 (36) 0.53
Shock day 7 9 (25) 15 (41) 0.21 4 (57) 20 (30) 0.21
Vasopressor use day 0-7 28 (54) 34 (74) 0.04 5 (39) 57 (67) 0.05
28-day mortality 9 (17) 17 (35) 0.03 2 (14) 24 (28) 0.29
potential ards risk factor on icu admission
Sepsis 14 (26) 17 (35) 0.39 3 (21) 28 (32) 0.54
Shock 8 (15) 12 (25) 0.23 2 (14) 18 (21) 0.73
Trauma 11 (21) 2(4) 0.02 1 (7) 12 (14) 0.69
General surgery 30 (57) 24 (50) 0.55 8 (57) 46 (33) 1.00
Vascular surgery 4 (8) 6 (13) 0.51 0 10 (12) 0.35
Cardiac surgery 3 (6) 3 (6) 1.00 0 6 (7) 0.59
Intracranial bleeding 10 (11) 4 (8) 0.16 5 (36) 9 (10) 0.02
CPR 6 (11) 4 (8) 0.74 1 (7) 9 (10) 1.00
Other 7 (13) 2 (40 0.17 3 (21) 6 (7) 0.11
potential ards risk factor on day 0
Sepsis 29 (56) 21 (43) 0.32 9 (64) 41 (48) 0.39
Shock 14 (26) 23 (48) 0.04 2 (14) 35 (40) 0.08
Pneumonia 3 (6) 6 (13) 0.30 1 (7) 8 (9) 1.00
Aspiration pneumonia 3 (6) 0 0.24 1 (7) 2 (2) 0.36
Peritonitis 3 (6) 2 (4) 1.00 1 (7) 4 (5) 0.53
Infected pancreatitis 2 (4) 0 1.00 2 (14) 1 (1) 0.05
Miscellaneous infections 20 (38) 15 (31) 0.54 7 (50) 28 (32) 0.23
Surgery within
48 hrs prior to inclusion
8 (15) 5 (9) 0.72 1 (7) 12 (14) 0.69
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SOFA scores, were more likely to need vasopressors, respiratory support and required 
more mechanical ventilation days. In 93% of Berlin ≥1 patients and 96% of LIS>1 
patients a potential ARDS risk factor was present on ICU documented and occasionally 
patients suffered two or more potential risk factors (Table 2). Forty-two patients never 
met the Berlin and 6 never the LIS definition of ARDS in the course of the study and 
severity in the other patients varied over time. In 30 and 26%, respectively, patients 
reached their maximum Berlin AND LIS category after day 0. Relatively low baseline 
CVP suggests that absence of overhydration.
Baseline biomarker levels and maximum ARDS severity within 7 
days
Only baseline PTX3 (P=0.03) and IL6 (P=0.04) differed across maximum Berlin 
categories, while baseline ANG2 (P=0.007), IL6 (P=0.02), and PCT (P=0.007) dif-
fered across maximum LIS categories (Table 3). However, in the sensitivity analysis 
the biomarker concentrations differed mainly at low Berlin and high LIS categories. 
Baseline ANG2 predicted maximum ARDS severity according to LIS (Table 4). Other 
biomarkers’ predictive values were poor.
day-by-day biomarker levels for monitoring ards
The following associations were independent of including sepsis as a factor. The ANG2 
and PCT levels were directly associated with Berlin and LIS categories, throughout the 
7-day course (Fig .1 and 2). IL6 and ProADM levels had a direct association with LIS 
table 2. Patient characteristics by Berlin definition and LIS at baseline. (continued)
Berlin 0 Berlin ≥1
p
LIS ≤1 lis >1
 pN=53 N=48 N=14 N=87
pulmonary indices day 0
Mechanical ventilation, yes 47 (87) 48 (100) 0.02 10 (71) 85 (98) <0.001
 duration, days 22 (10-39) 21 (13-37) 0.46 11 (7-27) 23 (12-40) 0.03
PaO2/FIO2 ratio 180 (138-214) 158 (115-183) 0.03 214 (187-317) 165 (125-191) <0.001
PEEP, cmH20 8 (5-12) 8 (8-12) 0.18 5 (4-6) 10 (7-12) <0.001
Compliance, mL/cmH20 33 (25-49) 38 (25-45) 0.91 44 (25-82) 36 (25-45) 0.35
Tidal volume, mL 500 (412-631) 520 (430-602) 0.96 409 (350-618) 520 (430-606) 0.19
Chest radiograph,  
no quadrants
1 (0-1) 2 (2-3) <0.001 0 (0-1) 2 (1-3) <0.001
CVP, mmHg 9 (5-10) 6 (5-9) 0.08 8 (4-10) 7 (5-10) 0.90
Median (interquartile range) or number (percentage) where appropriate. Abbreviations: ARDS- 
acute respiratory distress syndrome; CPR- cardiopulmonary resuscitation; CVP- central venous 
pressure; day* - insult within the 3 days preceding inclusion; ICU- intensive care unit; LIS- lung 
injury; PaO2/FIO2 - arterial O2 pressure over inspiratory O2 fraction; PEEP- positive end-expiratory 
pressure; SAPS- simplified acute physiology score; SOFA- sequential organ failure assessment.
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only. The day-by-day AUROC’s (Table 5) suggested greatest monitoring value for IL6 
and PCT, followed by ANG2 and then by proADM, depending on the ARDS definition.
mortality
Mortality of patients with maximum Berlin categories increased from 12% (Berlin 0) 
to 33 % (Berlin 1), 31% (Berlin 2) and 55% (Berlin 3, P=0.02). For maximum LIS 
category, mortality increased from 0 (LIS ≤1) to 24% (LIS 1-2.5) and 32% (LIS >2.5 
P=0.27). Baseline values of ANG2, PCT, IL6 and proADM were higher in 28-day non-
survivors than in survivors (Table 6). Mortality prediction was investigated in the entire 
cohort and in the subgroups of ARDS according to the Berlin criteria or the LIS score. 
In the entire cohort, multiple logistic regression showed that baseline ANG2 (P=0.001, 
table 3. Sensitivity analysis of baseline biomarker levels for maximum late ARDS 
severity by Berlin and LIS categories.
maximum Berlin category day 0-7
0 1 2 3 p
N=42 N=9 N=39 N=11 Berlin
≥1 vs 0
Berlin
≥2 vs ≤1
Berlin
3 vs ≤2
ANG2, ng/mL 2.3  
(1.3-4.7)
4.2
(1.8-7.2)
4.0
(2.0-7.1)
3.6
(2.3-7.7)
0.03 0.06 0.44
PTX3, ng/mL 9.3
(4.7-19.3)
14.6
(8.1-36.8)
15.2
(9.6-27.9)
13.8
(10.1-35.0)
0.002 0.01 0.38
IL6, pg/mL 49.2
(17.8-88.4)
72.5
(40.6-81.5)
66.0
(25.5-184.3)
232.6
(64.7-331.6)
0.02 0.02 0.03
PCT, ng/mL 0.44
(0.15-1.13)
1.36
(0.23-3.81)
0.68
(0.32-2.04)
0.65
(0.35-1.98)
0.02 0.09 0.37
proADM, nmol/L 1.53
(0.76-2.02)
2.04
(0.99-7.55)
1.52
(1.04-3.13)
2.46
(0.37-3.45)
0.05 0.27 0.47
maximum lis category day 0-7
≤1 1-2.5 >2.5 p
N=6 N=62 N=34 lis
>1 vs ≤1
lis
>2.5 vs ≤2.5
ANG2, ng/mL 1.1
(1.0-2.2)
2.8
(1.5-4.9)
4.2
(2.3-5.4)
0.02 0.01
PTX3, ng/mL 4.9
(4.0-26.3)
12.3
(5.9-25.7)
14.3
(9.9-29.9)
0.18 0.06
IL6, pg/mL 55.9
(9.5-133.3)
49.5
(19.4-100.2)
101.2
(62.0-240.7)
0.47 0.004
PCT, ng/mL 0.32
(0.18-0.57)
0.50
(0.17-1.24)
0.78
(0.55-3.20)
0.15 0.003
proADM, nmol/L 0.88
(0.66-1.66)
1.62
(0.81-2.65)
1.96
(1.26-3.47)
0.14 0.07
Median (interquartile range), P- Mann Whitney U test. Abbreviations: ANG2- angiopoietin 2, 
ARDS- acute respiratory distress syndrome, IL6- interleukin 6, LIS- lung injury score, max- 
maximum ARDS severity within 7 days of new onset fever, PCT- procalcitonin, PTX3- Pentraxin 3, 
proADM- midregional pro-adrenomedullin
Biomarkers of severity and course of late onset ARDS 145
table 4. Statistically significant prediction of baseline biomarker concentrations for 
maximum Berlin and LIS categories within one week after inclusion (day 0-7).
auroc p optimal cut off sn sp ppV npV
maximum Berlin ≥1 (N=59)
PTX3 0.68 0.001 6.0 ng/mL 92 41 69 77
IL6 0.64 0.01 61.7 pg/mL 64 61 70 54
PCT 0.64 0.01 0.49 ng/mL 68 56 69 55
maximum Berlin ≥2 (N=50)
PTX3 0.65 0.01 7.4 ng/mL 88 42 60 78
maximum LIS >1 (N=95)
ANG2 0.80 <0.001 2.5 ng/mL 57 100 100 11
maximum LIS >2.5 (N=34)
ANG2 0.65 0.006 1.8 ng/mL 97 32 42 96
IL6 0.68 0.002 63.1 pg/mL 76 59 49 83
PCT 0.68 <0.001 0.52 ng/mL 75 55 47 84
To correct for multiple testing an adjusted P-value ≤0.01 was considered statistically significant.
Abbreviations: ANG2- angiopoietin 2, ARDS- acute respiratory distress syndrome, AUC- area un-
der the receiver operating characteristics curve, IL6- interleukin 6, LIS- lung injury score, NPV- 
negative predictive value, PCT- procalcitonin, PPV- positive predictive value, PTX3- pentraxin 
3- proADM- midregional pro-adrenomedullin, SN- sensitivity, SP- specificity.
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figure 1. Monitoring value of plasma biomarker levels (median and interquartile 
range) per day for the Berlin definition on ARDS.
In critically ill patients with new onset fever, Berlin definition categories over one week are 
directly related with the levels of ANG2 (P=0.04) and PCT (P=0.006 ), independent of sepsis 
(P=0.77 and 0.57, respectively), in generalized estimating equations. ● no ARDS (Berlin 0), 
■ mild ARDS (Berlin 1), ▲ moderate ARDS (Berlin 2), ▼ severe ARDS (Berlin 3). Abbreviations: 
ARDS- acute respiratory distress syndrome, ANG2- angiopoietin-2, PTX3- pentraxin-3, IL6- in-
terleukin-6, PCT- procalcitonin, proADM- midregional pro-adrenomedullin.
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Hosmer-Lemeshow X2 11.4, df 8, P=0.18) and baseline proADM (P=0.001, Hosmer-
Lemeshow X2 7.0, df 8, P=0.53) predicted 28-day mortality, both independently from 
SAPS II and sepsis. The associated AUROC was 0.74 (P<0.001), while inclusion of 
SAPS II and sepsis did not further contribute. Furthermore, throughout the 7-day 
course, day-by-day levels of ANG2 (P<0.001), PTX3 (P=0.03), PCT (P=0.03) and 
proADM (P<0.001) were higher in non-survivors (Fig. 3). In patients with a maximum 
Berlin ≥1 or maximum LIS category >1, ANG2 and proADM at baseline were higher 
in non-survivors than survivors (Table 6). In patients with a maximum Berlin ≥1, 
multiple logistic regression showed that baseline ANG2 (P=0.02, Hosmer-Lemeshow 
table 5. Statistically significant areas under the receiver operating characteristic 
curve and associated variables for day-to-day biomarker values.
  auroc p optimal cut off sn sp ppV npV
Berlin ≥1
day 2 ANG2 0.67 0.003 1.7 ng/ml 76 53 55 74
day 7 ANG2 0.69 0.005 3.2 ng/ml 50 92 84 67
PCT 0.68 0.01 0.37 ng/ml 58 78 69 68
proADM 0.70 0.002 1.4 nmol/l 68 72 68 72
Berlin ≥2
day 7 IL6 0.71 0.003 27.5 pg/ml 68 80 63 84
Berlin ≥3
day 7 ANG2 0.79 <0.001 3.7 ng/ml 100 77 17 100
IL6 0.95 <0.001 65.6 pg/ml 100 86 25 100
lis >1
day 0 ANG2 0.73 0.005 1.5 ng/ml 86 57 93 40
IL6 0.71 0.005 12.6 pg/ml 91 43 91 43
PCT 0.71 0.002 0.49 ng/ml 64 79 95 26
proADM 0.73 <0.001 0.91 nmol/l 78 64 93 32
day 2 ANG2 0.74 <0.001 3.2 ng/ml 51 92 98 23
proADM 0.75 <0.001 1.02 nmol/l 68 77 95 27
day 7 IL6 0.77 <0.001 20.4 pg/ml 53 100 100 31
PCT 0.75 <0.001 0.35 ng/ml 49 100 100 29
lis >2.5
day 0 PCT 0.66 0.01 0.54 ng/ml 89 51 29 96
proADM 0.66 0.01 1.26 nmol/l 59 46 27 95
day 1 PCT 0.69 0.007 1.07 ng/ml 58 79 41 89
day 7 IL6 0.84 <0.001 29.5 pg/ml 82 75 38 96
PCT 0.73 0.003 0.23 ng/ml 90 54 25 97
To correct for multiple testing an adjusted P-value ≤0.01 was considered statistically significant. 
Abbreviations: ANG2- angiopoietin-2, ARDS- acute respiratory distress syndrome, AUC- area 
under the receiver operating characteristics curve, IL6- interleukin-6, LIS- lung injury score, 
NPV- negative predictive value, max- maximum ARDS severity within 7 days of new onset fever, 
PCT- procalcitonin, PPV- positive predictive value, PTX3- pentraxin-3- proADM- midregional pro-
adrenomedullin, SN- sensitivity, SP- specificity.
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figure 2. Monitoring value of plasma biomarker levels (median and interquartile 
range) per day for the lung injury score.
In critically ill patients with new-onset fever, LIS category over one week is directly related with 
the levels of ANG2 (P=0.03), IL6 (P<0.001), PCT (P<0.001) and proADM (P<0.001), indepen-
dent of sepsis (P= 0.06, 0.25, 0.50 and 0.56, respectively), in generalized estimating equations. 
● no ARDS, ■ mild ARDS, ▲ severe ARDS. Abbreviations: ARDS- acute respiratory distress 
syndrome, ANG2- angiopoietin-2, LIS- lung injury score, PTX3- pentraxin-3, IL6- Interleukin-6, 
PCT- procalcitonin, proADM- midregional pro-adrenomedullin.
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figure 3. Monitoring value of plasma biomarker levels (median and interquartile 
range) per day in 28-day survivors and non-survivors. 
Non-survival is directly related with ANG2 (P<0.001), PTX3 (P=0.01), PCT (P=0.006), and pro-
ADM (P<0.001) levels in generalized estimating equations. ● Survivors (N=75), ■ non-survivors 
(N=26). Abbreviations: ARDS- acute respiratory distress syndrome, ANG2- angiopoietin-2, PTX3- 
pentraxin-3, IL6- interleukin-6, PCT- procalcitonin, proADM- midregional pro-adrenomedullin.
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X2 5.7, df 8, P=0.68) and baseline proADM (P=0.003, Hosmer-Hemeshow X2 8.6, df 
8, P=0.38) predicted 28-day mortality independent from SAPS II and sepsis (AUROC 
0.74 and 0.76 (P<0.001), respectively). In patients with maximum LIS >1, baseline 
ANG2 (P=0.003, Hosmer-Lemeshow X2 7.9, df 8, P=0.44) predicted 28-day mortality 
independently from sepsis but not SAPS II (P=0.03), AUROC 0.73 (P<0.001). Baseline 
proADM (P=0.001, Hosmer-Hemeshow X2 12.3, df 8, P=0.14) predicted 28-day mor-
tality, independently from SAPS II and sepsis(AUROC 0.73, P<0.001).
discussion
In this longitudinal study in critically ill patients with or at risk for late ARDS after new 
onset fever, ANG2 was of value in predicting the maximum severity, monitoring the 
course and predicting the outcome of the syndrome, whereas IL6 and PCT had value 
for daily monitoring of severity, irrespective of underlying risk factor. ProADM only 
table 6. Baseline biomarker values in survivors and non-survivors.
all patients survivors non-survivors
pN = 75 N = 26
ANG2, ng/mL 2.5 (1.8-4.2) 5.7 (2.3-9.1) 0.001
PTX3, ng/mL 11.0 (6.6-25.7) 17.7 (9.5-35.4) 0.06
IL6, pg/mL 65.0 (22.8-122.3) 77.2 (31.0-223.42) 0.23
PCT, ng/mL 0.56 (0.21-1.23) 0.87 (0.34-2.6) 0.04
proADM, nmol/L 1.33 (0.79-2.08) 2.93 (1.33-4.78) <0.001
maximum Berlin >1 survivors non-survivors
pN = 38 N = 21
ANG2, ng/mL 2.8 (1.9-4.3) 5.95 (2.5-9.2) 0.004
PTX3, ng/mL 12.4 (9.2-28.1) 21.4 (13.0-35.9) 0.11
IL6, pg/mL 76.1 (26.6-233.7) 80.0 (29.3-237.3) 0.86
PCT, ng/mL 0.64 (0.23-1.94) 0.85 (0.45-3.31) 0.16
proADM, nmol/L 1.32 (0.87-2.21) 3.15 (1.8-6.5) 0.001
maximum lis >1 survivors non-survivors
pN = 69 N = 26
ANG2, ng/mL 2.6 (1.9-4.3) 5.7 (2.3-9.1) 0.001
PTX3, ng/mL 11.1 (7.1-25.8) 17.7 (9.5-35.4) 0.09
IL6, pg/mL 65.6 (24.2-124.1) 77.2 (31.0-223.4) 0.27
PCT, ng/mL 0.57 (0.20-1.36) 0.87 (0.34-2.63) 0.06
proADM, nmol/L 1.35 (0.81-2.10) 2.93 (1.33-4.78) 0.001
Median (interquartile range). Abbreviations: ANG2- angiopoietin-2, ARDS- acute respiratory dis-
tress syndrome, proADM- midregional pro-adrenomedullin, IL6- interleukin-6, LIS- lung injury 
score, PCT- procalcitonin, PTX3- pentraxin-3.
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predicted 28-day mortality, independent of the SAPS II score. The data suggest ANG2 
as the most specific ARDS biomarker, among those studied.
To the best of our knowledge, this is the first longitudinal study relating a panel of 
biomarkers to both Berlin and LIS-defined, late onset ARDS in the ICU. The differ-
ences between the classification systems may explain why the monitoring ability of 
biomarker levels better correlated with LIS than Berlin definitions. The Berlin definition 
requires bilateral radiographic consolidations and the severity of ARDS in the Berlin 
definition is expressed by gas exchange only, which is dependent of ventilator settings. 
Its focus is, therefore, more on diagnosis of ARDS than on monitoring of its severity.7,8 
In contrast, the LIS includes radiographic criteria, gas exchange, level of PEEP and 
compliance. As such, the LIS may better represent severity of lung injury than the 
Berlin definition, but carries the risk of oversensitivity and thus overestimation of the 
syndrome, since more patients may not have ARDS according to Berlin than LIS cat-
egories, as indicated by our current and previous studies.2,8 Conversely, relatively low 
ANG2 levels already predicted a maximum LIS >1, but this association at low disease 
severity may be clinically less useful than those at high disease severity. Indeed, 
the optimal cutoffs using the Youden index43 resulted in higher positive predictive 
values with less disease severity and higher negative predictive values with greater 
disease severity. We used both overlapping clinical systems to evaluate the uniform 
clinical value of biomarkers in the absence of a true reference standard, even though 
they may not accurately predict diffuse alveolar damage at autopsy.1,10,11 In any case, 
the mortality of our ARDS patients that somewhat increased with increasing severity 
roughly agrees with the literature.3,7,12-14,16,19,20,28,29 Of note, mortality increased across 
Berlin categories while the increase did not reach statistical significance for increasing 
LIS categories, possibly because of underpowering.
Even though the baseline predictive values of biomarkers for maximum Berlin and 
LIS categories within the study week were relatively poor, the day-to-day diagnostic 
value for severity and thus the monitoring value of these biomarkers were greater. This 
particularly applies to IL6, PCT and ANG2, irrespective of ARDS definitions. Indeed, al-
veolocapillary inflammation and increased vascular permeability with non-cardiogenic 
edema is the hallmark of ARDS, and ANG2 may be directly involved.12,17,19 Increasing 
cutoff values for ANG2 with increasing severity of ARDS, according to LIS mainly, 
supports a pathophysiologic role. The literature reports varying predictive values of 
ANG2 for early ARDS,12,16,19-24 while its monitoring value has not yet been reported. 
Furthermore, ANG2 predicted mortality independently of the SAPS II score and sepsis, 
in agreement with most,12,19,20,22 but not with another, small study.15 IL6 levels, which 
may reflect inflammation, were not predictive for 28-day mortality, in contrast to other 
studies.14,15,28-31 The value and limitations of IL6 to diagnose and monitor ARDS sever-
ity, resulting from community-acquired pneumonia, for instance, have been described 
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before.14,24,30,32,33 For PCT, we found no study to document its monitoring value for 
ARDS even though it may predict early ARDS development in community acquired 
pneumonia and a poor outcome.34,35,37 In contrast, another study found no relation 
between PCT levels and mortality in ARDS,15 in line with our results.
PTX3 behaves like an acute phase protein, is a marker of innate immunity and 
inflammation, and may have a role in the complement-mediated clearance of apop-
totic cells.25 PTX3 overexpression has been found in severe infections, mechanical 
ventilation and other risk factors for ARDS.25,26,27 Unlike previous reports,26,27 PTX3 
in our study was poorly associated with ARDS severity and non-survival. Of note, 
our PTX3 levels were relatively low as compared to those in previous studies on 
sepsis and ARDS, which may relate to differences in patient mix.26,27 As part of the 
calcitonin-gene family such as PCT, proADM levels rise during severe infections and 
inflammation and this has been associated with disease severity in pneumonia and 
sepsis in previous studies.36-39 ProADM had fair predictive value for maximum ARDS 
severity and non-survival and correlated to LIS but not to Berlin categories throughout 
the 7-day course. In multiple logistic regression, proADM predicted 28-day mortality, 
independently from SAPS II. To our best knowledge, this is the first study evaluating 
the value of proADM in predicting and monitor ARDS severity, which appeared limited.
The study has several limitations including moderate size and heterogeneity of the 
study population. We used fever as the inclusion criterion to define a general symptom 
of conditions that would predispose patients to late onset ARDS in the ICU.3 Moreover, 
fever may augment alveolocapillary inflammation.4. Potentially resultant patient het-
erogeneity can also be regarded as a factor favoring generalizability of results, which 
would have been less if a more specific condition as entry criterion had been chosen. 
We reviewed clinical symptoms, history, and the chest radiographs in combination with 
CVP levels in an attempt to exclude gross overhydration or congestive heart failure 
in classifying alveolar consolidations. However, we cannot fully exclude a cardiogenic 
component of edema in some of these ARDS patients. We also focused on the course of 
ARDS rather than its development since the study goal was to find biomarkers of value 
in predicting severity and monitoring of late onset ARDS rather than prediction of the 
development of the syndrome. In line with recent research that ARDS phenotypes may 
differ according to sepsis as an etiologic factor,13 we examined the contribution of this 
factor to the associations reported, as done before,15,29 which appeared negligible. The 
value of many biomarkers in our study was nevertheless imperfect with some AUROC 
<0.70, allowing future studies in search of better ARDS biomarkers. Nevertheless, the 
availability of rapid measurements could facilitate future studies on stratifying risks 
and monitoring treatment of ARDS by ANG2 for instance.
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conclusions
In conclusion, ANG2 was the only biomarker capable of both predicting the sever-
ity, monitoring the course, and predicting the outcome of late onset ARDS in febrile 
critically ill patients, irrespective of underlying risk factor, thereby yielding the most 
specific ARDS biomarker among those studied. In contrast to IL6 and PCT which had 
some disease monitoring value only.
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summary
In this thesis we evaluated the use of biomarkers in critically ill patients with new 
onset fever for diagnosis, monitoring and prognosis of infection and its complications, 
with special focus on ARDS. We chose fever as our main inclusion criterion because 
it still is an important symptom for clinicians to consider the presence of infection in 
their patients.
part i - Chapter 2 focuses on the prediction of the severity of infection invasiveness 
to the blood stream (bacteraemia), septic shock and survival in critically ill patients 
with new onset fever. A probable or proven local infection complicated by bacteraemia, 
septic shock or non-survival was considered as a high risk infection. We measured old 
(WBC, lactate and CRP) and new (PCT, proADM, proANP and COP) biomarkers for three 
days after fever onset in 101 critically ill patients. Fifty-seven patients had a probable 
or proven infection (45 only local infection and 12 bacteraemia). Our results suggest 
that elevated CRP levels (optimal cutoff >196 mg/L) are a sensitive indicator of the 
presence of microbial infection irrespective of its invasiveness or severity. High PCT 
levels, on the other hand, may be of value as an indicator of high risk ICU-acquired 
infection, (optimal cutoff >1.98 ng/mL). Low PCT values in particular (optimal cutoff 
<0.65 ng/mL) indicated the absence of bacteraemia, shock or mortality. Among the 
studied biomarkers, PCT had superior predictive value for all four major endpoints, it 
also peaked earlier than other markers.
The use of these inflammatory biomarkers early postoperative remains a matter of 
debate. Surgery itself, and oesophagectomy in particular, triggers an inflammatory 
response limiting the use of SIRS criteria for diagnosing early postoperative (infec-
tious) complications. The value of PCT early postoperative remains uncertain. As a 
proof of principle, we measured CRP and PCT in 45 consecutive patients undergoing 
elective oesophagectomy with gastric-tube reconstruction (chapter 3). The results 
suggest that increasing or high CRP levels within the first 3 days post-oesophagectomy 
contribute to the early diagnosis of any postoperative complication presenting be-
tween postoperative days 3 and 10, independent of the preoperative risk assessment 
scores. Elevated PCT levels may specifically indicate the development of more severe 
combined surgical/infectious complications, mainly associated with anastomotic leak-
age, that required longer hospitalisation. PCT did not signal infectious complications 
alone. Elevated PCT rather than CRP indicates a certain degree of urgency warranting 
empirical (antibiotic) treatment while awaiting results from microbiological cultures 
and diagnostic imaging. Low PCT levels may reassure clinicians to await definite test 
results to initiate targeted antibiotic therapy.
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In the majority of the literature PCT is used to diagnose sepsis and not proven infec-
tion. This may be one of the reasons why previous meta-analyses on the diagnostic 
use of PCT for sepsis and infection have been contradicting in their results. All through 
this thesis we have tried to study the use of biomarkers in diagnosing underlying dis-
ease rather than symptoms, or more precisely in diagnosing (culture) proven infection 
rather than sepsis. We performed a systematic review and meta-analysis to study the 
diagnostic accuracy of PCT for culture proven bacteraemia in patients suspected for 
infection or sepsis (chapter 4). The 58 included articles together study 17,155 patients 
of whom 3,420 suffered from bacteraemia Overall PCT at a cutoff value of 0.5 ng/
mL had good diagnostic value for bacteraemia area under the hierarchical summary 
receiver operating characteristics curve (HSROC) 0.79, sensitivity 76, specificity 69. 
In an attempt to reduce heterogeneity of the study population we performed the 
same analysis in a variety of subgroups. The area under the HSROC ranged from 
0.77-0.84, with sensitivities ranging from 66-89 and specificities ranging from 55-78. 
This meta-analysis shows that PCT has a good diagnostic accuracy for culture proven 
bacteraemia in adult patients suspected of infection or sepsis.
Finally in chapter 5 we focused on the monitoring value of CRP and PCT during a 
one week course. We studied fractional changes in CRP and PCT levels for predicting 
the evolution of microbial infection, its invasiveness (bacteraemia) and severity (septic 
shock, SOFA scores) in response to treatment. CRP levels decreased during the week 
when (bloodstream) infection and septic shock resolved (fractional change <0.14) and 
CRP levels increased when complications such as a new (bloodstream) infection or 
septic shock supervened (fractional change >2.57). PCT levels decreased when septic 
shock resolved (fractional change <0.13) and increased when a new bloodstream 
infection or septic shock supervened (fractional change >1.57). An increase in PCT 
levels also best predicted increasing or not declining SOFA scores (fractional change 
>1.23). We may conclude that CRP levels proved more sensitive for the evolution of 
(local) microbial infections than PCT levels. On the other hand, PCT increases predicted 
bloodstream invasion, septic shock, and organ failure and 28-day mortality, supporting 
the hypothesis that PCT is more useful in predicting infectious complications than CRP.
From the results generated in part I of this thesis we may conclude that CRP is 
a sensitive marker of infections irrespective of their severity, while PCT is a more 
specific marker of high risk invasive infections (bacteraemia) and its complications 
(septic shock, organ failure and mortality). The discriminative power of CRP levels 
between mild and life threatening infections was less than for PCT. To start empirical 
treatment based on CRP levels alone will lead to overtreatment if considered specific 
for infection. In the presence of elevated CRP levels (>196 mg/mL) low PCT levels 
(<0.5-0.65 ng/mL) could reassure clinicians that there is time to await definite culture 
and imaging results in order to start targeted (antibiotic) therapy. High PCT levels war-
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rant empirical treatment. Withholding unnecessary (empiric) antibiotic treatment will 
aid in the prevention of emerging microbial resistance and unnecessary adverse drug 
reactions, amongst others.1-7 Suffice to say that a grey area remains (PCT 0.5-2ng/
mL) where a high risk infection cannot be proven or excluded based on PCT levels. 
The change in CRP over a one week course could contribute in the assessment of a 
patients response to treatment (fractional change <0.14). Again, increasing PCT levels 
indicate a dismal course or outcome (fractional change >1.57). Therefore low PCT 
levels (<0.25 ng/mL) after one week of treatment indicate that withdrawing antibiotic 
treatment is justifiable. The safety of PCT as a single decision tool to withhold cultures 
and additional imaging in patients suspected of infection remains to be proven in 
future prospective studies.
part ii – There is a lack of simple, objective, and precise tools for ARDS diagnosis and 
monitoring in clinical practice. The current clinical classification systems, such as the 
relatively simple Berlin criteria and more extensive LIS, use parameters with known 
interobserver variability (chest radiographs), that are influenced by ventilator settings 
(chest radiographs, PaO2/FIO2 ratio) or by other pulmonary pathology (chest radio-
graphs, PaO2/FIO2 ratio, compliance, PEEP). In clinical practice it is especially difficult 
to discriminate ARDS from diffuse pulmonary infection. Furthermore, deterioration in 
gas exchange may also be due to sputum retention or diffuse (micro) atelectasis. As 
a result clinicians may underdiagnose ARDS especially when occurring late during ICU 
stay.8 This is reflected by the limited association between clinical ARDS and diffuse 
alveolar damage at autopsy.9
In the second part of the thesis, we longitudinally evaluated the use of routine bio-
chemical variables like albumin, CRP and LDH (chapter 6) and other potentially more 
specific biomarkers like ANG2, PCT, PTX3 and proADM (chapter 7) for diagnosing 
severity, monitoring course and predicting outcome in late onset ARDS. These new 
markers could also increase the pathophysiological understanding of ARDS. In the 
absence of a true reference standard we reasoned that the overlap between the Berlin 
definition and LIS would be a better reference standard for potential biomarkers than 
either system alone.
In chapter 6, overall, albumin but not CRP levels appeared valuable in daily monitor-
ing of ARDS severity and course at the bedside. Although the associative values were 
only moderate, low albumin levels (<22 g/L) were inversely related to Berlin and LIS 
severity categories from day 0 onward, while elevated CRP levels (>60 mg/mL)were 
associated with severe ARDS on day 7 only. During the week, a change in albumin 
levels was inversely related to a change in ARDS severity regardless of its definition. In 
contrast, increasing CRP levels were associated with increasing Berlin definition only. 
Of all conventional markers, LDH levels predicted 28-day mortality.
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The data in chapter 7 suggest that among the novel and more specific biomarkers 
ANG2 is the most specific and uniform ARDS biomarker. ANG2 was the only biomarker 
able to predict ARDS severity, to monitor its course and to predict mortality, irre-
spective of definitions and underlying risk factor. In contrast IL-6 and PCT had some 
disease monitoring value only. However, the predictive and monitoring values of ANG2 
were not perfect (AUROC 0.65-0.80) and warrant future studies in search of ARDS 
biomarkers.
In conclusion, albumin and ANG2, both linked to alveolocapilary permeability, were 
the most consistent and therefore most valuable markers in predicting severity, 
monitoring course and predicting outcome of late onset ARDS in critically ill patients 
within one week after new onset fever. Indeed, alveolocapillary inflammation and 
increased vascular permeability with non-cardiogenic edema is the hallmark of ARDS. 
Hypoalbuminemia lowers oncotic pressure and in the presence of increased vascular 
permeability this can increase pulmonary oedema and ARDS severity. As shown in 
previous cross-sectional studies low total protein and albumin levels, regardless of 
fluid state, are associated with the presence or development of ARDS.10-14 Whether 
this hypoalbuminemia is due to decreased synthesis, increased breakdown, leakage 
to the interstitium or fluid resuscitation we cannot conclude from this study. All have 
likely played a role. Up to now longitudinal data using albumin as a monitoring tool for 
ARDS severity are scarce. ANG2 may be directly involved in the activation of vascular 
endothelium through the angiopoietin-Tie2 system. The resultant modulation of the 
cell-cell junction stability, thrombin-induced cell contractility and gap formation lead to 
increased pulmonary vascular permeability.15-17 The increasing cutoff values for ANG2 
with increasing severity of ARDS, according to LIS, supports a pathophysiologic role.
future perspectiVes
Although biomarkers are of added value in identification of patients subject to high 
risk infection and its complications there are considerable challenges before further 
progress can be made. Some of the most prominent problems include the lack of 
easy access, unambiguous, objective diagnostic gold standards and definitions. Cur-
rent microbiological detection relies on gram, stain and laboratory identification after 
culture. There are several factors that make this approach suboptimal amongst which 
slow growth, resistance to cultivation in vitro and unability to prove causality when 
a pathogen is detected.5 Positive cultures do not discriminate with certainty between 
contamination, colonisation and infection. The wide variety of definitions currently 
used to diagnose infection and its severity, respectively, also complicate the interpre-
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tation of results. These problems regarding diagnostic standards and definitions apply 
to ARDS as well.
increasing the sensitivity and specificity of the diagnosis 
infection
The direct measurement of microbial DNA in blood by real-time polymerase chain 
reaction (PCR) in specimen has been suggested to improve the diagnostic process 
of infectious disease.20-23  However, on its own direct measurement of microbial DNA 
may be too sensitive and provides no information on clinical relevant bacterial load.20 
Biomarkers of host inflammation could be used to judge the clinical relevance of the 
PCR findings. Another potential diagnostic tool is gene expression microarray.24,25 The 
comparison of gene expression profiles of for instance peripheral blood leukocytes 
could be used to differentiate between inflammation and infection.24-26 In vivo studies 
have shown that micro array profiles were capable of discriminating between healthy 
controls, patients with bacterial infection, viral infection and a co-infection, amongst 
others.24-26 Furthermore, different microbes induce different gene expression profiles 
and these may be used to indicate the offending microbe, class, genus, species and 
even genetically distinct strains and their virulence specifically.24,25,27, Micro array can 
also be used to study the interactions between the host (i.e. inflammation) and patho-
gens and can thereby provide information on variability in disease severity and host 
susceptibility.24-31 There are some limitations to the use of micro arrays as well. Micro 
arrays generate enormous amounts of data resulting in challenging and complicated 
data analyses. Also, there is no clear consensus on the optimal way of interpret-
ing these data, they rely on large quantitative changes and may thereby overlook 
small changes in smaller biologically important genes (needle-in-a-haystack). Finally, 
they are technically sophisticated and not yet executable in smaller laboratories.24,25 
Furthermore, knowing that gene-expression is altered by certain microbes or as a 
response to microbes does not per se lead to understanding the mechanism.5,6 The 
next step may be the complete sequencing of human and microbial DNA which may 
prove to be a more reliable method.32-37 But this method will not resolve the limita-
tions mentioned for micro array techniques.32-37 Before these techniques can become 
the golden diagnostic standard in daily practice more research needs to be done. 
Furthermore, they have to become affordable and applicable on a wider scale.
Finally, in medicine, but also in life, we try to dichotomize and categorize complex 
problems. The transitions from colonisation to infection, from mild to severe local 
infection and from contained to systemic infection with multiple organ failure are 
gradual. Concluding from this thesis and the literature in general, we may have to 
consider a combination of biomarkers instead of looking for a single holy grail and be 
aware of the pathophysiological mechanism underlying the different biomarkers.
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increasing the sensitivity and specificity of the diagnosis of ards
The diagnosis of ARDS in clinical practice is challenged by its complex and multifacto-
rial underlying pathophysiology and lack of a gold diagnostic standard in vivo. The 
current clinical diagnostic criteria are non-specific and many pulmonary and cardiac 
conditions can influence these criteria. Due to its diverse aetiology, a single diagnostic 
and monitoring biomarker may not exist. The biomarkers in this thesis reflect inflam-
mation and capillary leak in general but may not be specific enough for pulmonary 
inflammation and leakage. Even more important, the many different possible ARDS 
risk factors suggest a final common inflammatory pathway with similar symptoms 
resulting from different provoking diseases. Microarray and DNA sequencing tech-
niques may help in discriminating between these different aetiologies of ARDS and 
genetic susceptibility.37-45 If we could reclassify patients with similar clinical symptoms 
into their underlying aetiological classes further targeted research on underlying 
pathophysiological mechanisms, clinical classification systems and therapy may again 
progress. 
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samenVattinG
In dit proefschrift wordt de rol van biomarkers voor het diagnosticeren, monitoren, 
prognosticeren van infecties en infectieuze complicaties bij kritiek zieke patiënten met 
koorts beschreven. We besteden extra aandacht aan ARDS ls complicatie van infectie 
en ontsteking in kritiek zieke patiënten met koorts. Het belangrijkste inclusiecriterium 
was koorts omdat dit nog steeds een van de belangrijkste symptomen is voor artsen 
om de aanwezigheid van een infectie bij hun patiënt te overwegen. Het is belangrijk 
om een onderscheid te kunnen maken tussen koorts ontstaan door de aanwezigheid 
van bacteriën en koorts ontstaan door "steriele" ontsteking. De eerste moet behandeld 
worden met antibiotica, voor de tweede is de behandeling afhankelijk van de oorzaak 
van de steriele ontsteking. 
deel i - In het eerste hoofdstuk ligt de focus op het diagnosticeren en voorspellen 
van de ernst van een infectie bij kritiek zieke patiënten met koorts. Al heel lang gebruikt 
men witte bloedcellen en andere ontstekingswaarden (bijvoorbeeld CRP) om de aan-
wezigheid van een infectie waarschijnlijker te maken, maar deze parameters kunnen 
ook verhoogd zijn bij een steriele ontsteking. De gedachte is dat de nieuwe biomarkers 
beter dan de oudere ontstekingswaarden een onderscheid kunnen maken tussen in-
fectie en steriele ontsteking. We vergeleken de diagnostische en voorspellende waarde 
van lang bekende ontstekingswaarden namelijk: witte bloedcellen, lactaat en CRP met 
nieuwere biomarkers (ontstekingsstoffen) zoals: PCT, proADM, proANP en COP. Er 
werden 3 groepen gedefinieerd: patiënten met koorts maar zonder infectie, patiënten 
met een lokale infectie (infectie van een weefsel of orgaan) en patiënten met bacteriën 
in de bloedbaan (bacteriëmie). Ernstige infecties werden gedefinieerd als een lokale 
infectie mét bacteriën in de bloedbaan (bacteriëmie) en/of septische shock (een lage 
bloeddruk ten gevolge van infectie) en/of overlijden binnen 28 dagen na het ontstaan 
van de koorts. In totaal werden er 101 kritiek zieke patiënten met koorts ontstaan 
op de intensive care geïncludeerd. Van hen hadden 45 een lokale infectie (infectie 
beperkt tot een orgaan of weefsel) en 12 een infectie met bacteriëmie. De resultaten 
suggereren dat verhoogde CRP waarden een gevoelige maat zijn voor de aanwezig-
heid van bacteriële infecties, onafhankelijk van hun ernst. Hoge PCT waarden, aan 
de andere kant, blijken een specifieke maat voor hoog risico infecties op de intensive 
care. Lage PCT waarden in het bijzonder duidden op de afwezigheid van bacteriëmie, 
septische shock of overlijden binnen 28 dagen na het ontstaan van koorts. Onder de 
bestudeerde biomarkers had PCT de beste voorspellende waarde voor eindpunten, 
daarnaast bereikte het eerder dan de andere markers zijn piekwaarde. 
Het gebruik van biomarkers vroeg na een operatie is lastig omdat een operatie veel 
steriele ontsteking veroorzaakt. Vooral een zogenoemde electieve oesofagectomie met 
buismaagreconstructie (verwijderen van de slokdarm omdat er een slokdarm tumor 
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is) brengt veel steriele ontsteking teweeg, maar gaat ook regelmatig gepaard met 
complicaties van chirurgische (waardoor er nog meer steriele ontsteking ontstaat) of 
infectieuze aard. Hierdoor is de voorspellende waarde van de langer bekende ontste-
kingsparameters (witte bloedcellen en CRP) kort na een operatie vaak beperkt. De 
waarde van PCT na een operatie is echter nog steeds niet helder, maar men denkt dat 
deze superieur zou kunnen zijn aan de waarde van CRP. We vergeleken de voorspel-
lende waarde van CRP en PCT voor het ontstaan van chirurgische en infectieuze com-
plicaties in 45 patiënten na een electieve oesofagectomie met buismaagreconstructie. 
De resultaten laten zien dat in deze groep hoge CRP waarden binnen 3 dagen na een 
oesofagectomie bijdragen aan de vroege diagnose van postoperatieve complicaties, 
ongeacht of deze van chirurgische of infectieuze aard zijn en onafhankelijk van pre-
operatieve risico scores. Verhoogde PCT waarden waren een specifieke maat voor de 
meer ernstige gecombineerde chirurgische-infectieuze complicaties en gingen meestal 
gepaard met anastomose lekkage, deze patiënten verbleven dan ook langer in het 
ziekenhuis. PCT kon helaas niet geïsoleerde infectieuze complicaties diagnosticeren. 
Verhoogde PCT waarden en niet CRP wijzen op een bepaalde mate van ernst en nood-
zaak tot spoedige behandeling, ook al is de precieze bacterie of complicatie nog niet 
bekend. Lage PCT waarden zijn geruststellend en geven artsen de tijd om aanvullend 
onderzoek af te wachten zodat zij met gerichte therapie kunnen starten.
In het overgrote deel van de literatuur is PCT gebruikt om sepsis te diagnosticeren 
en niet een bewezen infectie. Sepsis is een klinisch beeld dat ontstaat door een hef-
tige immuunreactie van het lichaam, regelmatig als gevolg van infectie, maar soms 
ten gevolge van steriele ontsteking.  Wij denken dat de tegenstrijdige resultaten in 
eerdere onderzoeken voor een deel te maken hebben met het gebruik van deze niet 
robuuste uitkomstmaat. Gedurende dit proefschrift hebben wij geprobeerd om de 
biomarkers te gebruiken ter diagnose van ziekte (infectie) en niet ter diagnose van 
symptomen (sepsis). In hoofdstuk 4 bekijken en vergelijken we de literatuur waarin 
de PCT waarde van patiënten met een bewezen bacteriëmie vergeleken wordt met de 
PCT waarde van patiënten zonder bewezen infectie. In totaal werden er 58 artikelen 
geïncludeerd, waaraan 17.155 patiënten deelnamen, van wie 3.420 een bacteriëmie 
hadden. PCT had bij een afkapwaarde van 0.5 ng/mL een goede diagnostische waarde 
voor bacteriëmie in patiënten die werden verdacht van een infectie.  
Tot slot onderzochten we in hoofdstuk 5 of CRP en PCT gebruikt kunnen worden 
om  een uitspraak te doen over de ontwikkeling van het ziektebeeld in de week na 
het ontstaan van koorts. We onderzochten de voorspellende waarde van een rela-
tieve verandering van CRP en PCT gedurende een week voor de ontwikkeling van een 
infectie, bacteriëmie en ziekte ernst. Uit de resultaten kunnen we concluderen dat 
CRP meer dan PCT een gevoelige marker is voor de evolutie van (lokale) infecties. 
Daartegenover staat dat een verhoogd PCT voorspellend is voor bacteriëmie en ziekte 
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ernst: septische shock, orgaanfalen en sterven binnen 28 dagen na het ontstaan van 
koorts. Dit sterkt de hypothese dat PCT waardevoller is voor het voorspellen van 
infectieuze complicaties dan CRP. 
Samenvattend kunnen we naar aanleiding van de resultaten uit deel I van dit 
proefschrift concluderen dat CRP een gevoelige biomarker is voor infecties ongeacht 
de ernst van deze infectie. PCT daarentegen is een specifiekere marker van hoog 
risico infecties en infectieuze complicaties. Het onderscheidende vermogen van CRP 
tussen milde en levensbedreigende infecties was kleiner dan die van PCT. Indien je 
CRP gebruikt als diagnosticum voor het starten van antibiotica zal je een deel van 
de patiënten onnodig antibiotica geven. Lage PCT waarden zouden artsen kunnen 
ondersteunen in hun beslissing dat het veilig is om onderzoeksresultaten af te wachten 
zodat gerichte therapie gestart kan worden. Het verminderen van onnodige antibioti-
sche behandelingen kan helpen in de preventie van resistente bacteriën en voorkomt 
onnodige allergische reacties bij patiënten. Er blijft echter wel een grijs gebied waarin 
de biomarker waarden wel verhoogd zijn, maar niet extreem verhoogd. De inter-
pretatie van de biomarker waarden in dit grijze gebied blijft lastig. Een interessante 
bevinding is ook dat een daling van de CRP waarden gedurende een week gebruikt kan 
worden om het slagen van de behandeling te objectiveren, terwijl het stijgen van PCT 
waarden met name gebruikt kan worden om een achteruitgang/verslechtering van 
het ziektebeeld te objectiveren. Lage PCT waarden 1 week na het begin van koorts bij 
kritiek zieke patiënten zouden gebruikt kunnen worden om het stoppen van antibiotica 
te verdedigen of het veilig is om PCT te gebruiken als enige maat om het starten 
van antibiotica op te baseren, kunnen we uit dit proefschrift niet concluderen. Verder 
onderzoek zal nodig zijn. 
deel ii – Het acute respiratory distress syndrome (ARDS) is longschade ontstaan 
door ontsteking van de kleine longblaasjes en de daaromheen gelegen bloedvaatjes. 
Hierdoor gaan de bloedvaatjes rondom de longblaasjes lekken en komt er ontstekings-
vocht in de longblaasjes. Door dit ontstekingsvocht wordt het moeilijk om genoeg 
zuurstof (O2) vanuit de longen naar het bloed te transporteren. Daarnaast worden de 
longen door de ontsteking  stugger, waardoor de uitwisseling van zuurstof en koolzuur 
(CO2) nog moeilijker is. ARDS is een ernstig ziektebeeld bij kritiek zieke patiënten 
waaraan mensen kunnen overlijden of beperkende restschade aan overhouden. Er is 
een gebrek aan simpele, objectieve methoden om ARDS te diagnosticeren aan bed van 
een kritiek zieke patiënt. Bij de huidige ARDS scoresystemen wordt gebruik gemaakt 
van onder andere het verschil tussen de hoeveelheid zuurstof in de beademingslucht 
en het bloed, röntgenfoto’s van de longen, en elasticiteit van de longen. Het blijkt 
echter dat ook bij andere longproblemen deze parameters afwijkend kunnen zijn en 
dat er veel verschil is in interpretatie. 
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In het tweede deel van dit proefschrift hebben we geprobeerd om met behulp van 
reeds bekende langer gebruikte bloedwaarden zoals albumine, LDH en CRP (hoofd-
stuk 6) en nieuwe biomarkers zoals ANG2, PCT, PTX3 en proADM (hoofdstuk 7) de 
ernst, het verloop en de uitkomst van ARDS te diagnosticeren. Het blijkt dat met 
name albumine en ANG2, beide een maat voor lekkende bloedvaten ten gevolge van 
ontsteking, gebruikt konden worden voor het diagnosticeren, vervolgen en voorspel-
len van de uitkomst van ARDS. De diagnostische en voorspellende waarde van deze 
twee biomarkers was echter niet perfect. Er zal verder onderzoek nodig zijn naar de 
onderliggende mechanismen van ARDS voordat deze markers gebruikt kunnen worden 
in de dagelijkse praktijk. 
toekomstiGe uitdaGinGen
Ondanks dat er een toegevoegde waarde is voor het gebruik van biomarkers bij 
het diagnosticeren van infecties en infectieuze complicaties liggen er verschillende 
uitdagingen in de toekomst. Zo is er nog winst te behalen in het vaststellen van de 
aanwezigheid van bacteriën. De huidige kweekmethodes zijn nog niet waterdicht. Zo 
kan het gebeuren dat er wel een bacterie aanwezig is maar dat je deze met de huidige 
kweekmethodes niet of pas relatief laat vindt. Een oplossing zou kunnen liggen in het 
screenen van DNA- en eiwitpatronen in bijvoorbeeld witte bloedcellen van patiënten 
verdacht voor een infectie. Dit soort methodes zijn echter bewerkelijk en kostbaar en 
kunnen nog niet in elk laboratorium worden uitgevoerd. 
De technieken waarbij DNA- en eiwitpatronen in cellen bestudeerd kunnen worden 
zouden ook gebruikt kunnen worden om een beter begrip te krijgen van het zeer 
diverse ziektebeeld dat ARDS is. Misschien dat patiënten die we nu diagnosticeren met 
ARDS wel een heel ander onderliggend ziektebeeld hebben maar dat de symptomen 
erg op elkaar lijken. 
Tot slot; in de geneeskunde maar ook in het dagelijks leven proberen wij complexe 
problemen in simpele categorieën in te delen, terwijl veel van deze problemen zich 
misschien meer op een continue schaal bevinden. Concluderend uit dit proefschrift, 
en de literatuur in het algemeen, zouden we moeten overwegen om de zoektocht 
naar de heilige graal der biomarkers te verschuiven naar het doorgronden van de 
mechanismen die ten grondslag liggen aan deze biomarkers.
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Neef Steef, de genius achter deze briljante cover, dank!
Vrienden
Dude! We did it! Vandaag voelt als ons feestje. Louise, van het begin tot het einde was 
je er bij. Achteraf ben ik blij dat we altijd de lift naar beneden hebben genomen vanuit 
de balkonkamer. Ik hoop dat ik de komende jaren van je mag blijven leren en met je 
mag blijven lachen. 
Fleur, vanaf moment één zat het goed. Zelden heb ik zo snel vertrouwen in iemand 
gehad. Zo nu en dan in de rol van grote zus om mij te corrigeren "niet zo mauwen 
Hoebie", of om me iets nieuws of goors te laten zien. Je hebt een belangrijke rol 
gespeeld in mijn eerste maanden als ANIOS, die ik zonder jou als loodzwaar zou 
hebben ervaren.
Tirza, wie had ooit gedacht dat ik bevriend zou zijn met een psychiater? We verschillen 
maar lijken ook enorm op elkaar. Bedankt dat ik altijd mijn onaangepaste en politiek 
incorrecte zelf bij je kan zijn.
Wessel, je bent bijzonder. Niet bang om mij een spiegel voor te houden of jezelf 
kritisch te beschouwen, dat kan ik waarderen. Ook wanneer er gewoon slap geouwe-
hoerd moet worden heb ik je er graag bij.
Usquert, Usjes zijn bijzondere wezens. Het maakt niet uit hoe lang we elkaar niet 
gezien hebben, tussen ons zit het altijd goed. Onvoorstelbaar dat we na al die jaren 
nog steeds een miljoen dingen te bespreken hebben, in hoog tempo en altijd op vol 
volume. Misschien moeten we weer eens bij Las Brasas gaan eten? Ik zou jullie niet 
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kunnen missen en ben blij dat jullie allemaal zo anders zijn. Ik kan van elk van jullie 
iets leren en weet dat er in nood altijd een Usje is om op terug te vallen. 
collega's
Diederik, ik kwam in Rotterdam als coassistent, werd arts-assistent en vertrek als 
doctor. Bedankt voor je vertrouwen en begeleiding in deze periode, maar ook voor de 
lol die we hebben gehad in Brussel en op skireis. Ik kan me mijn eerste jaargesprek 
nog goed herinneren; jouw woorden waren prikkelend en verbaasden me destijds (in 
positieve zin), ze hebben me doen inzien dat ik zoveel mogelijkheden heb. Jouw open 
deur beleid is voor mij heel waardevol geweest. Bedankt dat je naar me geluisterd 
hebt, vooral in de afgelopen anderhalf jaar. Wie weet kom ik nog eens terug, maar 
ongeacht of ik terugkom, zou ik toch nog eens mee op skireis mogen?
Hilde, Queen H, weloverwogen en genuanceerd. Toen ik het niet meer wist heb je naar 
me geluisterd en de mogelijkheden met mij doorlopen. Wanneer ik als dokter een 
balans vind tussen kennis, kunde en menselijkheid zoals jij dan ben ik tevreden. Het 
brengt me rust wanneer ik met jou kan sparren over de aanpak van een probleem.  
Patrick, waar te beginnen, waar te eindigen? Engeltje, poppedop, het was gezellig in 
ons hok. Een onderzoeksgroep begint bij 2 personen. Zullen we binnenkort maar weer 
een Chardonnay opentrekken?
Aan alle overige kakkerlakken van de IC :D bedankt dat jullie mij als 020'er hebben 
gedoogd. Ik heb mij altijd thuisgevoeld in jullie midden. De diversiteit in de staf heeft 
mij blootgesteld aan een grote verscheidenheid aan inzichten en aanpakken voor één 
en dezelfde casus. Van tijd tot tijd hebben jullie mij een hart onder de riem gestoken 
wanneer ik even niet zo soepel liep als ANIOS of promovendus. 
Assistenten anesthesiologie dankzij jullie heb ik een paar fantastische oneliners die het 
nog steeds erg leuk doen. "Assumption is the mother of all fuck ups" en "Never do the 
same thing twice". Aan alle verpleegkundigen van de IC EMC, jullie tough-love-aanpak 
maakte mijn eerste maanden als ANIOS niet altijd makkelijker, maar jullie hebben me 
uiteindelijk altijd op de goede weg geholpen. Zonder jullie hadden die nachtdiensten 
echt veel langer geduurd.
Lieve Sandra, omdat je trots mag zijn en het jezelf moet gunnen. 
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riculum vitae 173  list of puBlications 175  dankwoord 177  voor Johan chapter 1 general introduction general introduction sandra h hoeBoer general introduction part i - infections in the criti-
cally ill microBial infections, and associated complications, are still an important cause of intensive care (icu) admissions and mortality.1-6 despite the use of antiBiotics and guidelines for sup-
portive care mortality rates are up to 50% depending on disease severity.1-7 the most widely accepted definitions for infection are those of the “international sepsis forum consensus conference 
on definitions of infection in the intensive care unit” (isfcc).8 according to isfcc criteria the likelihood of infection is Based mainly on clinical suspicion and/or microBiological cultures.8 in clini-
cal practice new onset fever, leukocytosis, tachypnea, tachycardia and elevated c-reactive protein (crp) levels raise suspicion aBout the presence of infectious disease.9-11 they are, however, 
markers of host inflammation and their value for the definite diagnosis of infection has consideraBle limitations, especially in the icu.10, 12, 13 the comBination of fever, leukocytosis, tachypnea 
and tachycardia is considered the systemic inflammatory response syndrome to infection (sirs). an infection in the presence of sirs is called sepsis (taBle 1). the adverse sequelae of infection: sepsis, 
septic shock, and organ failure, are partly caused By this host inflammatory response and each negatively influences outcome.4, 7, 10, 14-16 in fear of undertreatment physicians repeatedly order 
cultures and start Broad spectrum, empiric antiBiotic treatment.17 however, overtreatment unnecessarily exposes patients to the risk of adverse drug reactions, amongst other risks. prolonged 
antiBiotic therapy also results in Bacterial selection in individual patients and microBial resistance on a population level.18, 19  the methods currently used for microBiological confirmation of 
infection have consideraBle limitations. the reporting of microBiological results takes at least 1 or 2 days after collection of specimenand  they are falsely negative in a third of patients suspect-
ed of infection.6, 9, 16 cultures can also Be falsely positive due to contaminants and may Be insensitive in patients already treated with antiBiotics.20 these limitations reduce the potential of micro-
Biological cultures to monitor the response to antiBiotic treatment. to support the early diagnosis of infection, to predict its prognosis, and to monitor response to treatment a wide variety of 
inflammatory Biomarkers have Been studied.21 nevertheless, controversy regarding the use of Biomarkers for the diagnosis and prognosis of infections in the icu remains.21 this could Be the re-
sult of heterogeneous study populations and endpoints. another explanation is that these Biomarkers have Been used to diagnose sepsis, the unspecific host inflammatory response to infection, 
and less often to diagnose microBiologically proven infection. part ii - the acute respiratory distress syndrome severe infections and the host inflammatory response have an effect on individual 
organ systems as well. around 75% of septic patients in the icu develop respiratory failure requiring mechanical ventilation, while the lung is the primary site of infection in aBout 40-60% of 
cases.1-4, 6, 14, 16 aBout half of the patients with sepsis fulfill the acute respiratory distress syndrome (ards) criteria.1, 4, 14, 16 mortality rates in ards patients vary Between 20-50%, depending on 
disease severity.22, 23 ards is caused By an insult to the alveolocapillary memBrane that results in alveolocapillary inflammation and permeaBility that leads to formation of pulmonary oede-
ma.22, 24, 25 there can Be a direct insult to the alveolocapillary memBrane such as pneumonia or an indirect insult due to the host inflammatory response. infections are the main cause of ards.22, 24-
26 the main symptom of ards is hypoxemia resulting from the generalised pulmonary oedema and reduced lung compliance.22, 27, 28 Besides the laBorious, invasive, direct measurement of alveolo-
capillary permeaBility there is no true reference standard for diagnosis and monitoring ards at the Bedside.27 to diagnose ards various clinical scoring systems have Been developed.23, 26, 29 the 
recently developed Berlin definition (taBle 2) is currently the preferred diagnostic standard in research23, But controversy regarding its diagnostic value remains.23, 30-33 a limitation of the Ber-
lin definition is its dependency on ventilator settings. the level of positive end-expiratory pressure (peep) affects the oxygenation ratio and chest radiograph in mechanically ventilated patients. 
moreover, the Berlin definition lacks a specific index of severity such as lung compliance. in contrast, the more extensive lung inJury score (lis, taBle 2) gradually includes peep and lung compli-
ance.29 finally, chest kakkerlak radiographs, an important feature of Both systems, are suBJect to consideraBle interoBserver variaBility.34 the correlation Between Both clinical diagnostic sys-
tems and diffuse alveolar damage on autopsy is limited.26, 35 particularly when occurring late in the intensive care unit (icu) clinicians may underdiagnose ards and may Be poorly aBle to quantify 
its severity and course, since clinical classification systems are not commonly used in daily practice.22, 26, 31, 35 availaBility of Biomarkers that are associated with the severity and course of ards 
in the critically ill could simplify diagnosis, monitoring and therefore management of the syndrome in daily clinical practice.36, 37 Biomarkers ideally, a Biomarker is an oBJective indicator of a 
physiologic or pathologic process that can Be used for diagnosis, prognosis of disease and/or monitoring of response to treatment.38 in recent years much effort has Been invested into research 
on Biomarkers of infection and organ failure. the Biomarkers under evaluation in this thesis represent markers of inflammation, circulatory homeostasis and endothelial Barrier function (taBle 
3). whether these Biomarkers are useful for the monitoring of infections and organ failure is not known or still under deBate. aim and outline of the thesis part i - we hypothesised that the increase 
in circulating inflammatory Biomarkers during icu-acquired infections depends on invasiveness and severity of disease. therefore, the first goal is to find a single Biomarker for discriminating 
Between patients with and without microBial infection and to discriminate Between those at low or high risk of developing infectious complications (i.e. Bacteraemia, septic shock, death). the sec-
ond is to determine its optimal cutoff value for Biomarker-guided diagnostics and therapy in clinical practice and for future studies. we study the diagnostic accuracy 010 isn’t Just a numBer and 
optimal cutoff of these Biomarkers in 101 critically ill patients with new onset fever (chapter 2), 45 patients after elective esophagectomy (chapter 3), and perform a systematic review and meta-
analysis of the literature on patients suspected of infection or sepsis (chapter 4). in addition, we hypothesised that the one-week course of roffa Biomarkers can Be used to distinguish resolving 
microBial infection with a Beneficial outcome from non-resolving or developing infections with a detrimental outcome associated with Bacteraemia, septic shock, organ failure and death. in chap-
ter 5 we try to define values mokum at which antiBiotic treatment can Be decided as appropriate and might allow safe discontinuation in 72 critically ill patients one-week after new onset fever. 
part ii - we aim to determine the association of routine Biochemical variaBles (chapter 6) and potentially more specific Biomarkers (chapter 7) with the severity and one-week course of late onset 
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Persévérer, secret de tous les triomphes.
-Victor	Hugo-
